0000021076-21-000020.txt : 20211101 0000021076-21-000020.hdr.sgml : 20211101 20211101171424 ACCESSION NUMBER: 0000021076-21-000020 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211101 DATE AS OF CHANGE: 20211101 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CLOROX CO /DE/ CENTRAL INDEX KEY: 0000021076 STANDARD INDUSTRIAL CLASSIFICATION: SPECIALTY CLEANING, POLISHING AND SANITATION PREPARATIONS [2842] IRS NUMBER: 310595760 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-07151 FILM NUMBER: 211368251 BUSINESS ADDRESS: STREET 1: THE CLOROX COMPANY STREET 2: 1221 BROADWAY CITY: OAKLAND STATE: CA ZIP: 94612-1888 BUSINESS PHONE: 5102717000 MAIL ADDRESS: STREET 1: P.O. BOX 24305 CITY: OAKLAND STATE: CA ZIP: 94612-1305 10-Q 1 clx-20210930.htm 10-Q clx-20210930
0000021076false--06-30Q1202200000210762021-07-012021-09-30xbrli:shares00000210762021-10-19iso4217:USD00000210762020-07-012020-09-30iso4217:USDxbrli:shares00000210762021-09-3000000210762021-06-3000000210762020-06-3000000210762020-09-30clx:entity0000021076clx:JointVentureInKingdomOfSaudiArabiaMemberclx:JointVentureInKingdomOfSaudiArabiaMember2020-07-09xbrli:pure0000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-012020-09-300000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-092020-07-090000021076clx:JointVentureInKingdomOfSaudiArabiaMember2020-07-090000021076clx:TotalCommodityPurchaseDerivativeContractsMember2021-07-012021-09-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2021-09-300000021076clx:SoybeanOilFuturesMember2021-09-300000021076clx:JetFuelSwapsMember2021-09-300000021076clx:TotalCommodityPurchaseDerivativeContractsMember2021-06-300000021076clx:SoybeanOilFuturesMember2021-06-300000021076clx:JetFuelSwapsMember2021-06-300000021076us-gaap:ForeignExchangeContractMemberclx:PurchasesofInventoryMember2021-09-300000021076us-gaap:ForeignExchangeContractMemberclx:PurchasesofInventoryMember2021-06-300000021076us-gaap:InterestRateContractMember2021-07-012021-09-300000021076us-gaap:InterestRateContractMember2021-06-300000021076us-gaap:InterestRateContractMember2021-09-300000021076us-gaap:CommodityContractMember2021-07-012021-09-300000021076us-gaap:CommodityContractMember2020-07-012020-09-300000021076us-gaap:ForeignExchangeContractMember2021-07-012021-09-300000021076us-gaap:ForeignExchangeContractMember2020-07-012020-09-300000021076us-gaap:InterestRateContractMember2020-07-012020-09-300000021076us-gaap:CommodityContractMemberclx:SoybeanOilFuturesMember2021-09-300000021076us-gaap:CommodityContractMemberclx:SoybeanOilFuturesMember2021-06-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-09-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Member2021-06-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-09-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:CommodityContractMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2021-06-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMember2021-09-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignExchangeForwardMember2021-06-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2021-09-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateContractMember2021-06-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-09-300000021076us-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMember2021-06-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CashAndCashEquivalentsMember2021-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2021-09-300000021076us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CashAndCashEquivalentsMember2021-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:CashAndCashEquivalentsMember2021-06-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CashAndCashEquivalentsMember2021-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMemberus-gaap:CashAndCashEquivalentsMember2021-09-300000021076us-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:CashAndCashEquivalentsMember2021-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberus-gaap:BankTimeDepositsMemberus-gaap:CashAndCashEquivalentsMember2021-06-300000021076clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2021-09-300000021076clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherAssetsMember2021-06-300000021076us-gaap:ShortTermDebtMemberclx:NotesAndLoansPayableMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ShortTermDebtMemberclx:NotesAndLoansPayableMemberus-gaap:FairValueInputsLevel2Member2021-09-300000021076us-gaap:ShortTermDebtMemberclx:NotesAndLoansPayableMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CarryingReportedAmountFairValueDisclosureMember2021-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:ShortTermDebtMemberclx:NotesAndLoansPayableMemberus-gaap:FairValueInputsLevel2Member2021-06-300000021076us-gaap:FairValueInputsLevel2Memberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LongTermDebtMember2021-09-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:LongTermDebtMember2021-09-300000021076us-gaap:FairValueInputsLevel2Memberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberus-gaap:LongTermDebtMember2021-06-300000021076us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Memberclx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMemberus-gaap:LongTermDebtMember2021-06-300000021076us-gaap:CommonStockMember2020-06-300000021076us-gaap:AdditionalPaidInCapitalMember2020-06-300000021076us-gaap:RetainedEarningsMember2020-06-300000021076us-gaap:TreasuryStockMember2020-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000021076us-gaap:NoncontrollingInterestMember2020-06-300000021076us-gaap:RetainedEarningsMember2020-07-012020-09-300000021076us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000021076us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000021076us-gaap:TreasuryStockMember2020-07-012020-09-300000021076us-gaap:CommonStockMember2020-09-300000021076us-gaap:AdditionalPaidInCapitalMember2020-09-300000021076us-gaap:RetainedEarningsMember2020-09-300000021076us-gaap:TreasuryStockMember2020-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000021076us-gaap:NoncontrollingInterestMember2020-09-300000021076us-gaap:CommonStockMember2021-06-300000021076us-gaap:AdditionalPaidInCapitalMember2021-06-300000021076us-gaap:RetainedEarningsMember2021-06-300000021076us-gaap:TreasuryStockMember2021-06-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000021076us-gaap:NoncontrollingInterestMember2021-06-300000021076us-gaap:RetainedEarningsMember2021-07-012021-09-300000021076us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000021076us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000021076us-gaap:TreasuryStockMember2021-07-012021-09-300000021076us-gaap:CommonStockMember2021-09-300000021076us-gaap:AdditionalPaidInCapitalMember2021-09-300000021076us-gaap:RetainedEarningsMember2021-09-300000021076us-gaap:TreasuryStockMember2021-09-300000021076us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000021076us-gaap:NoncontrollingInterestMember2021-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-07-012020-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-06-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-07-012021-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000021076us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000021076us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-09-300000021076us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000021076clx:LongTermInterCompanyLoansMember2020-07-012020-09-300000021076clx:LongTermInterCompanyLoansMember2021-07-012021-09-300000021076clx:RetirementIncomeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000021076clx:RetirementIncomeMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000021076clx:RetirementIncomeMembercountry:US2021-07-012021-09-300000021076clx:RetirementIncomeMembercountry:US2020-07-012020-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2021-06-300000021076clx:AlamedaCountyCaliforniaMatterMember2021-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2021-07-012021-09-300000021076clx:AlamedaCountyCaliforniaMatterMember2017-06-300000021076clx:DickinsonCountyMichiganMatterMember2021-09-300000021076clx:DickinsonCountyMichiganMatterMember2021-06-300000021076clx:DickinsonCountyMichiganMatterMember2021-07-012021-09-30clx:reportableSegment0000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2021-07-012021-09-300000021076us-gaap:OperatingSegmentsMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2021-07-012021-09-300000021076us-gaap:OperatingSegmentsMemberclx:HouseholdMember2020-07-012020-09-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2021-07-012021-09-300000021076us-gaap:OperatingSegmentsMemberclx:LifestyleMember2020-07-012020-09-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2021-07-012021-09-300000021076us-gaap:OperatingSegmentsMemberclx:InternationalMember2020-07-012020-09-300000021076us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000021076us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberclx:WalmartStoresIncMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMemberclx:WalmartStoresIncMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:CleaningMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:CleaningMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:ProfessionalProductsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:ProfessionalProductsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:VitaminsMineralsAndSupplementsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:VitaminsMineralsAndSupplementsMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HealthAndWellnessMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:BagsWrapsAndContainersMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:BagsWrapsAndContainersMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:CatLitterMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:CatLitterMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:GrillingMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:GrillingMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:HouseholdMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberclx:FoodProductsMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberclx:FoodProductsMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMemberclx:NaturalPersonalCareMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMemberclx:NaturalPersonalCareMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberclx:WaterFiltrationMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberclx:WaterFiltrationMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberclx:LifestyleMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:InternationalMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMemberclx:InternationalMember2020-07-012020-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2021-07-012021-09-300000021076us-gaap:RevenueFromContractWithCustomerMemberus-gaap:ProductConcentrationRiskMember2020-07-012020-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2021.
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                to
Commission File Number: 1-07151
clx-20210930_g1.jpg
THE CLOROX COMPANY
(Exact name of registrant as specified in its charter) 
Delaware31-0595760
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1221 Broadway, Oakland, California, 94612-1888
(Address of principal executive offices) (Zip code)
(510) 271-7000
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
___________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock - $1.00 par valueCLXNew York Stock Exchange
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.  
Large accelerated filer☑Accelerated filer☐Non-accelerated filer☐Smaller Reporting Company☐Emerging Growth Company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑
 
As of October 19, 2021, there were 122,862,766 shares outstanding of the registrant’s common stock ($1.00 par value).
1

PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
The Clorox Company
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)
(Dollars in millions, except per share data)
Three Months Ended
9/30/20219/30/2020
Net sales$1,806 $1,916 
Cost of products sold1,136 996 
Gross profit670 920 
Selling and administrative expenses236 238 
Advertising costs182 179 
Research and development costs33 32 
Interest expense25 25 
Other (income) expense, net9 (80)
Earnings before income taxes185 526 
Income taxes42 109 
Net earnings143 417 
Less: Net earnings attributable to noncontrolling interests12 
Net earnings attributable to Clorox$142 $415 
Net earnings per share attributable to Clorox
Basic net earnings per share$1.15 $3.28 
Diluted net earnings per share$1.14 $3.22 
Weighted average shares outstanding (in thousands)
Basic122,980 126,346 
Diluted124,042 128,729 
Comprehensive income$122 $434 
Less: Total comprehensive income attributable to noncontrolling interests12 
Total comprehensive income attributable to Clorox$121 $432 

See Notes to Condensed Consolidated Financial Statements (Unaudited)
2

The Clorox Company
Condensed Consolidated Balance Sheets
(Dollars in millions, except per share data)
9/30/20216/30/2021
(Unaudited)
ASSETS
Current assets
Cash and cash equivalents$210 $319 
Receivables, net654 604 
Inventories, net785 752 
Prepaid expenses and other current assets171 154 
Total current assets1,820 1,829 
Property, plant and equipment, net of accumulated depreciation and amortization
        of $2,422 and $2,382, respectively
1,301 1,302 
Operating lease right-of-use assets310 332 
Goodwill1,566 1,575 
Trademarks, net691 693 
Other intangible assets, net218 225 
Other assets368 378 
Total assets$6,274 $6,334 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Notes and loans payable$86 $— 
Current maturities of long-term debt899 300 
Current operating lease liabilities72 81 
Accounts payable and accrued liabilities1,582 1,675 
Total current liabilities2,639 2,056 
Long-term debt1,885 2,484 
Long-term operating lease liabilities288 301 
Other liabilities846 834 
Deferred income taxes69 67 
Total liabilities5,727 5,742 
Commitments and contingencies
Stockholders’ equity
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding
— — 
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September 30, 2021 and June 30, 2021; and 122,856,251 and 122,780,220 shares outstanding as of September 30, 2021 and June 30, 2021, respectively
131 131 
Additional paid-in capital1,166 1,186 
Retained earnings1,027 1,036 
Treasury stock, at cost: 7,885,210 and 7,961,241 shares as of September 30, 2021
        and June 30, 2021, respectively
(1,389)(1,396)
Accumulated other comprehensive net (loss) income(567)(546)
Total Clorox stockholders’ equity368 411 
Noncontrolling interests179 181 
Total stockholders’ equity547 592 
Total liabilities and stockholders’ equity$6,274 $6,334 

See Notes to Condensed Consolidated Financial Statements (Unaudited)
3

The Clorox Company
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in millions)
Three Months Ended
9/30/20219/30/2020
Operating activities:
Net earnings$143 $417 
Adjustments to reconcile net earnings to net cash provided by operations:
Depreciation and amortization55 51 
Stock-based compensation9 13 
Deferred income taxes2 20 
Other8 (71)
Changes in:
Receivables, net(53)(8)
Inventories, net(37)(70)
Prepaid expenses and other current assets(14)(18)
Accounts payable and accrued liabilities(96)20 
Operating lease right-of-use assets and liabilities, net— (1)
Income taxes payable / prepaid24 30 
Net cash provided by operations41 383 
Investing activities:
Capital expenditures(52)(69)
Businesses acquired, net of cash acquired— (85)
Other(4)3 
Net cash used for investing activities(56)(151)
Financing activities:
Notes and loans payable, net86 — 
Treasury stock purchased(25)(100)
Cash dividends paid to Clorox stockholders(142)(140)
Issuance of common stock for employee stock plans and other(11)(7)
Net cash used for financing activities(92)(247)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash(3)3 
Net increase (decrease) in cash, cash equivalents, and restricted cash(110)(12)
Cash, cash equivalents, and restricted cash:
Beginning of period324 879 
End of period$214 $867 


See Notes to Condensed Consolidated Financial Statements (Unaudited)
4

The Clorox Company
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in millions, except per share data)

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.
5

NOTE 2. BUSINESS ACQUIRED

Saudi Joint Venture Acquisition

On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture) from 30 percent to 51 percent. The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. With the additional investment, the Company has consolidated this joint venture into its consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests. As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, noncash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021.

The Saudi joint venture acquisition was accounted for under the acquisition method of accounting for business combinations. The total purchase consideration was $111 consisting of $100 cash paid and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date. The fair value of the total net assets and noncontrolling interests recorded as of the date of acquisition was $412 and $198, respectively. The purchase price allocation was finalized during the second quarter of fiscal year 2021.

Refer to the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 for the final purchase price allocation, valuation methodology and other information related to the Saudi joint venture acquisition.



6

NOTE 3. INVENTORIES, NET
Inventories, net, consisted of the following as of:
9/30/20216/30/2021
Finished goods$594 $543 
Raw materials and packaging220 229 
Work in process13 11 
LIFO allowances(42)(31)
Total$785 $752 


NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of September 30, 2021, the notional amount of commodity derivatives was $35, of which $24 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2021, the notional amount of commodity derivatives was $32, of which $23 related to soybean oil futures and $9 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $50 and $70, respectively, as of September 30, 2021 and June 30, 2021.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.

The notional amounts of outstanding interest rate contracts used by the Company were $300 as of both September 30, 2021 and June 30, 2021. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.

Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.
7
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contracts$— $1 
Foreign exchange derivative contracts1 (1)
Interest rate derivative contracts3 3 
Total$4 $3 

Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contractsCost of products sold$5 $(1)
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$3 $(3)

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2021, that is expected to be reclassified into Net earnings (losses) within the next twelve months is $7.

Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of both September 30, 2021 and June 30, 2021, $0 contained such terms. As of September 30, 2021 and June 30, 2021, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2021 and June 30, 2021, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2021 and June 30, 2021, the Company maintained cash margin balances related to exchange-traded futures contracts of $2 and $0, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.






8
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
Trust Assets

The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value of Financial Instruments

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2021 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
9
NOTE 4. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Continued)
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsPrepaid expenses and other current assets1$1 $1 $5 $5 
Commodity purchase swaps contractsPrepaid expenses and other current assets24 4 4 4 
Foreign exchange forward contractsPrepaid expenses and other current assets22 2 — — 
Interest rate contractsPrepaid expenses and other current assets226 26 24 24 
 $33 $33 $33 $33 

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
equivalents (1)
1$98 $98 $196 $196 
Time deposits
Cash and cash
equivalents (1)
21 1 11 11 
Trust assets for nonqualified deferred compensation plansOther assets1142 142 136 136 
 $241 $241 $343 $343 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$86 $86 $— $— 
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (3)
22,784 2,943 2,784 2,963 
$2,870 $3,029 $2,784 $2,963 

(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.
(3)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.


10

NOTE 5. INCOME TAXES
In determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 22.6% and 20.7% for the three months ended September 30, 2021, and 2020, respectively. The lower effective tax rate in the prior period was primarily due to the non-taxable portion of the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.


NOTE 6. NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20219/30/2020
Basic122,980126,346
Dilutive effect of stock options and other1,0622,383
Diluted124,042128,729
Antidilutive stock options and other1,068441 

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.


NOTE 7. COMPREHENSIVE INCOME
The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20219/30/2020
Net earnings $143 $417 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments(23)10 
Net unrealized gains (losses) on derivatives1 5 
Pension and postretirement benefit adjustments1 2 
Total other comprehensive (loss) income, net of tax(21)17 
Comprehensive income122 434 
Less: Total comprehensive income attributable to noncontrolling interests1 2 
Total comprehensive income attributable to Clorox$121 $432 


11

NOTE 8. STOCKHOLDERS’ EQUITY

Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interestsTotal Stockholders’ Equity
AmountShares AmountShares
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings— — — 415 — — — 2 417 
Other comprehensive (loss) income— — — — — — 17 — 17 
Dividends to Clorox stockholders ($1.11 per share declared)
— — — (141)— — — — (141)
Dividends to non-controlling interests— — — — — — — (4)(4)
Business combinations including purchase accounting adjustments— — — — — — — 198 198 
Stock-based compensation— — 13 — — — — — 13 
Other employee stock plan activities— — (4)(1)8 283 — — 3 
Treasury stock purchased— — — — (100)(444)— — (100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 
Balance as of June 30, 2021$131 130,741 $1,186 $1,036 $(1,396)(7,961)$(546)$181 $592 
Net earnings— — — 142 — — — 1 143 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($1.16 per share declared)
— — — (143)— — — — (143)
Dividends to non-controlling interests— — — — — — — (3)(3)
Stock-based compensation— — 9 — — — — — 9 
Other employee stock plan activities— — (29)(8)32 228 — — (5)
Treasury stock purchased— — — — (25)(152)— — (25)
Balance as of September 30, 2021$131 130,741 $1,166 $1,027 $(1,389)(7,885)$(567)$179 $547 





12
NOTE 8. STOCKHOLDERS’ EQUITY (Continued)
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense)1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)
Balance as of June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before reclassifications(22)4 — (18)
Amounts reclassified from Accumulated other comprehensive net (loss) income— (3)2 (1)
Income tax benefit (expense), and other(1)— (1)(2)
Net current period other comprehensive (loss) income(23)1 1 (21)
Balance as of September 30, 2021$(426)$22 $(163)$(567)

Included in foreign currency translation adjustments are remeasurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
13

NOTE 9. EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20219/30/2020
Service cost$— $— 
Interest cost4 4 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items2 3 
Total$2 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2021 and 2020.
During the three months ended September 30, 2021 and 2020, the Company made $3 and $2 in contributions to its domestic retirement income plans, respectively.
Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs, all other components are reflected in Other (income) expense, net.
14

NOTE 10. OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both September 30, 2021 and June 30, 2021, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of both September 30, 2021 and June 30, 2021, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2021 and June 30, 2021. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2021 and June 30, 2021.
As of September 30, 2021, the Company was party to a letter of credit of $14, related to one of its insurance carriers, of which $0 had been drawn upon.


15

NOTE 11. SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20219/30/2020
Health and Wellness$745 $813 
Household442 500 
Lifestyle331 318 
International288 285 
Corporate— — 
Total$1,806 $1,916 
Earnings (losses) before income taxes
Three Months Ended
9/30/20219/30/2020
Health and Wellness $105 $251 
Household36 109 
Lifestyle93 102 
International30 124 
Corporate(79)(60)
Total$185 $526 
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% for the three months ended September 30, 2021, and 2020.
16
NOTE 11. SEGMENT RESULTS (Continued)
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:
Net sales
Three Months Ended
9/30/20219/30/2020
Cleaning33 %29 %
Professional Products5 %9 %
Vitamins, Minerals and Supplements3 %4 %
Health and Wellness41 %42 %
Bags and Wraps12 %11 %
Cat Litter7 %6 %
Grilling6 %9 %
Household25 %26 %
Food Products9 %9 %
Natural Personal Care4 %4 %
Water Filtration5 %4 %
Lifestyle18 %17 %
International16 %15 %
Total100 %100 %



17

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The Clorox Company
(Dollars in millions, except per share data)
Management’s Discussion and Analysis of Financial Condition and Results of Operations (MD&A) is designed to provide a reader of The Clorox Company’s (the Company or Clorox) financial statements with a narrative from the perspective of management on the Company’s financial condition, results of operations, liquidity and certain other factors that may affect future results. The following discussion of the Company’s financial condition and results of operations should be read in conjunction with MD&A and the consolidated financial statements and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, which was filed with the SEC on August 10, 2021, and the unaudited condensed consolidated financial statements and related notes contained in this Quarterly Report on Form 10-Q (this Report). Unless otherwise noted, MD&A compares the three month period ended September 30, 2021 (the current period) to the three month period ended September 30, 2020 (the prior period), with percentage and basis point calculations based on rounded numbers, except for per share data and the effective tax rate.

EXECUTIVE OVERVIEW
Clorox is a leading multinational manufacturer and marketer of consumer and professional products with approximately 9,000 employees worldwide. Clorox sells its products primarily through mass retailers, grocery outlets, warehouse clubs, dollar stores, home hardware centers, drug, pet and military stores, third-party and owned e-commerce channels, and distributors. Clorox markets some of the most trusted and recognized consumer brand names, including its namesake bleach and cleaning products, Pine-Sol® cleaners; Liquid-Plumr® clog removers; Poett® home care products; Fresh Step® cat litter; Glad® bags and wraps; Kingsford® grilling products; Hidden Valley® dressings, dips, seasonings and sauces; Brita® water-filtration systems and filters; Burt’s Bees® natural personal care products; and RenewLife®, Rainbow Light®, Natural Vitality® and NeoCell® vitamins, minerals and supplements. The Company also markets industry-leading products and technologies for professional customers, including those sold under the CloroxPro™ and Clorox Healthcare® brand names. The Company has operations in more than 25 countries or territories and sells its products in more than 100 markets.
The Company primarily markets its leading brands in midsized categories considered to be financially attractive. Most of the Company’s products compete with other nationally advertised brands within each category and with “private label” brands.

The Company operates through strategic business units (SBUs) which are also the Company’s operating segments. These SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. These four reportable segments consist of the following:
•Health and Wellness consists of cleaning products, professional products and vitamins, minerals and supplement products mainly marketed and sold in the U.S. Products within this segment include cleaning products such as laundry additives and home care products, primarily under the Clorox®, Clorox2®, Scentiva®, Pine-Sol®, Liquid-Plumr®, Tilex® and Formula 409® brands; professional cleaning and disinfecting products under the CloroxPro™, Clorox Healthcare® and Clorox® TurboProTM brands; professional food service products under the Hidden Valley® brand; and vitamins, minerals and supplement products under the RenewLife®, Natural Vitality®, NeoCell® and Rainbow Light® brands.

•Household consists of cat litter products, bags and wraps and grilling products marketed and sold in the U.S. Products within this segment include cat litter products under the Fresh Step®, Scoop Away® and Ever Clean® brands, bags and wraps under the Glad® brand; and grilling products under the Kingsford® brand.

•Lifestyle consists of food, natural personal care products and water-filtration marketed and sold in the U.S. Products within this segment include dressings, dips, seasonings and sauces, primarily under the Hidden Valley® brand; natural personal care products under the Burt’s Bees® brand; and water-filtration systems and filters under the Brita® brand.

•International consists of products sold outside the U.S. Products within this segment include laundry additives; home care products; water-filtration systems and filters; digestive health products; grilling products; cat litter products; food products; bags and wraps; natural personal care products; and professional cleaning and disinfecting products marketed primarily under the Clorox®, Ayudin®, Clorinda®, Poett®, Pine-Sol®, Glad®, Brita®, RenewLife®, Ever Clean® and Burt’s Bees® brands.

18

RECENT EVENTS RELATED TO COVID-19

For our fiscal quarter ended September 30, 2021, the coronavirus (COVID-19) pandemic continued to cause economic and social disruptions that led to ongoing uncertainties. Demand for many of the products across the Company portfolio remained elevated compared to pre-pandemic levels even while U.S. consumers continued to adjust some behaviors as vaccination rates improved. The Company expects a continuing inflationary environment, marked by higher manufacturing and logistics costs as well as increased commodity costs. While we have not experienced significant disruptions in our operations during fiscal year 2022 to date, risks of future negative impacts due to transportation, logistical or supply constraints and higher commodity costs for certain raw materials remain present. We are continuing to address these impacts to our operations.

We have taken an active role in addressing the ongoing pandemic’s impact on our employees, operations, customers, consumers and communities, including taking precautionary measures, such as implementing contingency plans, making operational adjustments where necessary, and providing support to organizations that support front-line workers. As the world moves into new phases of the pandemic, the Company will continue to focus on these priorities, while continuing to strive to serve people as consumer behaviors evolve inside and outside the home.

The extent of COVID-19’s effect on the Company’s operational and financial performance in the future will depend on future developments, including the duration, spread and intensity of the pandemic in different countries, the emergence of COVID-19 variants and the effectiveness of vaccines against these variants, the Company’s continued ability to manufacture and distribute its products, any future government actions affecting consumers and the economy in general, and timing and effectiveness of global vaccines, all of which are uncertain and difficult to predict considering the rapidly evolving landscape as the Company continues to expect a variable operating environment going forward.

For additional information on the impacts and our response to the coronavirus pandemic, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.


RESULTS OF OPERATIONS
CONSOLIDATED RESULTS
Three Months Ended
9/30/20219/30/2020% Change
Net sales$1,806 $1,916 (6)%
Three Months Ended September 30, 2021
Percentage change versus the year-ago period
Reported (GAAP) Net Sales Growth / (Decrease)Reported VolumeAcquisitions & DivestituresForeign Exchange Impact
Price/Mix/Other (1)
Organic Sales Growth / (Decrease) (Non-GAAP) (2)
Organic Volume (3)
Health and Wellness(8)%(1)%— %— %(7)%(8)%(1)%
Household(12)(8)— — (4)(12)(8)
Lifestyle4 5 — — (1)4 5 
International1 (1)— (2)4 3 (1)
Total(6)%(2)%— %(1)%(3)%(5)%(2)%

(1) This represents the net impact on net sales growth / (decrease) from pricing actions, mix and other factors.
(2) Organic sales growth/ (decrease) is defined as net sales growth/ (decrease) excluding the effect of any acquisitions and divestitures and foreign exchange rate changes. See “Non-GAAP Financial Information” below for reconciliation of organic sales growth to net sales growth/ (decrease), the most directly comparable GAAP financial information.
(3) Organic volume represents volume excluding the effect of any acquisitions and divestitures.


19

Net sales in the current period decreased by 6%, reflecting lower shipments primarily in the Health and Wellness and Household reportable segments, partially offset by higher shipments in the Lifestyle reportable segment. Volume decreased by 2% versus the prior period. The variance between volume and net sales was primarily due to the impacts of unfavorable price mix and foreign currency exchange rates.


Three Months Ended
9/30/20219/30/2020% Change
Gross profit$670 $920 (27)%
Gross margin37.1 %48.0 %

Gross margin decreased by 1090 basis points in the current period from 48.0% to 37.1%. The decrease was primarily driven by unfavorable commodity costs and higher manufacturing and logistics costs.

Expenses
Three Months Ended
% of Net Sales
9/30/20219/30/2020% Change9/30/20219/30/2020
Selling and administrative expenses$236 $238 (1)%13.1 %12.4 %
Advertising costs182 179 2 10.1 9.3 
Research and development costs33 32 3 1.8 1.7 

Selling and administrative expenses, as a percentage of net sales, were essentially flat in the current period as compared to the prior period.

Advertising costs, as a percentage of net sales, increased by 80 basis points in the current period. The Company’s U.S. retail advertising spend as a percentage of net sales was approximately 11% in the current and prior periods.

Research and development costs, as a percentage of net sales, were essentially flat in the current period as compared to the prior period. The Company continues to invest behind product innovation and cost savings.

Interest expense, Other (income) expense, net, and the effective tax rate on earnings
Three Months Ended
9/30/20219/30/2020
Interest expense$25 $25 
Other (income) expense, net9 (80)
Effective tax rate on earnings (losses)22.6 %20.7 %

Other (income) expense, net was $9 and ($80) in the current and prior period, respectively. The variance was primarily due to the one-time, noncash remeasurement gain recognized in the prior period from the Company’s previously held equity interest in the Kingdom of Saudi Arabia (Saudi joint venture).

The effective tax rate on earnings (losses) was 22.6% and 20.7% for the current and prior period, respectively. The lower effective tax rate in the prior period was primarily due to the non-taxable portion of the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.

Diluted net earnings per share
Three Months Ended
9/30/20219/30/2020% Change
Diluted net earnings per share$1.14 $3.22 (65)%

20

Diluted net earnings per share (EPS) decreased by $2.08, or 65%, in the current period, primarily due to lower gross margin and lower net sales, in addition to the one-time, noncash remeasurement gain recognized on the previously held equity interest in the Saudi joint venture in the prior period.


SEGMENT RESULTS

The following presents the results of the Company’s reportable segments and certain unallocated costs reflected in Corporate
(see Notes to Condensed Consolidated Financial Statements for a reconciliation of segment results to consolidated results):

Health and Wellness
Three Months Ended
9/30/20219/30/2020% Change
Net sales$745 $813 (8)%
Earnings before income taxes105 251 (58)

Volume, net sales and earnings before income taxes decreased by 1%, 8% and 58%, respectively, during the current period. The volume decrease was primarily driven by lower shipments in the Professional Products portfolio as customers continued to work through high inventory levels, partially offset by higher shipments in Cleaning primarily driven by COVID-19 Delta variant trends, merchandising support and increased supply. The variance between volume and net sales was primarily due to unfavorable mix, partially offset by lower trade promotion. The decrease in earnings before income taxes in the current period was primarily due to unfavorable mix, higher manufacturing and logistics costs and unfavorable commodity costs.


Household
Three Months Ended
9/30/20219/30/2020% Change
Net sales$442 $500 (12)%
Earnings before income taxes36 109 (67)

Volume, net sales and earnings before income taxes decreased by 8%, 12% and 67%, respectively, during the current period. The volume decrease was primarily driven by lower shipments in Grilling due to higher demand and retailer inventory builds in the prior period, partially offset by higher shipments in Litter due to a shift in timing of merchandising support in the club channel, innovation and continued growth in the ecommerce channel. The variance between volume and net sales was primarily due to unfavorable mix, partially offset by lower trade promotion. The decrease in earnings before income taxes was mainly due to unfavorable commodity costs and lower net sales.


Lifestyle
 
Three Months Ended
9/30/20219/30/2020% Change
Net sales$331 $318 4 %
Earnings before income taxes93 102 (9)

Volume and net sales increased by 5% and 4%, respectively, and earnings before income taxes decreased by 9% during the current period. Both volume and net sales growth were primarily driven by higher shipments of Brita water-filtration products due to merchandising support and Natural Personal Care products mainly due to higher consumption in key categories previously impacted by lower store traffic, increased merchandising support and earlier shipments of holiday gift packs as compared to the prior period. The decrease in earnings before income taxes was primarily due to unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by net sales growth.



21

International
Three Months Ended
9/30/20219/30/2020% Change
Net sales$288 $285 1 %
Earnings before income taxes30 124 (76)

Volume decreased by 1%, net sales increased by 1% and earnings before income taxes decreased by 76% during the current period. The variance between volume and net sales was mainly due to the benefit of price increases, partially offset by unfavorable mix and foreign currency exchange rates. The decrease in earnings before income taxes was primarily due to the one-time, noncash remeasurement gain recognized on the previously held equity interest in the Saudi joint venture recognized in the prior period, unfavorable commodity costs and higher manufacturing and logistics costs, partially offset by the benefit of price increases.

Argentina

Effective July 1, 2018, under the requirements of U.S. GAAP, Argentina was designated as a highly inflationary economy, and as a result the U.S. dollar replaced the Argentine peso as the functional currency of the Company’s subsidiaries in Argentina. Consequently, gains and losses from non-U.S. dollar denominated monetary assets and liabilities of Clorox Argentina are recognized in Other (income) expense, net in the condensed consolidated statement of earnings. The business environment in Argentina continues to be challenging due to significant volatility in Argentina’s currency, high inflation, economic recession, impacts of COVID-19 and temporary price controls. As of September 30, 2021 and June 30, 2021, the net asset position, excluding goodwill, of Clorox Argentina was $45 and $48, respectively. Of these net assets, cash balances were approximately $7 and $11 as of September 30, 2021 and June 30, 2021, respectively. Net sales from Clorox Argentina represented approximately 2% of the Company’s consolidated net sales for the three months ended September 30, 2021 and the fiscal year ended June 30, 2021.

For additional information on the impacts of, and our response to, the business environment in Argentina, refer to “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.

Corporate

Corporate includes certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses.
Three Months Ended
9/30/20219/30/2020% Change
Losses before income taxes$(79)$(60)32 %

Losses before income taxes increased by $19 in the current three month period primarily due to the investments in the Company’s digital capabilities and productivity enhancements beginning in the current period.
22

FINANCIAL POSITION AND LIQUIDITY
The Company’s financial condition and liquidity remained strong as of September 30, 2021. The following table summarizes cash activities:
Three Months Ended
9/30/20219/30/2020
Net cash provided by operations$41 $383 
Net cash used for investing activities(56)(151)
Net cash used for financing activities(92)(247)

Operating Activities

Net cash provided by operations was $41 in the current three month period, compared with $383 in the prior three month period. The decrease was primarily driven by lower cash earnings in the current period, higher working capital mainly due to decreased Accounts payable and accrued expenses driven by timing of payments in the current period, partially offset by lower employee incentive compensation and tax payments in the current period.

Investing Activities

Net cash used for investing activities was $56 in the current three month period, compared with $151 in the prior three month period. The year-over-year decrease was mainly due to the acquisition of an additional interest in the Company’s Saudi joint venture in the prior period.

Financing Activities

Net cash used for financing activities was $92 in the current three month period, compared with $247 in the prior three month period. The year-over-year decrease was mainly due to higher cash sourced from short-term borrowings and lower treasury stock purchases in the current period.

Capital Resources and Liquidity

Global financial markets have experienced a significant increase in volatility due to heightened uncertainty over the adverse economic impact caused by the COVID-19 outbreak. Notwithstanding these potential adverse market conditions, the Company believes it will have the funds necessary to support our short-term liquidity and operating needs based on our anticipated ability to generate positive cash flows from operations in the future, access to capital markets enabled by our strong short-term and long-term credit ratings, and current borrowing availability under the credit agreement.

Credit Arrangements

As of September 30, 2021, the Company maintained a $1,200 revolving credit agreement that matures in November 2024 (the Credit Agreement). There were no borrowings under the Credit Agreement as of September 30, 2021 and June 30, 2021, and the Company believes that borrowings under the Credit Agreement are and will continue to be available for general corporate purposes. The Credit Agreement includes certain restrictive covenants and limitations. The primary restrictive covenant is a minimum ratio of 4.0, calculated as total earnings before interest, taxes, depreciation and amortization and other similar non-cash charges (Consolidated EBITDA) to total interest expense for the trailing four quarters (Interest Coverage ratio), as defined and described in the Credit Agreement.

The Company was in compliance with all restrictive covenants and limitations in the Credit Agreement as of September 30, 2021, and anticipates being in compliance with all restrictive covenants for the foreseeable future.

As of September 30, 2021, the Company maintained $34 of foreign and other credit lines, of which $3 was outstanding.

23

Stock Repurchases and Dividend Payments

As of September 30, 2021, the Company had two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date. During the three months ended September 30, 2021 and 2020, the Company repurchased 152 and 444 thousand shares of common stock at a cost of $25 and $100, respectively.

Dividends per share declared and total dividends paid to Clorox stockholders were as follows for the periods indicated:
Three Months Ended
9/30/20219/30/2020
Dividends per share declared$1.16 $1.11 
Total dividends paid142 140 

24

CONTINGENCIES
See Notes to Condensed Consolidated Financial Statements for information on the Company’s contingencies.

RECENTLY ISSUED ACCOUNTING STANDARDS
See Notes to Condensed Consolidated Financial Statements for a summary of recently issued accounting standards relevant to the Company.

NON-GAAP FINANCIAL MEASURES

The non-GAAP financial measures that are included in this MD&A and the reasons management believes they are useful to investors are described below. These measures should be considered supplemental in nature and are not intended to be a substitute for the related financial information prepared in accordance with U.S. GAAP. In addition, these measures may not be the same as similarly named measures presented by other companies.

Organic sales growth / (decrease) is defined as net sales growth / (decrease) excluding the effect of foreign exchange rate changes and any acquisitions and divestitures. Management believes that the presentation of organic sales growth / (decrease) is useful to investors because it excludes sales from any acquisitions and divestitures, which results in a comparison of sales only from the businesses that the Company was operating throughout the relevant periods, and the impact of foreign exchange rate changes, which are out of the control of the Company and management.

The following table provides a reconciliation of organic sales growth / (decrease) (non-GAAP) to net sales growth / (decrease) (GAAP), the most comparable GAAP measure:
Three Months Ended September 30, 2021
Percentage change versus the year-ago period
Health and WellnessHouseholdLifestyleInternationalTotal
Net sales growth / (decrease) (GAAP)(8)%(12)%4 %1 %(6)%
Add: Foreign Exchange— — — 2 1 
Add/(Subtract): Divestitures/Acquisitions— — — — — 
Organic sales growth / (decrease) (non-GAAP)(8)%(12)%4 %3 %(5)%

25

Cautionary Statement
This Report, including the exhibits hereto and the information incorporated by reference herein, contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of governments, consumers, customers, suppliers, employees and the Company, on our business, operations, employees, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, organic sales growth, foreign currencies, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, foreign currency exchange rates, tax rates, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “will,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021, and in this Report, as updated from time to time in the Company’s Securities and Exchange Commission filings. These factors include, but are not limited to:
•intense competition in the Company’s markets;
•the impact of the changing retail environment, including the growth of alternative retail channels and business models, and changing consumer preferences;
•the impact of COVID-19 on the availability of, and efficiency of the supply, manufacturing and distribution systems for, the Company’s products, including any significant disruption to such systems; on the demand for the Company’s products; and on worldwide, regional and local adverse economic conditions, including increased risk of inflation;
•volatility and increases in the costs of raw materials, energy, transportation, labor and other necessary supplies or services;
•risks related to supply chain issues and product shortages as a result of increased supply chain dependencies due to an expanded supplier network and a reliance on certain single-source suppliers;
•risks relating to the significant increase in demand for disinfecting and other products due to the COVID-19 pandemic continuing;
•dependence on key customers and risks related to customer consolidation and ordering patterns;
•risks related to the Company’s use of and reliance on information technology systems, including potential security breaches, cyber-attacks, privacy breaches or data breaches that result in the unauthorized disclosure of consumer, customer, employee or Company information, or service interruptions, especially at a time when a large number of the Company’s employees are working remotely and accessing its technology infrastructure remotely;
•the ability of the Company to drive sales growth, increase prices and market share, grow its product categories and manage favorable product and geographic mix;
•risks relating to acquisitions, new ventures and divestitures, and associated costs, including for asset impairment charges related to, among others, intangible assets, including trademarks and goodwill, in particular the impairment charges relating to the carrying value of the Company’s Vitamins, Minerals and Supplements business; and the ability to complete announced transactions and, if completed, integration costs and potential contingent liabilities related to those transactions;
•the Company’s ability to maintain its business reputation and the reputation of its brands and products;
•lower revenue, increased costs or reputational harm resulting from government actions and compliance with regulations, or any material costs imposed by changes in regulation;
•the ability of the Company to successfully manage global political, legal, tax and regulatory risks, including changes in regulatory or administrative activity;
26

•the operations of the Company and its suppliers being subject to disruption by events beyond the Company’s control, including work stoppages, cyber-attacks, weather events or natural disasters, political instability or uncertainty, disease outbreaks or pandemics, such as COVID-19, and terrorism;
•risks related to international operations and international trade, including foreign currency fluctuations, such as devaluations, and foreign currency exchange rate controls; changes in governmental policies, including trade, travel or immigration restrictions, new or additional tariffs, and price or other controls; labor claims and civil unrest; inflationary pressures, particularly in Argentina; impact of the United Kingdom’s exit from the European Union; potential negative impact and liabilities from the use, storage and transportation of chlorine in certain international markets where chlorine is used in the production of bleach; widespread health emergencies, such as COVID-19; and the possibility of nationalization, expropriation of assets or other government action;
•the ability of the Company to innovate and to develop and introduce commercially successful products, or expand into adjacent categories and countries;
•the impact of product liability claims, labor claims and other legal, governmental or tax proceedings, including in foreign jurisdictions and in connection with any product recalls;
•the ability of the Company to implement and generate cost savings and efficiencies, and successfully implement its business strategies;
•the accuracy of the Company’s estimates and assumptions on which its financial projections, including any sales or earnings guidance or outlook it may provide from time to time, are based;
•risks related to additional increases in the estimated fair value of P&G’s interest in the Glad business;
•the performance of strategic alliances and other business relationships;
•the Company’s ability to attract and retain key personnel;
•the impact of Environmental, Social, and Governance (ESG) issues, including those related to climate change and sustainability on our sales, operating costs or reputation;
•environmental matters, including costs associated with the remediation and monitoring of past contamination, and possible increases in costs resulting from actions by relevant regulators, and the handling and/or transportation of hazardous substances;
•the Company’s ability to effectively utilize, assert and defend its intellectual property rights, and any infringement or claimed infringement by the Company of third-party intellectual property rights;
•the effect of the Company’s indebtedness and credit rating on its business operations and financial results and the Company’s ability to access capital markets and other funding sources;
•the Company’s ability to pay and declare dividends or repurchase its stock in the future;
•the impacts of potential stockholder activism; and
•risks related to any litigation associated with the exclusive forum provision in the Company’s bylaws.

The Company’s forward-looking statements in this Report are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this Report. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.

In this Report, unless the context requires otherwise, the terms “the Company,” “Clorox,” “we,” “us,” and “our” refer to The Clorox Company and its subsidiaries.

27

Item 3. Quantitative and Qualitative Disclosures About Market Risk
There have not been any material changes to the Company’s market risk since June 30, 2021. For additional information, refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Exhibit 99.1 of the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021.

Item 4. Controls and Procedures
The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures, as of the end of the period covered by this Report, were effective such that the information required to be disclosed by the Company in reports filed under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
No change in the Company’s internal control over financial reporting occurred during the first fiscal quarter of the fiscal year ending June 30, 2022, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
28

PART II – OTHER INFORMATION
Item 1.A. Risk Factors
For information regarding Risk Factors, please refer to Item 1.A. in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 and the information in “Cautionary Statement” included in this Report.

29

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

In May 2018, the Board of Directors authorized the Company to repurchase up to $2,000 million in shares of common stock on the open market (the 2018 Open-Market Program), which has no expiration date.

In August 1999, the Board of Directors authorized a stock repurchase program to reduce or eliminate dilution upon the issuance of common stock pursuant to the Company’s stock compensation plans (the Evergreen Program). In November 2005, the Board of Directors authorized the extension of the Evergreen Program to reduce or eliminate dilution in connection with issuances of common stock pursuant to the Company’s 2005 Stock Incentive Plan. The Evergreen Program has no expiration date and has no specified limit as to dollar amount and therefore is not included in column [d] below.

The following table sets forth the purchases of the Company’s securities by the Company and any affiliated purchasers within the meaning of Rule 10b-18(a)(3) (17 CFR 240.10b-18(a)(3)) during the first quarter of fiscal year 2022.
[a][b][c][d]
PeriodTotal Number of
Shares Purchased
Average Price Paid
per Share (1)
Total Number of
Shares Purchased as
Part of Publicly
Announced Plans or
Programs		Maximum Number (or
Approximate Dollar
Value) of Shares that
May Yet Be Purchased
Under the Plans or
Programs
July 1 to 31, 2021— $— — $993 million
August 1 to 31, 2021152,470 163.97 152,470 $993 million
September 1 to 30, 2021— — — $993 million
Total152,470 $163.97 152,470 
____________________

(1)Average price paid per share in the period includes commission.
30

Item 6. Exhibits
See Exhibit Index below, which is incorporated by reference herein.
EXHIBIT INDEX
Exhibit No.
101.SCHXBRL Taxonomy Extension Schema Document.
101.CALXBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFXBRL Taxonomy Extension Definition Linkbase Document.
101.LABXBRL Taxonomy Extension Label Linkbase Document.
101.PREXBRL Taxonomy Extension Presentation Linkbase Document.
104Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101).
31

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
THE CLOROX COMPANY
(Registrant)
DATE: November 1, 2021BY/s/ Laura Peck
Laura Peck
Vice President – Chief Accounting Officer and Corporate Controller

32
 EX-10.1 2 clxq1fy22exhibit101.htm EX-10.1 Document

Exhibit 10.1
THE CLOROX COMPANY
ANNUAL INCENTIVE PLAN
As Amended and Restated Effective
as of September 21, 2021

1. Purpose.

The purpose of The Clorox Company Annual Incentive Plan (the “Plan”) is to attract and retain the best available personnel for positions of substantial responsibility and to provide an incentive for employees of The Clorox Company, a Delaware corporation (the “Company”) and its subsidiaries to recognize and reward those employees. The Company’s executives are eligible to earn short‑term incentive awards under this Plan.

2. Definitions. The following terms will have the following meaning for purposes of the Plan:

(a)    "Award" means a bonus paid in cash under the Plan.

(b)    “Board” means the Board of Directors of the Company.

(c)     “Chief Executive Officer” means the chief executive officer of the Company.

(d)    “Code” means the Internal Revenue Code of 1986, as amended.

(e)    “Committee” means the Management Development and Compensation Committee of the Board, or such other Committee designated by the Board to administer the Plan.

(f)    “Employee” means any person employed by the Company or any Subsidiary.

(g)    “Executive Committee” means the executives who are members of the Company’s management executive committee.

(h)    “Vice President” means a regular salaried Employee scheduled to work more than 20 hours per week who is in salary grade 30 or above and who is not a member of the Executive Committee, but is a Vice President.

(i)    “Participant” means an Employee selected by the Committee to participate in the Plan.

(j)    “Retirement” means termination of employment with the Company, other than by reason of death or disability, (1) at age 65, (2) at least age 55 with at least ten years of vesting service, which solely for purposes of this Plan, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Participant with respect to the 401(k) Plan or (3) with at least 20 years of vesting service (as defined in clause (2)).

(k)    “Subsidiary” means any corporation in which the Company, directly or indirectly, controls 50 percent or more of the total combined voting power of all classes of stock.

(l)    “Year” means a fiscal year of the Company.



3. Awards.

(a)    Within 90 days after the beginning of each Year, the Committee will select Participants for the Year and establish in writing the method by which the Awards will be calculated for that Year. The Committee may provide for payment of all or part of the Award in the case of retirement, death, disability or change of ownership of control of the Company or a Subsidiary during the Year in accordance with Section 409A (as defined in Section 16 below).

(b)    For the Chief Executive Officer and the Executive Committee, the Committee shall determine and certify the amount of the Award, if any, to be made. The Committee may decrease or eliminate any Award calculated under the methodology established in accordance with paragraph (a) in order to reflect additional considerations relating to performance.

(c)     For Vice Presidents and all other participants, the Chief Executive Officer shall determine and certify the amount of the Award, if any, to be made. The Chief Executive Officer may increase, decrease or eliminate, any Award calculated under the methodology established in accordance with paragraph (a) in order to reflect additional considerations relating to performance.

(d)    Awards will be paid to the Participants following certification and no later than ninety (90) days following the close of the Year with respect to which the Awards are made, unless all or a portion of a Participant’s Award is deferred pursuant to the Participant’s timely and validly made election made in accordance with such terms as the Company, the Board or a committee thereof may determine. A timely election is one that satisfies the requirements of Section 409A (as defined in Section 16 below) and typically for performance-based compensation must be made at least six months before the end of the Performance Period, provided that the Participant performs services continuously from the later of the beginning of the Performance Period or the date the performance criteria are established through the date an election is made and provided further that in no event may a deferral be made after such compensation has become readily ascertainable as set forth in Section 409A (as defined in Section 16 below).

(e)    The Company shall withhold from the payment of any Award hereunder any amount required to be withheld for taxes.

(f)    In the event of a restatement of the Company’s financial results to correct a material error resulting from fraud or intentional misconduct, as determined by the Board or the Committee, the Board, or the Committee, will review all compensation that was made pursuant to this Plan on the basis of having met or exceeded specific performance targets for performance periods beginning after June 30, 2008 which occur during the years for which financial statements are restated. If a lower payment of performance‑based compensation would have been made to the Participants based upon the restated financial results, the Board or the Committee, as applicable, will, to the extent permitted by governing law and subject to the following sentence, seek to recoup for the benefit of the Company the amount by which the individual Participant’s Award(s) for the restated years exceeded the lower payment that would have been made based on the restated financial results, plus a reasonable rate of interest; provided, however, that neither the Board nor the Committee will seek to recoup Awards paid more than three years prior to the date on which the Company announces the need for the applicable financial statements to be restated. The Board, or the Committee, will only seek to recoup Awards paid to Participants whose fraud or intentional misconduct was a significant contributing factor to the need for such restatement, as determined by the Board or the Committee, as applicable. Notwithstanding the foregoing, this Section 3(f) shall not apply to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”) and subject instead to the clawback provisions contained in the Policy, as provided in Section 7 hereof.

4. Termination of Employment.

Except as may be specifically provided in an Award pursuant to Section 3(a), a Participant shall have no right to an Award under the Plan for any Year in which the Participant is not actively employed by the Company or its Subsidiaries on June 30 of such Year. When establishing Awards each Year, the Committee may also provide that in the event a Participant is not employed by the Company or its Subsidiaries on the date on which the Award is paid, the Participant may forfeit his or her right to the Award paid under the Plan.





5. Administration.

The Plan will be administered by the Committee. The Committee will have the authority to interpret the Plan, to prescribe rules relating to the Plan and to make all determinations necessary or advisable in administering the Plan. Decisions of the Committee with respect to the Plan will be final and conclusive.

6. Unfunded Plan.

Awards under the Plan will be paid from the general assets of the Company, and the rights of Participants under the Plan will be only those of general unsecured creditors of the Company.

7. Clawback.

Awards under the Plan granted to Participants who are “Covered Employees” (as defined in the Policy) are subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.

8. Amendment or Termination of the Plan. The Committee may from time to time suspend, revise, amend or terminate the Plan.

9. Applicable Law.

To the extent not preempted by federal law, the Plan shall be construed in accordance with and governed by the laws of the State of California, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Plan to the substantive law of another jurisdiction.

10. No Rights to Employment.

Nothing contained in the Plan shall give any person the right to be retained in the employment of the Company or any of its Subsidiaries. The Company reserves the right to terminate any Participant at any time for any reason notwithstanding the existence of the Plan.

11. No Assignment.

Except as otherwise required by applicable law, any interest, benefit, payment, claim or right of any Participant under the Plan shall not be sold, transferred, assigned, pledged, encumbered or hypothecated by any Participant and shall not be subject in any manner to any claims of any creditor of any Participant or beneficiary, and any attempt to take any such action shall be null and void. During the lifetime of any Participant, payment of an Award shall only be made to such Participant. Notwithstanding the foregoing, the Committee may establish such procedures as it deems necessary for a Participant to designate a beneficiary to whom any amounts would be payable in the event of any Participant’s death.

12. Gender, Number and References.

Except where otherwise indicated by the context, any masculine term used herein also shall include the feminine, the plural shall include the singular and the singular shall include the plural. Any reference in the Plan to a Section of the Plan either in the Plan or to an act or code or to any section thereof or rule or regulation thereunder shall be deemed to refer to such Section of the Plan, act, code, section, rule or regulation, as may be amended from time to time, or to any successor Section of the Plan, act, code, section, rule or regulation.

13. Severability.

If any one or more of the provisions contained in this Plan, or any application thereof, shall be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein and all other applications thereof shall not in any way be affected or impaired thereby. This Plan shall be construed and enforced as if such invalid, illegal or unenforceable provision has never comprised a part hereof, and the remaining provisions hereof shall remain in full force and effect and shall not be affected by the invalid, illegal or unenforceable provision or by its severance herefrom. In lieu of such invalid, illegal or unenforceable provisions there shall be added automatically as a part hereof a provision as similar in terms and economic effect to such invalid, illegal or unenforceable provision as may be possible and be valid, legal and enforceable.



14. Requirements of Law.

The issuance of cash under the Plan shall be subject to all applicable laws and to such approvals by any governmental agencies or national securities exchanges as may be required.

15. Non‑Exclusive Plan.

The adoption of the Plan by the Board shall not be construed as creating any limitations on the power of the Board or a committee thereof to adopt such other incentive arrangements as it may deem desirable.

16. Section 409A Compliance.

To the extent applicable, it is intended that this Plan and any Awards granted hereunder comply with the requirements of Section 409A of the Code and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision that would cause the Plan or any Award granted hereunder to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.



END OF DOCUMENT

 EX-10.2 3 clxq1fy22exhibit102.htm EX-10.2 Document

Exhibit 10.2
AMENDMENT NO. 1 TO
THIRD AMENDED AND RESTATED
2005 STOCK INCENTIVE PLAN
OF
THE CLOROX COMPANY

This AMENDMENT NO. 1 to the Third Amended and Restated 2005 Stock Incentive Plan (the “Plan”) of The Clorox Company (the “Company”) was approved by the Management Development and Compensation Committee of the Board of Directors of the Company, effective as of September 21, 2021.

Pursuant to this amendment, Section 14(b) of the Plan shall be deleted in its entirety and replaced with the below:

Unless otherwise determined by the Committee and reflected in the terms of an Award at the time of grant, measurement of performance goals with respect to the Performance Measures above shall exclude the impact of charges for restructurings, discontinued operations, extraordinary items, other unusual or non-recurring items and the cumulative effects of tax or accounting changes, each as determined in accordance with generally accepted accounting principles or identified in the Company’s financial statements, notes to the financial statements, management’s discussion and analysis or other filings with the SEC or as otherwise based on the Company’s accounting as set forth in its books and records (including business projections) and/or in the annual budgets and/or long range plans of the Company pursuant to which such performance goals were established.

 EX-10.3 4 clxq1fy22exhibit103.htm EX-10.3 Document

Exhibit 10.3
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
NONQUALIFIED STOCK OPTION AWARD AGREEMENT

NOTICE OF STOCK OPTION GRANT
The Clorox Company, a Delaware company (the “Company”), grants to the Optionee named below an option (the “Option”) to purchase, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this nonqualified stock option agreement (the “Agreement”), the number of shares of Common Stock of the Company (the “Shares”) at the exercise price per share (the “Exercise Price”) set forth as follows:

OPTIONEE:<<<Optionee Name - 1>>>
OPTIONS GRANTED:<<<Total Shares Granted>>>
GRANT ID:<<<Grant ID>>>
EXERCISE PER SHARE:<<<Grant Price - 1>>>
DATE OF GRANT:<<<Grant Date - 2>>>
EXPIRATION DATE:Ten years from Date of Grant
VESTING SCHEDULE:25% vests on each of October 5 of 2022, 2023, 2024 and 2025, or the first trading day immediately preceding each such date if such date is not a trading day.

AGREEMENT

1.Grant of Option. The Company hereby grants to the Optionee the Option to purchase the Shares at the Exercise Price, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Option set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Exercise of Option.

a.Right to Exercise. This Option shall be exercisable prior to the expiration date set forth above (the “Expiration Date”), in accordance with the vesting schedule set forth above (the “Vesting Schedule”) and with the applicable provisions of the Plan and this Agreement. Except as otherwise specifically provided in this Agreement, in no event may this Option be exercised after the Expiration Date. Although vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists once the options become exercisable according to the Vesting Schedule above, the Options will not be earned until the Optionee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Sections 7(b), 7(c), 7(d), 7(e) and Section 8, and the Optionee shall have no right to retain the Shares or the value thereof upon vesting or exercise of the Options until all conditions precedent have been satisfied.
b.Method of Exercise. This Option shall be exercisable only by delivery of an exercise notice (the “Exercise Notice”), available on the UBS website, the Company’s designee, which shall state the election to exercise the Option, the whole number of vested Shares in respect of which the Option is being exercised and such other provisions as may be required by the Committee. Such Exercise Notice shall be signed by the Optionee and shall be delivered by mail or fax, to the Company’s designee accompanied by payment of the Exercise Price. The Company may require the Optionee to furnish or execute such other documents as the


Company shall reasonably deem necessary (1) to evidence such exercise and (2) to comply with or satisfy the requirements of the Securities Act of 1933, as amended, the Exchange Act, or any Applicable Laws. The Option shall be deemed to be exercised upon receipt by the Company’s designee of such written notice accompanied by the Exercise Price.

No Shares will be issued pursuant to the exercise of the Option unless such issuance and such exercise shall comply with all Applicable Laws. Assuming such compliance, for income tax purposes, the Shares shall be considered transferred to the Optionee on the date on which the Option is exercised with respect to such Shares.

c.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Optionee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Option. The Committee may condition the issuance of Shares upon the Optionee’s satisfaction of such withholding obligations. The Optionee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Optionee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

3.Method of Payment. Pursuant to Section 6(f) of the Plan and subject to such limitations as the Committee may impose (including prohibition of one or more of the following payment methods), payment of the Exercise Price may be made in cash or by check, Shares or a combination thereof.

4.Termination of Employment or Service and Expiration of Exercise Period.

a.Termination of Employment or Service. If the Optionee’s employment or service with the Company and its Subsidiaries is terminated, the Optionee may exercise all or part of this Option prior to the expiration dates set forth in paragraph (b) herein, but only to the extent that the Option had become vested before the Optionee’s employment or service terminated. Notwithstanding the above, if the Optionee’s termination of employment or service is due to (1) Retirement and is more than 6 months from the Date of Grant set forth in this Agreement, then the Option shall continue to vest in accordance with the Vesting Schedule, or (2) death or Disability, the Option shall become 100% vested, and, in each case, shall remain exercisable until the expiration date determined pursuant to paragraph (b) of this Section.

Except as otherwise provided in this Section 4 or Section 5, when the Optionee’s employment or service with the Company and its Subsidiaries terminates (except when due to Retirement, death or Disability), this Option shall expire immediately with respect to the number of Shares for which the Option is not yet vested. If the Optionee dies after termination of employment or service, but before the expiration of the Option, all or part of this Option may be exercised (prior to expiration) by the personal representative of the Optionee or by any person who has acquired this Option directly from the Optionee by will, bequest or inheritance, but only to the extent that the Option was vested and exercisable upon termination of the Optionee’s employment or service.

b.Expiration of Exercise Period. Upon termination of the Optionee’s employment or service with the Company and its Subsidiaries, subject to Section 19 of the Plan, the Option shall expire on the earliest of the following occasions:

i.The Expiration Date;

ii.The date ninety (90) days following the termination of the Optionee’s employment or service for any reason other than Cause, death, Disability, or Retirement;



iii.The date one year following the termination of the Optionee’s employment or service due to death or Disability;

iv.The date five (5) years following the termination of the Optionee’s employment or service due to Retirement, provided the Optionee’s Retirement is more than 6 months from the Date of Grant set forth in this Agreement; or

v.The date of termination of the Optionee’s employment or service for Cause.

c.Definition of “Retirement.” For purposes of this Agreement, the Optionee’s employment or service shall be deemed to have terminated due to “Retirement” if the Optionee terminates employment or service as an Employee for any reason, including Disability (but other than for Cause) after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Optionee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five (55) with ten (10) or more years of Vesting Service.

d.Definition of “Disability.” For purposes of this Agreement, the Optionee’s employment shall be deemed to have terminated due to the Optionee’s Disability if the Optionee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Optionee’s employment.

5.Change in Control. Upon the occurrence of a Change in Control (including in the event the Optionee’s employment is terminated without Cause or by the Optionee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control), the Option shall be treated in accordance with Section 19 of the Plan.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Optionee:
(a) the assignment to the Optionee of any duties inconsistent in any material respect with the Optionee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Optionee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Optionee;
(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Optionee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Optionee;
(c) the Company’s requiring the Optionee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Optionee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;
(d) any purported termination by the Company of the Optionee’s employment other than (A) due to the death or Disability of the Optionee or (B) a termination of the Optionee’s employment by the Company for Cause; or
(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to


assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.
Any termination by the Optionee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Optionee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Optionee’s employment under the provision so indicated and (3) the Optionee’s intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

6.Transferability of Option. This Option shall not be transferable by the Optionee other than by will or the laws of descent and distribution, and the Option shall be exercisable during the Optionee’s lifetime only by the Optionee or on his or her behalf by the Optionee’s guardian or legal representative.

7.Protection of Trade Secrets and Limitations on Exercise.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Optionee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Optionee shall have worked during the two years prior to the Optionee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Optionee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Optionee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Shares Contingent on Protection of Confidential Information. In partial consideration for the award of this Option, the Optionee agrees that at all times, both during and after the term of the Optionee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Optionee, any and all Confidential Information of the Company or any Affiliated Company. The Optionee understands that for purposes of this Section 7(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is


either information not known (or known as a result of a wrongful act of the Optionee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the unexercised portion of the Option, whether vested or not, will be immediately forfeited and cancelled, and the Optionee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of this Option, in order to forestall the disclosure or use of Confidential Information as well as to avoid the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the term of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee breaches his/her obligation not to Interfere, the Optionee’s right to the Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

d.No Solicitation of Employees. In partial consideration for the award of this Option, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee breaches his/her obligation not to Solicit, the Optionee’s right to the Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE


UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

e.Injunctive and Other Available Relief. By acceptance of this Option, the Optionee acknowledges that, if the Optionee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Option pursuant to any of Sections 7(b) through 7(d) above shall not restrict, abridge or limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Optionee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Optionee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Optionee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Optionee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s Chief Legal Officer. Any reporting or disclosure permitted under this Section 7(f) shall not result in the cancellation of Options. Optionee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

8.Right to Retain Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of this Option in order to forestall the disclosure or use of Confidential Information, as well as to deter the Optionee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Optionee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Optionee agrees that the Optionee’s right to exercise this Option is contingent upon the Optionee refraining, prior to the expiration of the Option and for a period of one (1) year after the date of exercise, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Optionee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Optionee and the Conflicting Organization that the Optionee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Option or at any time within one (1) year after the date of exercise of all or any portion of the Option, the Optionee shall render services to any Conflicting Organization other than as expressly permitted herein, the Optionee’s right to the Shares upon exercise of the Option shall not have been earned and the unexercised portion of the Option, whether vested or not, will be immediately cancelled, and the Optionee shall immediately return to the Company any Shares acquired upon exercise of the Option or the pre-tax income derived from any disposition of such Shares. THE OPTIONEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE OPTIONEE FROM RENDERING SERVICES TO A CONFLICTING


ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNEXERCISED PORTION OF THE OPTION AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF SHARES ISSUED UPON AN EXERCISE OF THE OPTION IF THE OPTIONEE SHOULD CHOOSE TO RENDER SUCH SERVICES PRIOR TO THE EXPIRATION OF THE OPTION OR WITHIN ONE (1) YEAR AFTER EXERCISE.

9.Repayment Obligations.

a.[Restatement of Financials. In the event that (1) the Company issues a significant restatement of financial results and (2) the Committee determines, in good faith, that the Optionee’s fraud or misconduct was a significant contributing factor to such restatement and (3) some or all of the Option that was granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Optionee shall immediately return to the Company the unexercised portion of the Option and any Shares or the pre-tax income derived from any disposition of the Shares previously received in upon exercise of the Option that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). Notwithstanding anything herein to the contrary, in no event shall the Repayment Obligation apply to any portion of the Option that vested more than four years prior to the date the applicable restatement is announced. The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Optionee.]1

b.[Clawback Policy. The award of this Option under the Plan granted to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”) is subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.]2 3

10.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Optionee nor the Optionee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Option until the Option has been exercised and Share certificates have been issued to the Optionee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Optionee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Optionee hereby consents to the jurisdiction over the Optionee of any such courts and waives all objections based on venue or inconvenient forum.
1 To be included in agreements for individuals who are not subject to the Policy.
2 To be included in agreements for individuals who are required to file disclosure statements under Section 16(a) of the Securities Exchange Act or otherwise subject to the Policy.
3 Note to Draft: Grants should include either section 9(a) (for individuals who are not subject to the Policy) OR section 9(b) (for individuals who are subject to the Policy).



c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Optionee, without such Optionee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Option for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Optionee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Optionee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Optionee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Options set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Optionee shall constitute the Optionee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.







THE CLOROX COMPANY
                                
                            By:

    Its: Chief Executive Officer


THE OPTIONEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE OPTIONEE’S RIGHT TO THE SHARES PURSUANT TO THE OPTION HEREOF IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE OPTIONEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE OPTIONEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE OPTIONEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE OPTIONEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.


The Optionee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox website at http://investors.thecloroxcompany.com/sec.cfm. The Optionee hereby consents to receive the Prospectus Information electronically or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Optionee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Optionee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Optionee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Optionee further agrees to notify the Company upon any change in the residence address indicated below.

Dated:______________________________ Signed:___________________________________
                            Optionee


                Residence Address:

                ___________________________________

                ___________________________________

 EX-10.4 5 clxq1fy22exhibit104.htm EX-10.4 Document
    

Exhibit 10.4
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
PERFORMANCE SHARE AWARD AGREEMENT

NOTICE OF PERFORMANCE SHARE GRANT        
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this performance share award agreement (the “Agreement”), the following number of Performance Shares on the terms set forth below:

GRANTEE:<<<Participant Name>>>
TARGET AWARD:<<<Target Shares Granted>>>
GRANT ID:<<<Grant ID>>>
PERFORMANCE PERIOD:July 1, 2021 through June 30, 2024
DATE OF GRANT:<<<Grant Date - 2>>>
SETTLEMENT DATE:Within 120 days following the last day of the Performance Period, provided the Grantee has remained in the employment or service of the Company or its Subsidiaries through such date (except for a termination of employment or service due to death, Disability or Retirement, as provided below)

AGREEMENT

1.Grant of Performance Shares. The Company hereby grants to the Grantee the Target Award set forth above, payment of which is dependent upon the achievement of certain performance goals more fully described in Section 3 of this Agreement. This Award is subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Performance Shares set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Performance Shares awarded pursuant to this Agreement represent the opportunity to receive Shares of the Company and Dividend Equivalents on such Shares (as described in Section 4 below). The Company shall issue to the Grantee one Share for each vested Performance Share (plus any Dividend Equivalents accrued with respect to such vested Performance Shares), rounded to the nearest whole share, less any Shares withheld in accordance with the provisions of Section 7 of this Agreement. Settlement shall occur on a date chosen by the Committee, which date shall be within one hundred and twenty (120) days following the last day of the Performance Period (the “Settlement Date”), or any Deferred Settlement Date established pursuant to Section 6 of this Agreement, whichever is later, and except as specifically provided in Section 5 of this Agreement, provided the Grantee has remained in the employment or service of the Company or its Subsidiaries through the Settlement Date; provided, that, in connection with a Change in Control as described in Section 8 of this Agreement, the Settlement Date shall be within sixty (60) days of either the Change in Control or the date of termination of employment without Cause or for “Good Reason” (as defined below), as applicable. Although vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists at the Settlement Date, the Performance Shares (and any associated Dividend Equivalents) will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Sections 10(b), 10(c), 10(d), 10(e)
- 1 -


and Section 11, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Performance Shares until all such conditions precedent have been satisfied.

3.Determination of Number of Performance Shares Vested. The number of Performance Shares vested, if any, for the Performance Period shall be determined in accordance with the following formula:
# of Performance Shares = Average Payout Percentage x Target Award
The “Average Payout Percentage” is equal to the sum of the Payout Percentage for each of the fiscal years in the Performance Period, divided by three.
“Payout Percentage” for the first fiscal year in the Performance Period is based on the actual economic profit (“EP”) for such fiscal year, calculated as described below and , determined in accordance with the following table:
EP
(for the first fiscal year in the Performance Period)
EP Threshold*$
EP Target**$
EP Max***$


“Payout Percentage” for the second and third fiscal years in the Performance Period is based on the growth of annual EP, calculated as described below, for the applicable fiscal year as compared to the prior fiscal year (“EP Growth”), expressed as a percentage and calculated based upon EP at the end of each such fiscal year of the Performance Period, determined in accordance with the following table:

EP Growth
(for each of the second and third fiscal years in the Performance Period)
EP Growth Threshold*%
EP Growth Target**%
EP Growth Max***%


* Achievement of the EP Threshold amount (or below) or the EP Growth Threshold amount (or below), as the case may be, shall result in a Payout Percentage of 0% for the applicable fiscal year of the Performance Period.

** Achievement of the EP Target amount or the EP Growth Target amount, as the case may be, shall result in a Payout Percentage of 100% for the applicable fiscal year of the Performance Period.

*** Achievement of the EP Max amount (or above) or the EP Growth Max amount (or above), as the case may be, shall result in a Payout Percentage of 200% for the applicable fiscal year of the Performance Period.
Note: Achievement of EP or EP Growth in between the Threshold and Target levels and in between the Target and Max levels shall be determined through linear interpolation. For the avoidance of doubt, if the EP or EP
- 2 -


Growth in excess of the Threshold level is not achieved, the Payout Percentage for the applicable fiscal year of the Performance Period shall be 0%.
EP is defined as Earnings Before Interest & Taxes, adjusted for non-cash restructuring charges, times one minus the tax rate, less capital charge.
Notwithstanding any other provision in this Agreement to the contrary, if EP for any fiscal year in the Performance Period is negative, the Payout Percentage for such fiscal year in the Performance Period shall be 0%.
For avoidance of doubt, while the expectation is that EP for a given fiscal year shall be calculated based upon the Company’s financial statements for such fiscal year that are filed with the SEC, the Committee shall have the authority to include information not reflected in such financial statements for purposes of determining EP for such fiscal year if the Committee determines that the inclusion of such information more accurately reflects the financial performance of the Company for such fiscal year. To the extent that such information used in a prior fiscal year is reflected in the filed financial statements for a subsequent fiscal year, appropriate changes shall be made to relevant information in such filed financial statements for purposes of calculating EP for such subsequent fiscal year to avoid double counting of the same information.
Notwithstanding the above, the applicable EP amount for the corresponding fiscal year that is used as the basis for calculating either EP or EP Growth results for such fiscal year shall be adjusted, fairly and appropriately, in accordance with the Plan and, as provided in this Agreement, to reflect accurately the direct and measurable effect of the impact of each of the following events not otherwise reflected in the determination of the EP goals or the initial EP levels (each, an “Event”) including, without limitation, the financial statement impact on the Company on account of the occurrence or potential occurrence of an Event: (1) the acquisition or divestiture of a business, (2) a Change in Control, (3) U.S Federal changes in tax statutes or the addition or deletion of taxes to which the Company or any Affiliated Company is subject, (4) force majeure (including events known as “Acts of God”), (5) the adoption of new or revised accounting pronouncements or changes to application of accounting pronouncements, (6) an asset impairment charge other than for the final fiscal year of the Performance Period, and (7) any extraordinary, unusual or non-recurring item not previously listed. Notwithstanding the foregoing, an event listed in the preceding sentence shall not qualify as an Event, and therefore no adjustment shall be made to the EP goals or EP levels, unless the impact of the occurrence or potential occurrence of such an event listed in the preceding sentence exceeds $2 million in EP. The purpose of any adjustments on account of the occurrence of an Event is to keep the probability of achieving the EP or EP Growth goals the same as if the Event triggering such adjustment had either not occurred or had not resulted in any financial statement impact. The determination of any adjustments shall be based on the Company’s accounting as set forth in its books and records (including business projections) and/or in the annual budgets and/or long range plans of the Company pursuant to which the EP and EP Growth goals were established. The amount of any such adjustment shall be approved by the Committee in its good faith determination in accordance with the provisions of this paragraph. To the extent applicable, the Committee shall condition the determination of the number of Performance Shares vested under this Section 3 upon the satisfaction of the adjusted EP goals or EP levels, as the case may be. All Performance Shares that are not vested for the Performance Period shall be forfeited as of the last day of the Performance Period.
4.Dividend Equivalent Rights. No Dividend Equivalents shall be paid to the Grantee prior to the settlement of the award. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s Performance Share account and paid out at the Payout Percentage in the form of additional Shares rounded down to the nearest whole Share (the “Dividend Equivalent Shares”) upon settlement of the award, as described in Section 2 above.

5.Termination of Continuous Service. Except as otherwise provided in this Section 5 or Section 8, if the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason prior to
- 3 -


the Settlement Date, all Performance Shares and Dividend Equivalents subject to this Agreement shall be immediately forfeited.

a.Termination due to Death or Disability. If the Grantee’s termination of employment or service is due to death or Disability, all Performance Shares and Dividend Equivalents shall immediately vest and will be paid upon completion of the Performance Period based on the level of performance achieved as of the end of such Performance Period.

b.Termination due to Retirement. If the Grantee’s termination of employment or service is due to Retirement, the Performance Shares shall vest on a pro rata monthly basis, including full credit for partial months elapsed and rounded to the nearest whole Share, and will be paid upon completion of the Performance Period based on the level of performance achieved as of the end of such Performance Period; provided, however, that this provision shall not apply in the event the Grantee’s employment or service is terminated for Cause. The amount of the vested Award may be computed under the following formula: Target Award times (number of full months elapsed in Performance Period (i.e., rounding up for any partial month) divided by number of full months in Performance Period) times percent performance level achieved as of the end of the Performance Period. Dividend Equivalents accrued through the Grantee’s date of termination due to Retirement shall be paid at the same time as the settlement of the vested Performance Shares.

c.Definition of “Retirement.” For purposes of this Agreement, the term “Retirement” shall mean termination of employment or service as an Employee after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Grantee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five with ten (10) or more years of Vesting Service.

d.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.

6.Election to Defer Settlement. Prior to the commencement of the last year of the Performance Period, the Grantee may elect to defer the settlement of the Performance Shares from the last day of the Performance Period until a date at least two years following such date, or until the Grantee’s later termination of employment or service. Such date shall be referred to as the “Deferred Settlement Date”. If the Grantee makes such an election, it will become irrevocable on the date of such election. If the Grantee makes such an election, any Dividend Equivalents awarded with respect to such deferred Performance Shares shall also be deferred under the same terms. If the Grantee makes such an election, but a transaction occurs that subjects the Grantee’s Performance Shares to Section 19 of the Plan prior to the Deferred Settlement Date, the Grantee’s deferral election will terminate and the Grantee’s Performance Shares and Dividend Equivalents will be settled as of the date of that transaction. The Company may terminate any deferral hereunder if a change in law requires such termination.

7.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Award. The Committee may condition the issuance of Shares upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is
- 4 -


acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restriction or limitations that the Committee, in its sole discretion, deems appropriate.

8.Change in Control. Upon the occurrence of a Change in Control, including in the event of the termination of the Grantee by the Company without Cause or the resignation of the Grantee for Good Reason within twenty-four (24) months following consummation of a Change in Control, the Performance Shares shall be treated in accordance with Section 19 of the Plan.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee’s intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

9.Transferability of Performance Shares. Performance Shares shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Performance Shares pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.
- 5 -



10.Protection of Trade Secrets and Limitations on Retention.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Performance Shares, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 10(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Performance Shares, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to the
- 6 -


Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, for a period of one (1) year after the Settlement Date of the Performance Shares, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or to interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the term of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing , or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

d.No Solicitation of Employees. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to the Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

e.Injunctive and Other Available Relief. By acceptance of these Performance Shares, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Performance Shares pursuant to any of Sections 10(b)
- 7 -


through 10(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s Chief Legal Officer. Any reporting or disclosure permitted under this Section 10(f) shall not result in the cancellation of Performance Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

11.Right to Retain Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Performance Shares, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to the Shares upon settlement of the Performance Shares is contingent upon the Grantee refraining, during the term of the Performance Period and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Performance Period or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Performance Shares shall not have been earned and the Performance Shares, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares or the pre-tax income derived from any disposition of the Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE PERFORMANCE SHARES AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE TERM OF THE PERFORMANCE PERIOD OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

12.Repayment Obligations.

a.[Restatement of Financials. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Performance Shares that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company the Performance Shares or any Shares or the pre-tax income derived from any disposition of the Shares previously received in settlement of the Performance Shares that would
- 8 -


not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.]1

b.[Clawback Policy. Awards under the Plan granted to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”) are subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.]2 3

13.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Performance Shares have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

1 To be included in agreements for individuals who are not subject to the Policy.
2 To be included in agreements for individuals who are required to file disclosure statements under Section 16(a) of the Securities Exchange Act or otherwise subject to the Policy.
3 Note to Draft: Grants should include either section 12(a) (for individuals who are not subject to the Policy) OR section 12(b) (for individuals who are subject to the Policy).
- 9 -


e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Performance Shares set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 13(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.

- 10 -





                        THE CLOROX COMPANY
                            
                        By:
    Its: Chief Executive Officer

THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY ACHIEVEMENT OF THE PERFORMANCE CRITERIA AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox website at http://investors.thecloroxcompany.com/sec.cfm. The Grantee hereby consents to receive the Prospectus Information electronically or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of the Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.



Dated: ____________________________    Signed: _________________________________
                            Grantee


                    Residence Address:
                    __________________________________
                    __________________________________
- 11 -
 EX-10.5 6 clxq1fy22exhibit105.htm EX-10.5 Document

Exhibit 10.5
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
(US Employees)

SUMMARY OF RESTRICTED STOCK UNIT AWARD
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the following number of Restricted Stock Units (the “Units”), on the terms set forth below:

GRANTEE<<Participant ID>>
TOTAL RESTRICTED UNITS AWARDED<<Units Granted>>
DATE OF AWARD<<Grant Date>>
PERIOD OF RESTRICTION
25% vests on each of October 5, 2022, 2023, 2024 and 2025, or the first trading day immediately preceding each such date if such date is not a trading day; provided that [the Committee][a committee consisting of the Chief Executive Officer and the Chief People Officer] may provide in its sole discretion for the vesting of additional Units in an amount sufficient to satisfy any applicable tax withholding amounts arising due to Grantee’s eligibility under this Agreement to terminate employment or services due to “Retirement”.1,2

TERMS OF AGREEMENT

1.Grant of Units. The Company hereby grants to the Grantee the Units set forth above, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Units set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Units represent an unfunded, unsecured promise by the Company to issue Shares. Units will become vested and be settled in Shares on a one Share for one Unit basis, rounded to the nearest whole Share, less any Shares withheld in accordance with the provisions of Section 4 of this Agreement. Settlement shall occur as soon as practicable after the Period of Restriction lapses as provided in the Summary of Restricted Stock Unit Award above, but in any event, within the period ending on the later to occur of the date that is 2 ½ months from the end of (1) the Grantee’s tax year that includes the date of the lapse of the Period of Restriction, or (2) the Company’s tax year that includes the date of the lapse of the Period of Restriction (which payment schedule is intended to comply with the “short-term deferral” exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)) (the “Settlement Date”). Although the Units shall be vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists after the Period of Restriction lapses,
    1    To be included in agreements for individuals who are members of the Clorox Executive Committee and/or required to file disclosure statements under Section 16(a) of the Securities Exchange Act.
    2    To be included in agreements for individuals who are neither members of the Clorox Executive Committee nor required to file disclosure statements under Section 16(a) of the Securities Exchange Act.
    - 1 -

the Units will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Section 9(b), 9(c), 9(d), 9(e) and Section 10, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Units until all such conditions precedent have been satisfied.

3.Dividend Equivalents. No Dividend Equivalents shall be paid to the Grantee prior to the lapse of the Period of Restriction. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s RSU account and paid out in the form of additional Shares, rounded down to the nearest whole Share, after the lapse of the Period of Restriction, within the time period described in Section 2 above.

4.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Award. The Committee may condition the issuance of Shares in settlement of Units upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

5.Termination of Employment or Service.

a.Except as otherwise provided in this Section 5 or Section 8, if the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason, any Units for which the Period of Restriction has not lapsed before such termination of employment or service (the “Unvested Units”) and/or any Dividend Equivalents related thereto shall be forfeited. Notwithstanding the above, if the Grantee’s termination of employment or service is due to (i) Retirement and is more than 6 months from the date of award set forth in this Agreement, then the restrictions on the Units and all Dividend Equivalents related thereto shall continue to lapse in accordance with the Period of Restriction provided in the Summary of Restricted Stock Unit Award above, provided that the “Settlement Date” for such Units and Dividend Equivalents shall occur no later than December 31 of the calendar year in which the applicable Period of Restriction lapses or (ii) death or Disability, the Units shall become 100% vested and the Period of Restriction on the Units shall lapse and all Dividend Equivalents related thereto shall become immediately vested and payable as of such termination date.

b.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.

c.Definition of “Retirement.” For purposes of this Agreement, the Grantee’s employment or service shall be deemed to have terminated due to “Retirement” if the Grantee terminates employment or service as an Employee for any reason, including Disability (but other than for Cause) after (1) twenty (20) or more years of “vesting service,” which solely for purposes of this Agreement, shall be calculated under Article III of The Clorox Company 401(k) Plan (the “401(k) Plan”) entitled “Service” along with any other relevant provisions of the 401(k) Plan necessary or desirable to give full effect thereto, or any successor provisions, regardless of the status of the Grantee with respect to the 401(k) Plan (“Vesting Service”), or (2) attaining age fifty-five (55) with ten (10) or more years of Vesting Service.
    
6.Authorization to Return Forfeited Units. The Grantee authorizes the Company or its designee to return to the Company all Units and related Dividend Equivalents and Shares subject thereto which are forfeited along with any cash or other property held with respect to or in substitution of such Units, related Dividend Equivalents and/or Shares. Any such action shall comply with all applicable provisions of this Agreement or the Plan.

- 2 -

7.Transferability of Units. Unless otherwise determined by the Committee, Units shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Units pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.

8.Change in Control. Upon the occurrence of a Change in Control (including in the event the Grantee’s employment is terminated without Cause or by the Grantee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control), the Units shall be treated in accordance with Section 19 of the Plan.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee’s intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

- 3 -

9.Protection of Trade Secrets and Limitations on Retention.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Units/Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Units, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 9(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Units, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated
- 4 -

Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

d.No Solicitation of Employees. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

e.Injunctive and Other Available Relief. By acceptance of these Units and any Shares issued in settlement thereof, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Units pursuant to any of Sections 9(b) through 9(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the
- 5 -

Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s Chief Legal Officer. Any reporting or disclosure permitted under this Section 9(f) shall not result in the cancellation of Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

10.Right to Retain Units/Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Units in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE PERIOD OF RESTRICTION OR WITHIN ONE YEAR AFTER THE SETTLEMENT DATE.

11.Repayment Obligations.

a.[Restatement of Financials. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Units that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company any Units or any Shares or the pre-tax income derived from any disposition of any Shares previously received in settlement of the Units that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.]3

3 To be included in agreements for individuals who are not subject to the Policy.
- 6 -

b.[Clawback Policy. Awards under the Plan granted to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”) are subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.]4 5

12.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Units have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and
4 To be included in agreements for individuals who are required to file disclosure statements under Section 16(a) of the Securities Exchange Act or otherwise subject to the Policy.
5 Note to Draft: Grants should include either section 12(a) (for individuals who are not subject to the Policy) OR section 12(b) (for individuals who are subject to the Policy).
- 7 -

binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Units set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Code, and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 12(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.


- 8 -

THE CLOROX COMPANY
                                
                        By:

    Its: Chief Executive Officer


THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox web site at http://CLOROXWEB/hr/stock. The Grantee hereby consents to receive the Prospectus Information electronically, or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.


Dated:______________________________ Signed:___________________________________
                            Grantee

                Residence Address:

                ___________________________________

                ___________________________________
- 9 -
 EX-10.6 7 clxq1fy22exhibit106.htm EX-10.6 Document


Exhibit 10.6
THE CLOROX COMPANY
2005 STOCK INCENTIVE PLAN
RESTRICTED STOCK UNIT AWARD AGREEMENT
(US Employees)

SUMMARY OF RESTRICTED STOCK UNIT AWARD
The Clorox Company, a Delaware company (the “Company”), grants to the Grantee named below, in accordance with the terms of The Clorox Company 2005 Stock Incentive Plan (the “Plan”) and this restricted stock unit award agreement (the “Agreement”), the following number of Restricted Stock Units (the “Units”), on the terms set forth below:

GRANTEE<<Participant ID>>
TOTAL RESTRICTED UNITS AWARDED<<Units Granted>>
DATE OF AWARD<<Grant Date>>
PERIOD OF RESTRICTION100% vests 36 months from the date of award

TERMS OF AGREEMENT

1.Grant of Units. The Company hereby grants to the Grantee the Units set forth above, subject to the terms, definitions and provisions of the Plan and this Agreement. All terms, provisions, and conditions applicable to the Units set forth in the Plan and not set forth herein are incorporated by reference. To the extent any provision hereof is inconsistent with a provision of the Plan, the provisions of the Plan will govern. All capitalized terms that are used in this Agreement and not otherwise defined herein shall have the meanings ascribed to them in the Plan.

2.Nature and Settlement of Award. The Units represent an unfunded, unsecured promise by the Company to issue Shares. Units will become vested and be settled in Shares on a one Share for one Unit basis, rounded to the nearest whole Share, less any Shares withheld in accordance with the provisions of Section 4 of this Agreement. Settlement shall occur as soon as practicable after the Period of Restriction lapses as provided in the Summary of Restricted Stock Unit Award above, but in any event, within the period ending on the later to occur of the date that is 2 ½ months from the end of (1) the Grantee’s tax year that includes the date of the lapse of the Period of Restriction, or (2) the Company’s tax year that includes the date of the lapse of the Period of Restriction (which payment schedule is intended to comply with the “short-term deferral” exemption from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”)) (the “Settlement Date”). Although the Units shall be vested within the meaning of Section 83 of the Internal Revenue Code since no substantial risk of forfeiture exists after the Period of Restriction lapses, the Units will not be earned until the Grantee has fulfilled all of the conditions precedent set forth in this Agreement, including, but not limited to, the obligations set forth in Section 9(b), 9(c), 9(d), 9(e) and Section 10, and the Grantee shall have no right to retain the Shares or the value thereof upon vesting or settlement of the Units until all such conditions precedent have been satisfied.

3.Dividend Equivalents. No Dividend Equivalents shall be paid to the Grantee prior to the lapse of the Period of Restriction. Rather, such Dividend Equivalent payments will accrue and be notionally credited to the Grantee’s RSU account and paid out in the form of additional Shares, rounded down to the nearest whole Share, after the lapse of the Period of Restriction, within the time period described in Section 2 above.

4.Taxes. Pursuant to Section 16 of the Plan, the Committee shall have the power and the right to deduct or withhold, or require the Grantee to remit to the Company, an amount sufficient to satisfy any applicable tax withholding requirements applicable to this Award. The Committee may condition the issuance of Shares in settlement of Units upon the Grantee’s satisfaction of such withholding obligations. The Grantee may elect to satisfy all or part of such withholding requirement by tendering previously-owned Shares or by having the
- 1 -

Company withhold Shares having a Fair Market Value equal to the minimum statutory tax withholding rate that could be imposed on the transaction (or such other rate that will not result in a negative accounting impact) or in such other manner as is acceptable to the Company. Such election shall be irrevocable, made in writing, signed by the Grantee, and shall be subject to any restrictions or limitations that the Committee, in its sole discretion, deems appropriate.

5.Termination of Employment or Service.

a.Except as otherwise provided in this Section 5 or Section 8, if the Grantee’s employment or service with the Company and its Subsidiaries is terminated for any reason, any Units for which the Period of Restriction has not lapsed before such termination of employment or service (the “Unvested Units”) and/or any Dividend Equivalents related thereto shall be forfeited. Notwithstanding the above, if the Grantee’s termination of employment or service is due to death or Disability, the Units shall become 100% vested and the Period of Restriction on the Units shall lapse and all Dividend Equivalents related thereto shall become immediately vested and payable as of such termination date.

b.Definition of “Disability.” For purposes of this Agreement, the Grantee’s employment shall be deemed to have terminated due to the Grantee’s Disability if the Grantee is entitled to long-term disability benefits under the Company’s long-term disability plan or policy, as in effect on the date of termination of the Grantee’s employment.
    
6.Authorization to Return Forfeited Units. The Grantee authorizes the Company or its designee to return to the Company all Units and related Dividend Equivalents and Shares subject thereto which are forfeited along with any cash or other property held with respect to or in substitution of such Units, related Dividend Equivalents and/or Shares. Any such action shall comply with all applicable provisions of this Agreement or the Plan.

7.Transferability of Units. Unless otherwise determined by the Committee, Units shall not be transferable by the Grantee other than by will or by the laws of descent or distribution. For avoidance of doubt, Shares issued to the Grantee in settlement of Units pursuant to Section 2 of this Agreement shall not be subject to any of the foregoing transferability restrictions.

8.Change in Control. Upon the occurrence of a Change in Control (including in the event the Grantee’s employment is terminated without Cause or by the Grantee for Good Reason upon or within twenty-four (24) months following consummation of a Change in Control), the Units shall be treated in accordance with Section 19 of the Plan.

For purposes of this Agreement, “Good Reason” shall mean the occurrence of any of the following with respect to the Grantee:

(a) the assignment to the Grantee of any duties inconsistent in any material respect with the Grantee’s position (including offices and reporting requirements), authority, duties or responsibilities, as in effect immediately prior to the occurrence of the Change in Control or the date of the Grantee’s termination of employment, whichever is greater, or any other action by the Company which results in a material diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

(b) any failure by the Company to substantially comply with, or any reduction by the Company in, any of the material provisions of the Grantee’s compensation plans, programs, agreements or arrangements as in effect immediately prior to the Change in Control, including, without limitation, any material reduction in base salary, cash incentive compensation target bonus opportunity, equity compensation opportunity in the aggregate, or employee benefits and perquisites in the aggregate, other than an isolated, insubstantial and inadvertent failure or reduction not occurring in bad faith and which is remedied by the Company promptly after receipt of notice thereof given by the Grantee;

- 2 -

(c) the Company’s requiring the Grantee to be based at any office or location other than that in effect immediately prior to the Change in Control or any office or location not requiring the Grantee’s commute to increase by more than 35 miles from his or her commute immediately prior to the Change in Control;

(d) any purported termination by the Company of the Grantee’s employment other than (A) due to the death or Disability of the Grantee or (B) a termination of the Grantee’s employment by the Company for Cause; or

(e) any material failure by the Company to require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume the obligations of the Company under this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place.

Any termination by the Grantee for Good Reason shall be communicated by a written notice to the Company within a period not to exceed ninety (90) days of such Grantee’s knowledge of the condition. Such written notice (1) must indicate the specific termination provision in the Good Reason definition relied upon, (2) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Grantee’s employment under the provision so indicated and (3) the Grantee’s intended date of termination if the Company does not cure the issue (which date shall be not less than thirty (30) days after the giving of such notice). After receipt by the Company of such written notice, the Company shall have thirty (30) days during which it may remedy the condition and thereby cure the event or circumstance constituting “Good Reason”.

9.Protection of Trade Secrets and Limitations on Retention.

a.Definitions.

i.“Affiliated Company” means any organization controlling, controlled by or under common control with the Company.

ii.“Confidential Information” means the Company’s technical or business or personnel information not readily available to the public or generally known in the trade, including inventions, developments, trade secrets and other confidential information, knowledge, data and know-how of the Company or any Affiliated Company, whether or not they originated with the Grantee, or information which the Company or any Affiliated Company received from third parties under an obligation of confidentiality.

iii.“Conflicting Product” means any product, process, machine, or service of any person or organization, other than the Company or any Affiliated Company, in existence or under development that (1) resembles or competes with a product, process, machine, or service upon or with which the Grantee shall have worked during the two years prior to the Grantee’s termination of employment with the Company or any Affiliated Company or (2) with respect to which during that period of time the Grantee, as a result of his/her job performance and duties, shall have acquired knowledge of Confidential Information, and whose use or marketability could be enhanced by application to it of Confidential Information. For purposes of this section, it shall be conclusively presumed that the Grantee has knowledge of information to which s/he has been directly exposed through actual receipt or review of memorandum or documents containing such information or through actual attendance at meetings at which such information was discussed or disclosed.

iv.“Conflicting Organization” means any person or organization that is engaged in or about to become engaged in research on or development, production, marketing or selling of a Conflicting Product.

b.Right to Retain Units/Shares Contingent on Protection of Confidential Information. In partial consideration for the award of these Units, the Grantee agrees that at all times, both during and after the term of the Grantee’s employment with the Company or any Affiliated Company, to hold in the strictest confidence, and not to use (except for the benefit of the Company at the Company’s direction) or disclose (except for
- 3 -

the benefit of the Company at the Company’s direction), regardless of when disclosed to the Grantee, any and all Confidential Information of the Company or any Affiliated Company. The Grantee understands that for purposes of this Section 9(b), Confidential Information further includes, but is not limited to, information pertaining to any aspect of the business of the Company or any Affiliated Company which is either information not known (or known as a result of a wrongful act of the Grantee or of others who were under confidentiality obligations as to the item or items involved) by actual or potential competitors of the Company or other third parties not under confidentiality obligations to the Company. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee discloses or uses, or threatens to disclose or use, any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the Units, whether vested or not, will be immediately forfeited and cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares.

c.No Interference with Customers or Suppliers. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from using Confidential Information to (1) divert or attempt to divert from the Company (or any Affiliated Company) any business of any kind in which it is engaged, or (2) intentionally solicit its customers with which it has a contractual relationship as to Conflicting Products, or interfere with the contractual relationship with any of its suppliers or customers (collectively, “Interfere”). If, during the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Interfere, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. For avoidance of doubt, the term “Interfere” shall not include any advertisement of Conflicting Products through the use of media intended to reach a broad public audience (such as television, cable or radio broadcasts, generalized online marketing, or newspapers or magazines) or the broad distribution of coupons through the use of direct mail or through independent retail outlets. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS “NO INTERFERENCE WITH CUSTOMERS OR SUPPLIERS” PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

d.No Solicitation of Employees. In partial consideration for the award of these Units, in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, for himself/herself or any third party, directly or indirectly, from soliciting for employment any person employed by the Company, or by any Affiliated Company, during the period of the solicited person’s employment and for a period of one (1) year after the termination of the solicited person’s employment with the Company or any Affiliated Company (collectively “Solicit”). If, during the term of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee breaches his/her obligation not to Solicit, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS
- 4 -

PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE CONDUCT DESCRIBED, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO VIOLATE THIS NON-SOLICITATION OF EMPLOYEES PROVISION DURING THE PERIOD OF RESTRICTION OR WITHIN ONE (1) YEAR AFTER THE SETTLEMENT DATE.

e.Injunctive and Other Available Relief. By acceptance of these Units and any Shares issued in settlement thereof, the Grantee acknowledges that, if the Grantee were to breach or threaten to breach his/her obligation hereunder not to Interfere or Solicit or not to disclose or use any Confidential Information other than in the course of performing authorized services for the Company (or any Affiliated Company), the harm caused to the Company by such breach or threatened breach would be, by its nature, irreparable because, among other things, damages would be significant and the monetary harm that would ensue would not be able to be readily proven, and that the Company would be entitled to injunctive and other appropriate relief to prevent threatened or continued breach and to such other remedies as may be available at law or in equity. To the extent not prohibited by law, any cancellation of the Units pursuant to any of Sections 10(b) through 10(d) above shall not restrict, abridge or otherwise limit in any fashion the types and scope of injunctive and other available relief to the Company. Notwithstanding any provision of this Agreement to the contrary, nothing under this Agreement shall limit, abridge, modify or otherwise restrict the Company (or any Affiliated Company) from pursuing any or all legal, equitable or other appropriate remedies to which the Company may be entitled under any other agreement with the Grantee, any other plan, program, policy or arrangement of the Company (or any Affiliated Company) under which the Grantee is covered or participates, or any applicable law, all to the fullest extent not prohibited under applicable law.

f.Permitted Reporting and Disclosure. Notwithstanding any language in this Agreement to the contrary, nothing in this Agreement prohibits Grantee from reporting possible violations of federal law or regulation to any governmental agency or governmental entity, or making other disclosures that are protected under federal law or regulation; provided, that, in each case such communications and disclosures are consistent with applicable law. Notwithstanding the foregoing, under no circumstance is Grantee authorized to disclose any information covered by the Company’s attorney-client privilege or attorney work product or the Company’s trade secrets without prior written consent of the Company’s Chief Legal Officer. Any reporting or disclosure permitted under this Section 9(f) shall not result in the cancellation of Shares. Grantee is entitled to certain immunities from liability under state and federal law for disclosing trade secrets if the disclosure was made to report or investigate an alleged violation of law, subject to certain conditions. Please see the Company’s Confidential Information Policy for further details.

10.Right to Retain Units/Shares Contingent on Continuing Non-Conflicting Employment. In partial consideration for the award of these Units in order to forestall the disclosure or use of Confidential Information, as well as to deter the Grantee’s intentional interference with the contractual relations of the Company or any Affiliated Company, the Grantee’s intentional interference with prospective economic advantage of the Company or any Affiliated Company, and to promote fair competition, the Grantee agrees that the Grantee’s right to receive the Shares upon settlement of the Units is contingent upon the Grantee refraining, during the Period of Restriction and for a period of one (1) year after the Settlement Date, from rendering services, directly or indirectly, as director, officer, employee, agent, consultant or otherwise, to any Conflicting Organization except a Conflicting Organization whose business is diversified and that, as to that part of its business to which the Grantee renders services, is not a Conflicting Organization, provided that the Company shall receive separate written assurances satisfactory to the Company from the Grantee and the Conflicting Organization that the Grantee shall not render services during such period with respect to a Conflicting Product. If, prior to the expiration of the Period of Restriction or at any time within one (1) year after the Settlement Date, the Grantee shall render services to any Conflicting Organization other than as expressly permitted herein, the Grantee’s right to the Shares upon settlement of the Units shall not have been earned and the Units, whether vested or not, will be immediately cancelled, and the Grantee shall immediately return to the Company the Shares issued in settlement of the Units or the pre-tax income derived from any disposition of such Shares. THE GRANTEE UNDERSTANDS THAT THIS PARAGRAPH IS NOT INTENDED TO AND DOES NOT PROHIBIT THE GRANTEE FROM
- 5 -

RENDERING SERVICES TO A CONFLICTING ORGANIZATION, BUT PROVIDES FOR THE CANCELLATION OF THE UNITS AND A RETURN TO THE COMPANY OF THE SHARES OR THE GROSS TAXABLE PROCEEDS OF THE SHARES IF THE GRANTEE SHOULD CHOOSE TO RENDER SUCH SERVICES DURING THE PERIOD OF RESTRICTION OR WITHIN ONE YEAR AFTER THE SETTLEMENT DATE.

11.Repayment Obligations.

a.[Restatement of Financials. In the event that (1) the Company issues a restatement of financial results to correct a material error and (2) the Committee determines, in good faith, that the Grantee’s fraud or willful misconduct was a significant contributing factor to the need to issue such restatement and (3) some or all of the Units that were granted and/or vested prior to such restatement would not have been granted and/or vested, as applicable, based upon the restated financial results, the Grantee shall immediately return to the Company any Units or any Shares or the pre-tax income derived from any disposition of any Shares previously received in settlement of the Units that would not have been granted and/or vested based upon the restated financial results (the “Repayment Obligation”). The Company shall be able to enforce the Repayment Obligation by all legal means available, including, without limitation, by withholding such amount from other sums owed by the Company to the Grantee.]1

b.[Clawback Policy. Awards under the Plan granted to Participants who are “Covered Employees” (as defined in the Company’s Policy Regarding Clawback of Incentive Compensation, the “Policy”) are subject to clawback in accordance with the terms of the Policy, as amended from time to time, and pursuant to any other policy the Company may adopt as required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. No recovery of any Award granted hereunder pursuant to such a clawback policy shall be treated as an event giving rise to a Participant’s right to terminate employment for “good reason” or “constructive termination” (or any similar term) under any agreement with the Company.]2 3

12.Miscellaneous Provisions.

a.Rights as a Stockholder. Neither the Grantee nor the Grantee’s transferee or representative shall have any rights as a stockholder with respect to any Shares subject to this Award until the Units have been settled and Share certificates have been issued to the Grantee, transferee or representative, as the case may be.

b.Choice of Law, Exclusive Jurisdiction and Venue. This Agreement shall be governed by, and construed in accordance with, the laws of the State of Delaware, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The courts of the State of Delaware shall have exclusive jurisdiction over any disputes or other proceedings relating to this Agreement, and venue shall reside with the courts in New Castle County, Delaware, including if jurisdiction shall so permit, the U.S. District Court for the District of Delaware. Accordingly, the Grantee agrees that any claim of any type relating to this Agreement must be brought and maintained in the appropriate court located in New Castle County, Delaware, including if jurisdiction will so permit, in the U.S. District Court for the State of Delaware. The Grantee hereby consents to the jurisdiction over the Grantee of any such courts and waives all objections based on venue or inconvenient forum.

c.Modification or Amendment. This Agreement may be modified or amended by the Board or the Committee at any time; provided, however, no modification or amendment to this Agreement shall be made
1 To be included in agreements for individuals who are not subject to the Policy.
2 To be included in agreements for individuals who are required to file disclosure statements under Section 16(a) of the Securities Exchange Act or otherwise subject to the Policy.
3 Note to Draft: Grants should include either section 12(a) (for individuals who are not subject to the Policy) OR section 12(b) (for individuals who are subject to the Policy).
- 6 -

which would materially and adversely affect the rights of the Grantee, without such Grantee’s written consent.

d.Severability. In the event any provision of this Agreement shall be held illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions of this Agreement, and this Agreement shall be construed and enforced to reflect the intent of the parties to the fullest extent not prohibited by law, and in the event that such provision is not able to be so construed and enforced, then this Agreement shall be construed and enforced as if such illegal or invalid provision had not been included. In amplification of the preceding sentence, in the event that the time period or scope of any provision is declared by a court or arbitrator of competent jurisdiction to exceed the maximum time period or scope that such court or arbitrator deems enforceable, then such court or arbitrator shall have the power to reduce the time period or scope to the maximum time period or scope permitted by law.

e.References to Plan. All references to the Plan shall be deemed references to the Plan as may be amended.

f.Headings. The captions used in this Agreement are inserted for convenience and shall not be deemed a part of this Agreement for construction or interpretation.

g.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or by the Company forthwith to the Board or the Committee, which shall review such dispute at its next regular meeting. The resolution of such dispute by the Board or the Committee shall be final and binding on all persons. It is the intention of the Company and the Grantee to make the promises contained in this Agreement reasonable and binding only to the extent that it may be lawfully done under existing applicable laws. This Agreement and the Plan constitute the entire and exclusive agreement between the Grantee and the Company, and it supersedes all prior agreements or understandings, whether written or oral, with respect to the grant of Units set forth in this Agreement.

h.Section 409A Compliance. To the extent applicable, it is intended that the Plan and this Agreement comply with the requirements of Section 409A of the Code, and any related regulations or other guidance promulgated with respect to such Section by the U.S. Department of the Treasury or the Internal Revenue Service (“Section 409A”). Any provision of the Plan or this Agreement that would cause this Award to fail to satisfy Section 409A shall have no force or effect until amended to comply with Section 409A, which amendment may be retroactive to the extent permitted by Section 409A.

Notwithstanding any provision of the Plan to the contrary, if the Grantee is a “specified employee” (as defined in Section 1.409A-1(i) of the Treasury Department Regulations) at the time of the Grantee’s “separation from service” (as defined in Section 1.409A-1(h) of the Treasury Department Regulations and including a termination of employment or service on account of Disability that does not satisfy the definition of “disability” under Section 409A-3(i)(4) of the Treasury Department Regulations), and payments to the Grantee hereunder are not exempt from Section 409A as a short-term deferral or otherwise, these payments, to the extent otherwise payable within six (6) months after the Grantee’s separation from service shall be delayed until the earlier of the date which is six (6) months after the date of the Grantee’s separation from service or the date of death of the Grantee. Any payments that were scheduled to be paid during the six (6) month period following the Grantee’s separation from service, but which were delayed pursuant to this Section 12(h), shall be paid without interest on, or as soon as administratively practicable after, the first day following the six (6) month anniversary of the Grantee’s separation from service (or, if earlier, the date of the Grantee’s death). Any payments that were originally scheduled to be paid following the six (6) months after the Grantee’s separation from service shall continue to be paid in accordance with their predetermined schedule.

i.Agreement with Terms. Receipt of any benefits under this Agreement by the Grantee shall constitute the Grantee’s acceptance of and agreement with all of the provisions of this Agreement and of the Plan that are applicable to this Agreement, and the Company shall administer this Agreement accordingly.

- 7 -


THE CLOROX COMPANY
                                
                        By:

    Its: Chief Executive Officer


THE GRANTEE ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT IS A UNILATERAL CONTRACT AND THAT THE GRANTEE’S RIGHT TO THE SHARES PURSUANT TO THIS AGREEMENT IS ACCEPTED AND EARNED ONLY BY CONTINUING EMPLOYMENT (FOR PURPOSES OF THIS PARAGRAPH, IGNORING ANY ELECTION TO DEFER SETTLEMENT PURSUANT TO SECTION 6) AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR ACQUIRING SHARES HEREUNDER) AND BY COMPLIANCE WITH THE GRANTEE’S VARIOUS OBLIGATIONS UNDER THIS AGREEMENT. THE GRANTEE FURTHER ACKNOWLEDGES AND AGREES THAT NOTHING IN THIS AGREEMENT, NOR IN THE PLAN, SHALL CONFER UPON THE GRANTEE ANY RIGHT WITH RESPECT TO CONTINUATION OF EMPLOYMENT BY THE COMPANY, NOR SHALL IT INTERFERE IN ANY WAY WITH THE GRANTEE’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE GRANTEE’S EMPLOYMENT AT ANY TIME, FOR ANY REASON OR NO REASON, WITH OR WITHOUT CAUSE, AND WITH OR WITHOUT ADVANCE NOTICE EXCEPT AS MAY BE REQUIRED BY APPLICABLE LAW.

The Grantee acknowledges that a copy of the Plan and Plan Information are available for viewing on the Company’s internal HR website at https://clxweb.clorox.com/hr/Pages/HRatClorox/HRContentPages/StockIncentiveProgram.aspx, and the Company’s Annual Report and Proxy Statement (the “Prospectus Information”) are available for viewing on the Company’s Clorox web site at http://CLOROXWEB/hr/stock. The Grantee hereby consents to receive the Prospectus Information electronically, or, in the alternative, to contact the HR Service Center at 1-800-709-7095 to request a paper copy of the Prospectus Information. The Grantee represents that s/he is familiar with the terms and provisions thereof, and hereby accepts this Agreement subject to all of the terms and provisions thereof. The Grantee has reviewed the Plan and this Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Agreement and fully understands all provisions of this Agreement. The Grantee acknowledges and hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Committee upon any questions arising under the Plan or this Agreement. The Grantee further agrees to notify the Company upon any change in the residence address indicated below.


Dated:______________________________ Signed:___________________________________
                            Grantee

                Residence Address:

                ___________________________________

                ___________________________________
- 8 -
 EX-31.1 8 clxq1fy22exhibit311.htm EX-31.1 Document
Exhibit 31.1
CERTIFICATION
I, Linda Rendle, certify that:
1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2021
 
/s/ Linda Rendle
Linda Rendle
Chief Executive Officer


 EX-31.2 9 clxq1fy22exhibit312.htm EX-31.2 Document
Exhibit 31.2
CERTIFICATION
I, Kevin B. Jacobsen, certify that:
1.I have reviewed this quarterly report on Form 10-Q of The Clorox Company;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 1, 2021
 
/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer


 EX-32 10 clxq1fy22exhibit32.htm EX-32 Document
Exhibit 32
CERTIFICATION

In connection with the periodic report of The Clorox Company (the “Company”) on Form 10-Q for the period ended September 30, 2021, as filed with the Securities and Exchange Commission (the “Report”), we, Linda Rendle, Chief Executive Officer of the Company, and Kevin B. Jacobsen, Executive Vice President - Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for purposes of Title 18, Chapter 63, Section 1350 of the United States Code, that to our knowledge:

(1)the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, and
(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.

This Certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission.

Date: November 1, 2021

/s/ Linda Rendle
Linda Rendle
Chief Executive Officer
 
 
/s/ Kevin B. Jacobsen
Kevin B. Jacobsen
Executive Vice President - Chief Financial Officer


 EX-101.SCH 11 clx-20210930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - BUSINESS ACQUIRED link:presentationLink link:calculationLink link:definitionLink 2404401 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - INVENTORIES, NET link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - INVENTORIES, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - INVENTORIES, NET (Details) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - INCOME TAXES (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2115106 - Disclosure - NET EARNINGS PER SHARE (EPS) link:presentationLink link:calculationLink link:definitionLink 2316303 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) link:presentationLink link:calculationLink link:definitionLink 2417407 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) link:presentationLink link:calculationLink link:definitionLink 2118107 - Disclosure - COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 2319304 - Disclosure - COMPREHENSIVE INCOME (Tables) link:presentationLink link:calculationLink link:definitionLink 2420408 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) link:presentationLink link:calculationLink link:definitionLink 2121108 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 2322305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 2423409 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) link:presentationLink link:calculationLink link:definitionLink 2424410 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2425411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 2126109 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2327306 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) link:presentationLink link:calculationLink link:definitionLink 2428412 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) link:presentationLink link:calculationLink link:definitionLink 2429413 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2130110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES link:presentationLink link:calculationLink link:definitionLink 2431414 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details) link:presentationLink link:calculationLink link:definitionLink 2132111 - Disclosure - SEGMENT RESULTS link:presentationLink link:calculationLink link:definitionLink 2333307 - Disclosure - SEGMENT RESULTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2434415 - Disclosure - SEGMENT RESULTS (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 12 clx-20210930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 13 clx-20210930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 14 clx-20210930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Net unrealized gains (losses) on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Balance Sheet Location [Axis] Balance Sheet Location [Axis] COMPREHENSIVE INCOME Comprehensive Income (Loss) Note [Text Block] Customer [Domain] Customer [Domain] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Number of entities in joint venture Number of Entities in Joint Venture Number of Entities in Joint Venture Amounts reclassified from accumulated other comprehensive net (loss) income Amounts reclassified from Accumulated other comprehensive net (loss) income Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax Interest expense Interest Expense Weighted average long-term expected rate or return on plan assets Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Net earnings attributable to Clorox Net Income (Loss) Attributable to Parent Total Net periodic benefit cost (benefit) Defined Benefit Plan, Net Periodic Benefit Cost (Credit) Entity Emerging Growth Company Entity Emerging Growth Company Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Interest cost Defined Benefit Plan, Interest Cost City Area Code City Area Code Interest rate contracts Interest Rate Contract [Member] Retained earnings Retained Earnings (Accumulated Deficit) Entity Address, Address Line One Entity Address, Address Line One Operating Segments Operating Segments [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Segment Results Segment Reporting, Policy [Policy Text Block] Income Statement [Abstract] Income Statement [Abstract] Amendment Flag Amendment Flag Concentration Risk [Table] Concentration Risk [Table] Pension and postretirement benefit adjustments Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Additional paid-in capital Additional Paid in Capital, Common Stock Entity Filer Category Entity Filer Category Estimated Fair Value Estimate of Fair Value Measurement [Member] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Loss on settlement Business Combination, Settlement Of Pre-Existing Net Liabilities Business Combination, Settlement Of Pre-Existing Net Liabilities Other assets Other Assets, Noncurrent Remediation period (in years) Remediation period Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site. Investment, Name [Axis] Investment, Name [Axis] Cleaning Cleaning [Member] Cleaning [Member] Segments [Axis] Segments [Axis] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Retirement Benefits [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Net increase (decrease) in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Raw materials and packaging Inventory, Raw Materials and Supplies, Net of Reserves Total stockholders’ equity Balance, beginning Balance, ending Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Income taxes Income Tax Expense (Benefit) Lifestyle Lifestyle [Member] Lifestyle [Member] Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition Receivables, net Accounts Receivable, after Allowance for Credit Loss, Current Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Commodity Purchase Derivative Contracts [Axis] Equity Components [Axis] Equity Components [Axis] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Investment Type [Axis] Investment Type [Axis] Total current assets Assets, Current Net unrealized gains (losses) on derivatives Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member] Document Fiscal Year Focus Document Fiscal Year Focus Concentration Risk Type [Domain] Concentration Risk Type [Domain] Transaction [Domain] Transaction [Domain] Inventories, net Total Inventory, Net Selected Financial Information Relating to the Company's Segments Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Schedule of Stockholders Equity Schedule of Stockholders Equity [Table Text Block] Entity File Number Entity File Number Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Joint Venture In Kingdom Of Saudi Arabia Joint Venture In Kingdom Of Saudi Arabia [Member] Joint Venture In Kingdom Of Saudi Arabia Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Vitamins, Minerals and Supplements Vitamins, Minerals and Supplements [Member] Vitamins, Minerals and Supplements Antidilutive stock options and other (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Inventories, Net Schedule of Inventory, Current [Table Text Block] Business combinations including purchase accounting adjustments Noncontrolling Interest, Increase from Business Combination Fair Value Measurement Fair Value Measurement, Policy [Policy Text Block] Current maturities of long-term debt Long-term Debt, Current Maturities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares Schedule of Weighted Average Number of Shares [Table Text Block] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Entity Small Business Entity Small Business Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Combination and Asset Acquisition [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Equity Component [Domain] Equity Component [Domain] Other employee stock plan activities (in shares) Other Employee Stock Plan Activities, Shares Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards. Grilling Grilling [Member] Grilling [Member] ASSETS Assets [Abstract] Subsegments [Axis] Subsegments [Axis] Amortization of unrecognized items Defined Benefit Plan, Amortization of Gain (Loss) Domestic Plan Domestic Plan [Member] Long-Term Inter-Company Loans Long-Term Inter-Company Loans [Member] Long-term inter-company loans included in foreign currency adjustments. Notes and loans payable Commercial Paper Concentration percentage Concentration Risk, Percentage Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding Preferred Stock, Value, Issued Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block] Dividends to non-controlling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Retirement Plan Type [Domain] Retirement Plan Type [Domain] Short-term Debt, Type [Axis] Short-term Debt, Type [Axis] Entity Address, City or Town Entity Address, City or Town Retained Earnings Retained Earnings [Member] Professional Products Professional Products [Member] Professional Products [Member] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Current maturities of long-term debt and Long-term debt Debt Instrument, Fair Value Disclosure Entity Address, State or Province Entity Address, State or Province Noncontrolling interest, ownership percentage by parent Noncontrolling Interest, Ownership Percentage by Parent Trademarks, net Trademarks, net Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit. Earnings before income taxes Earnings (losses) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Corporate, Non-Segment Corporate, Non-Segment [Member] Segment Reporting [Abstract] Segment Reporting [Abstract] Household Household [Member] Household [Member] Customer [Axis] Customer [Axis] Commodity contract Commodity Contract [Member] EMPLOYEE BENEFIT PLANS Retirement Benefits [Text Block] Entity Shell Company Entity Shell Company Letter of credit Letter of credit Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding. Local Phone Number Local Phone Number Total other comprehensive (loss) income, net of tax Other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Short-term Debt Short-term Debt [Member] Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months Comprehensive income Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Interactive Data Current Entity Interactive Data Current Income tax benefit (expense) Other Comprehensive Income (Loss), Tax Total assets Assets Investment, Name [Domain] Investment, Name [Domain] Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Basic net earnings per share (in dollars per share) Earnings Per Share, Basic Non-controlling interests Noncontrolling Interest [Member] Research and development costs Research and Development Expense Total Commodity Purchase Derivative Contracts Total Commodity Purchase Derivative Contracts [Member] Total Commodity Purchase Derivative Contracts [Member] Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Fair value of net assets acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Less: Net earnings attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Retirement Income Plans Retirement Income Plans [Member] Retirement Income [Member] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Entity Current Reporting Status Entity Current Reporting Status Cash margin balances amount Margin Deposit Assets Net cash provided by operations Net Cash Provided by (Used in) Operating Activities Current maturities of long-term debt and Long-term debt CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember Current Maturities of Long-term Debt and Long-term Debt [Member] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Entity Tax Identification Number Entity Tax Identification Number Notes and loans payable, net Proceeds from (Repayments of) Short-term Debt Other Other Noncash Income (Expense) Alameda County, California Matter Alameda County, California Matter [Member] Alameda County, California Matter [Member] Bags and Wraps Bags, Wraps, And Containers [Member] Bags, Wraps, And Containers [Member] Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Diluted net earnings per share (in dollars per share) Earnings Per Share, Diluted Segments [Domain] Segments [Domain] Gains (losses) recognized in Other comprehensive (loss) income Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Trust assets for nonqualified deferred compensation plans Deferred Compensation Plan Assets Purchase consideration Business Combination, Consideration Transferred Service cost Defined Benefit Plan, Service Cost Total other liabilities in the fair value hierarchy Financial Liabilities Fair Value Disclosure Jet Fuel Swaps Jet Fuel Swaps [Member] Jet Fuel Swaps [Member] Plan Name [Axis] Plan Name [Axis] Total comprehensive income attributable to Clorox Comprehensive Income (Loss), Net of Tax, Attributable to Parent Current maturities of long-term debt and Long-term debt Long-term Debt Total other assets in the fair value hierarchy Assets, Fair Value Disclosure Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash used for financing activities Net Cash Provided by (Used in) Financing Activities Document Transition Report Document Transition Report Other comprehensive (loss) income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Treasury stock, at cost: 7,885,210 and 7,961,241 shares as of September 30, 2021 and June 30, 2021, respectively Treasury Stock, Value Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Weighted average shares outstanding (in thousands) Weighted Average Number of Shares Outstanding, Diluted [Abstract] Cash and Cash Equivalents Cash and Cash Equivalents [Member] Deferred income taxes Deferred Income Tax Liabilities, Net Schedule of Comprehensive Income Comprehensive Income (Loss) [Table Text Block] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Total liabilities and stockholders’ equity Liabilities and Equity Transaction Type [Axis] Transaction Type [Axis] Subsegments [Domain] Subsegments [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Depreciation and amortization Depreciation, Depletion and Amortization Operating lease right-of-use assets and liabilities, net Operating Lease, Right-of-Use Asset And Liability, Net Operating Lease, Right-of-Use Asset And Liability, Net Concentration Risk [Line Items] Concentration Risk [Line Items] Trust assets for nonqualified deferred compensation plans Trust Assets for nonqualified deferred compensation plans [Member] Trust Assets For Nonqualified Deferred Compensation Plans [Member] LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Accumulated Other Comprehensive Net (Loss) Income AOCI Attributable to Parent [Member] Derivative [Line Items] Derivative [Line Items] OTHER CONTINGENCIES AND GUARANTEES [Abstract] OTHER CONTINGENCIES AND GUARANTEES [Abstract] Inventories, net Increase (Decrease) in Inventories Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities, Current Short-term Debt, Type [Domain] Short-term Debt, Type [Domain] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Treasury stock purchased Treasury Stock, Value, Acquired, Cost Method NET EARNINGS PER SHARE (EPS) Earnings Per Share [Text Block] Derivative [Table] Derivative [Table] Effects of Derivative Instruments Designated as Hedging Instruments on OCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Cost of products sold Cost of Goods and Services Sold Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Percentage of liability for aggregate remediation and associated costs, other than legal fees Percentage of liability for aggregate remediation and associated costs, other than legal fees The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site. Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES [Text Block] This item represents the complete disclosure regarding the entity's exposure to loss pertaining to environmental matters, litigation and potential losses not disclosed in other notes and guarantees. Gross profit Gross Profit Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents International International [Member] International [Member] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Less: Total comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Selling and administrative expenses Selling, General and Administrative Expense Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Trust assets for nonqualified deferred compensation plans Investments, Fair Value Disclosure Maximum duration, interest rate contracts (in years) Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge Other comprehensive (loss) income before reclassifications Other Comprehensive Income (Loss), before Reclassifications, before Tax Trading Symbol Trading Symbol Loss Contingencies [Line Items] Loss Contingencies [Line Items] Property, plant and equipment, net of accumulated depreciation and amortization of $2,422 and $2,382, respectively Property, Plant and Equipment, Net Purchases of Inventory Purchases of Inventory [Member] Purchases of Inventory [Member] Other liabilities Other Liabilities, Noncurrent Food Products Food Products [Member] Food Products [Member] LIFO allowances Inventory, LIFO Reserve Current liabilities Liabilities, Current [Abstract] Maximum duration, foreign exchange contracts (in years) Maximum Length of Time, Foreign Currency Cash Flow Hedge Cash, cash equivalents, and restricted cash: Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Treasury stock purchased (in shares) Treasury Stock, Shares, Acquired Businesses acquired, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Net earnings per share attributable to Clorox Earnings Per Share [Abstract] Derivative assets Derivative Asset Dickinson County, Michigan Matter Dickinson County, Michigan Matter [Member] Dickinson County, Michigan Matter [Member] Fair value of non-controlling interest acquired Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value Cash dividends paid to Clorox stockholders Payments of Ordinary Dividends, Common Stock Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent INVENTORIES, NET Inventory Disclosure [Text Block] Revenue from Contract with Customer Revenue from Contract with Customer Benchmark [Member] Accounting Policies [Abstract] Accounting Policies [Abstract] Document Quarterly Report Document Quarterly Report Derivative Instrument [Axis] Derivative Instrument [Axis] Number of reportable segments Number of Reportable Segments Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Time deposits Bank Time Deposits [Member] Foreign exchange derivative contracts Foreign Exchange Contract [Member] Letter of credit, amount outstanding Letters of Credit Outstanding, Amount FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Text Block] The entire disclosure for financial instruments and fair value measurements. Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September 30, 2021 and June 30, 2021; and 122,856,251 and 122,780,220 shares outstanding as of September 30, 2021 and June 30, 2021, respectively Common Stock, Value, Issued Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Customer Concentration Risk Customer Concentration Risk [Member] Long-term debt Long-term Debt, Excluding Current Maturities Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Postretirement Benefits Plan Other Postretirement Benefits Plan [Member] Commitments and contingencies Commitments and Contingencies Intercompany Foreign Currency Balance, Name [Domain] Intercompany Foreign Currency Balance, Name [Domain] Accumulated other comprehensive net (loss) income Accumulated Other Comprehensive Income (Loss), Net of Tax Schedule of Assets and Liabilities for Fair Value Disclosure Fair Value, by Balance Sheet Grouping [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus BUSINESS ACQUIRED Business Combination Disclosure [Text Block] Effective tax rate on earnings from continuing operations Effective Income Tax Rate Reconciliation, Percent Net earnings Net earnings Net earnings Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Investments [Domain] Investments [Domain] Product Concentration Risk Product Concentration Risk [Member] Ownership [Axis] Ownership [Axis] Document Period End Date Document Period End Date Dilutive effect of stock options and other (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Business Combination, Separately Recognized Transactions [Line Items] Business Combination, Separately Recognized Transactions [Line Items] Beginning of period End of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Balance, beginning (in shares) Balance, ending (in shares) Shares, Issued Dividends Dividends Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] Commodity Purchase Derivative Contracts [Domain] UNITED STATES UNITED STATES Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Entity Registrant Name Entity Registrant Name Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Treasury stock, shares (in shares) Treasury Stock, Shares Current assets Assets, Current [Abstract] Intercompany Foreign Currency Balance by Description [Axis] Intercompany Foreign Currency Balance by Description [Axis] Entity Central Index Key Entity Central Index Key Work in process Inventory, Work in Process, Net of Reserves Security Exchange Name Security Exchange Name Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Other employee stock plan activities Other Employee Stock Plan Activities, Amount Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other (income) expense, net Other Expense (Income), Net The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract] Financial Instruments and Fair Value Measurements [Abstract] Water Filtration Water Filtration [Member] Water Filtration [Member] Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Net current period other comprehensive (loss) income Other Comprehensive Income (Loss), Net of Tax Dividends declared per share (in dollars per share) Common Stock, Dividends, Per Share, Declared Net sales Revenue from Contract with Customer, Excluding Assessed Tax Maximum undiscounted costs Maximum Exposure, Undiscounted Cost Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period. Income taxes payable / prepaid Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable INCOME TAXES Income Tax Disclosure [Text Block] Natural Personal Care Natural Personal Care [Member] Natural Personal Care [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Current Fiscal Year End Date Current Fiscal Year End Date Finished goods Inventory, Finished Goods, Net of Reserves STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] Schedule of Components of Net Periodic Benefit Cost Schedule of Net Benefit Costs [Table Text Block] Measurement Basis [Axis] Measurement Basis [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Equity [Abstract] Equity [Abstract] Carrying Amount Reported Value Measurement [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Class of Stock [Line Items] Class of Stock [Line Items] Common Stock Common Stock [Member] Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Changes in: Increase (Decrease) in Operating Capital [Abstract] Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Property, plant and equipment, accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Other intangible assets, net Other Intangible Assets, Net SEGMENT RESULTS Segment Reporting Disclosure [Text Block] Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Current operating lease liabilities Operating Lease, Liability, Current Total current liabilities Liabilities, Current Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Cash paid Payments to Acquire Businesses, Gross Stock-based compensation Share-based Payment Arrangement, Noncash Expense Health and Wellness Health and Wellness [Member] Health and Wellness Long-term Debt Long-term Debt [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Foreign exchange forward contracts Foreign Exchange Forward [Member] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Interest-bearing investments, including money market funds Money Market Funds [Member] Loss Contingencies [Table] Loss Contingencies [Table] Treasury Stock Treasury Stock [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership [Domain] Ownership [Domain] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Business Combination, Separately Recognized Transactions [Table] Business Combination, Separately Recognized Transactions [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Notional amount Derivative, Notional Amount Title of 12(b) Security Title of 12(b) Security Other assets Other Assets [Member] Non-recurring, non-cash gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net Liability for aggregate future remediation costs Accrual for Environmental Loss Contingencies Recently Adopted Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Other Payments for (Proceeds from) Other Investing Activities Advertising costs Advertising Expense Capital expenditures Payments to Acquire Property, Plant, and Equipment Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Discretionary contributions Defined Benefit Plan, Plan Assets, Contributions by Employer Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Soybean Oil Futures Soybean Oil Futures [Member] Soybean Oil Futures [Member] Total liabilities Liabilities Cover page. Cover [Abstract] Issuance of common stock for employee stock plans and other Issuance Of Common Stock For Employee Stock Plans And Other The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities. Stockholders' Equity Note [Abstract] Stockholders' Equity Note [Abstract] Receivables, net Increase (Decrease) in Receivables Cat Litter Cat Litter [Member] Cat Litter [Member] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Goodwill Goodwill Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Noncontrolling interests Stockholders' Equity Attributable to Noncontrolling Interest Consolidation Items [Axis] Consolidation Items [Axis] Total Clorox stockholders’ equity Balance, beginning Balance, ending Stockholders' Equity Attributable to Parent Short-term debt, fair value Short-term Debt, Fair Value Common stock, shares issued (in shares) Common Stock, Shares, Issued Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Maximum duration, commodity contracts (in years) Maximum Length of Time Hedged in Cash Flow Hedge Accounts payable and accrued liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Walmart Stores, Inc. Walmart Stores, Inc. [Member] Walmart Stores, Inc. and its affiliates [Member] Adjustments to reconcile net earnings to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] NotesAndLoansPayableMember NotesAndLoansPayableMember Notes and Loans Payable [Member] Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Pension and postretirement benefit adjustments Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Derivative instruments subject to contractually defined counterparty liability position limits Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits Derivative instruments subject to contractually defined counterparty liability position limits. Treasury stock purchased Payments for Repurchase of Common Stock Stockholders’ equity Stockholders' Equity Attributable to Parent [Abstract] Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Deferred income taxes Deferred Income Tax Expense (Benefit) Retirement Plan Type [Axis] Retirement Plan Type [Axis] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] EX-101.PRE 15 clx-20210930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 16 clx-20210930_g1.jpg begin 644 clx-20210930_g1.jpg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clx-20210930_htm.xml IDEA: XBRL DOCUMENT 0000021076 2021-07-01 2021-09-30 0000021076 2021-10-19 0000021076 2020-07-01 2020-09-30 0000021076 2021-09-30 0000021076 2021-06-30 0000021076 2020-06-30 0000021076 2020-09-30 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-01 2020-09-30 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 2020-07-09 0000021076 clx:JointVentureInKingdomOfSaudiArabiaMember 2020-07-09 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-07-01 2021-09-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-09-30 0000021076 clx:SoybeanOilFuturesMember 2021-09-30 0000021076 clx:JetFuelSwapsMember 2021-09-30 0000021076 clx:TotalCommodityPurchaseDerivativeContractsMember 2021-06-30 0000021076 clx:SoybeanOilFuturesMember 2021-06-30 0000021076 clx:JetFuelSwapsMember 2021-06-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2021-09-30 0000021076 us-gaap:ForeignExchangeContractMember clx:PurchasesofInventoryMember 2021-06-30 0000021076 us-gaap:InterestRateContractMember 2021-07-01 2021-09-30 0000021076 us-gaap:InterestRateContractMember 2021-06-30 0000021076 us-gaap:InterestRateContractMember 2021-09-30 0000021076 us-gaap:CommodityContractMember 2021-07-01 2021-09-30 0000021076 us-gaap:CommodityContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:ForeignExchangeContractMember 2021-07-01 2021-09-30 0000021076 us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:InterestRateContractMember 2020-07-01 2020-09-30 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2021-09-30 0000021076 us-gaap:CommodityContractMember clx:SoybeanOilFuturesMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CommodityContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-09-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:CashAndCashEquivalentsMember us-gaap:BankTimeDepositsMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2021-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-09-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-06-30 0000021076 us-gaap:OtherAssetsMember us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:TrustAssetsForNonqualifiedDeferredCompensationPlansMember 2021-06-30 0000021076 us-gaap:ShortTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2021-09-30 0000021076 us-gaap:ShortTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2021-09-30 0000021076 us-gaap:ShortTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember clx:NotesAndLoansPayableMember 2021-06-30 0000021076 us-gaap:ShortTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember clx:NotesAndLoansPayableMember 2021-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2021-09-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2021-09-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LongTermDebtMember 2021-06-30 0000021076 clx:CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LongTermDebtMember 2021-06-30 0000021076 us-gaap:CommonStockMember 2020-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-06-30 0000021076 us-gaap:TreasuryStockMember 2020-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-06-30 0000021076 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000021076 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000021076 us-gaap:CommonStockMember 2020-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000021076 us-gaap:RetainedEarningsMember 2020-09-30 0000021076 us-gaap:TreasuryStockMember 2020-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2020-09-30 0000021076 us-gaap:CommonStockMember 2021-06-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-06-30 0000021076 us-gaap:TreasuryStockMember 2021-06-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-06-30 0000021076 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-01 2021-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0000021076 us-gaap:TreasuryStockMember 2021-07-01 2021-09-30 0000021076 us-gaap:CommonStockMember 2021-09-30 0000021076 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0000021076 us-gaap:RetainedEarningsMember 2021-09-30 0000021076 us-gaap:TreasuryStockMember 2021-09-30 0000021076 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-30 0000021076 us-gaap:NoncontrollingInterestMember 2021-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2020-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-06-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-06-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-07-01 2021-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-07-01 2021-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-07-01 2021-09-30 0000021076 us-gaap:AccumulatedTranslationAdjustmentMember 2021-09-30 0000021076 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2021-09-30 0000021076 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-09-30 0000021076 clx:LongTermInterCompanyLoansMember 2020-07-01 2020-09-30 0000021076 clx:LongTermInterCompanyLoansMember 2021-07-01 2021-09-30 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2021-07-01 2021-09-30 0000021076 clx:RetirementIncomeMember us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000021076 clx:RetirementIncomeMember country:US 2021-07-01 2021-09-30 0000021076 clx:RetirementIncomeMember country:US 2020-07-01 2020-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-06-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2021-07-01 2021-09-30 0000021076 clx:AlamedaCountyCaliforniaMatterMember 2017-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-09-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-06-30 0000021076 clx:DickinsonCountyMichiganMatterMember 2021-07-01 2021-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2021-07-01 2021-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HealthAndWellnessMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2021-07-01 2021-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:HouseholdMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2021-07-01 2021-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:LifestyleMember 2020-07-01 2020-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2021-07-01 2021-09-30 0000021076 us-gaap:OperatingSegmentsMember clx:InternationalMember 2020-07-01 2020-09-30 0000021076 us-gaap:CorporateNonSegmentMember 2021-07-01 2021-09-30 0000021076 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2021-07-01 2021-09-30 0000021076 clx:WalmartStoresIncMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:CleaningMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:ProfessionalProductsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember clx:VitaminsMineralsAndSupplementsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HealthAndWellnessMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:BagsWrapsAndContainersMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:CatLitterMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:GrillingMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember clx:GrillingMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:HouseholdMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:FoodProductsMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:NaturalPersonalCareMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember clx:WaterFiltrationMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:LifestyleMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember clx:InternationalMember 2020-07-01 2020-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2021-07-01 2021-09-30 0000021076 us-gaap:RevenueFromContractWithCustomerMember us-gaap:ProductConcentrationRiskMember 2020-07-01 2020-09-30 shares iso4217:USD iso4217:USD shares clx:entity pure clx:reportableSegment 0000021076 false --06-30 Q1 2022 10-Q true 2021-09-30 false 1-07151 THE CLOROX COMPANY DE 31-0595760 1221 Broadway Oakland CA 94612-1888 510 271-7000 Common Stock - $1.00 par value CLX NYSE Yes Yes Large Accelerated Filer false false false 122862766 1806000000 1916000000 1136000000 996000000 670000000 920000000 236000000 238000000 182000000 179000000 33000000 32000000 25000000 25000000 9000000 -80000000 185000000 526000000 42000000 109000000 143000000 417000000 1000000 2000000 142000000 415000000 1.15 3.28 1.14 3.22 122980000 126346000 124042000 128729000 122000000 434000000 1000000 2000000 121000000 432000000 210000000 319000000 654000000 604000000 785000000 752000000 171000000 154000000 1820000000 1829000000 2422000000 2382000000 1301000000 1302000000 310000000 332000000 1566000000 1575000000 691000000 693000000 218000000 225000000 368000000 378000000 6274000000 6334000000 86000000 0 899000000 300000000 72000000 81000000 1582000000 1675000000 2639000000 2056000000 1885000000 2484000000 288000000 301000000 846000000 834000000 69000000 67000000 5727000000 5742000000 1.00 1.00 5000000 5000000 0 0 0 0 0 0 1.00 1.00 750000000 750000000 130741461 130741461 122856251 122780220 131000000 131000000 1166000000 1186000000 1027000000 1036000000 7885210 7961241 1389000000 1396000000 -567000000 -546000000 368000000 411000000 179000000 181000000 547000000 592000000 6274000000 6334000000 143000000 417000000 55000000 51000000 9000000 13000000 2000000 20000000 -8000000 71000000 53000000 8000000 37000000 70000000 14000000 18000000 -96000000 20000000 0 -1000000 24000000 30000000 41000000 383000000 52000000 69000000 0 85000000 4000000 -3000000 -56000000 -151000000 86000000 0 25000000 100000000 142000000 140000000 -11000000 -7000000 -92000000 -247000000 -3000000 3000000 -110000000 -12000000 324000000 879000000 214000000 867000000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.</span></div> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.</span></div> BUSINESS ACQUIRED<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Saudi Joint Venture Acquisition</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture) from 30 percent to 51 percent. The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. With the additional investment, the Company has consolidated this joint venture into its consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests. As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, noncash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Saudi joint venture acquisition was accounted for under the acquisition method of accounting for business combinations. The total purchase consideration was $111 consisting of $100 cash paid and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date. The fair value of the total net assets and noncontrolling interests recorded as of the date of acquisition was $412 and $198, respectively. The purchase price allocation was finalized during the second quarter of fiscal year 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Refer to the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 for the final purchase price allocation, valuation methodology and other information related to the Saudi joint venture acquisition.</span></div> 2 0.30 0.51 85000000 111000000 100000000 11000000 412000000 198000000 INVENTORIES, NET<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, consisted of the following as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories, net, consisted of the following as of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and packaging</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIFO allowances</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 594000000 543000000 220000000 229000000 13000000 11000000 42000000 31000000 785000000 752000000 FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Risk Management and Derivative Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity Price Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the notional amount of commodity derivatives was $35, of which $24 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2021, the notional amount of commodity derivatives was $32, of which $23 related to soybean oil futures and $9 related to jet fuel swaps.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $50 and $70, respectively, as of September 30, 2021 and June 30, 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk Management</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The notional amounts of outstanding interest rate contracts used by the Company were $300 as of both September 30, 2021 and June 30, 2021. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commodity, Foreign Exchange and Interest Rate Derivatives </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:70.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.566%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:39.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2021, that is expected to be reclassified into Net earnings (losses) within the next twelve months is $7. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterparty Risk Management and Derivative Contract Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of both September 30, 2021 and June 30, 2021, $0 contained such terms. As of September 30, 2021 and June 30, 2021, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard &amp; Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2021 and June 30, 2021, the Company and each of its counterparties had been assigned investment grade ratings by both Standard &amp; Poor’s and Moody’s.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2021 and June 30, 2021, the Company maintained cash margin balances related to exchange-traded futures contracts of $2 and $0, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trust Assets</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:24.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest-bearing investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">term debt and Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,029 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div> P2Y 35000000 24000000 11000000 32000000 23000000 9000000 P2Y 50000000 70000000 P3Y 300000000 300000000 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.368%"><tr><td style="width:1.0%"/><td style="width:70.821%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.563%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.566%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) recognized in Other comprehensive (loss) income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 0 1000000 1000000 -1000000 3000000 3000000 4000000 3000000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:39.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.751%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.729%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.732%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earnings</span></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange derivative contracts</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate derivative contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 5000000 -1000000 0 0 -2000000 -2000000 3000000 -3000000 7000000 0 0 2000000 0 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Quoted market prices in active markets for identical assets or liabilities.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.</span></div> The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:24.231%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.022%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.479%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase futures contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commodity purchase swaps contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign exchange forward contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:24.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.942%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.501%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.506%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6/30/2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance Sheet<br/>Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value<br/>Hierarchy<br/>Level</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest-bearing investments, including money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trust assets for nonqualified deferred compensation plans</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes and loans payable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-term debt and Long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current maturities of long-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">term debt and Long-term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">debt </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,943 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,870 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,029 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,784 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,963 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:8.68pt">Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.</span></div> 1000000 1000000 5000000 5000000 4000000 4000000 4000000 4000000 2000000 2000000 0 0 26000000 26000000 24000000 24000000 33000000 33000000 33000000 33000000 98000000 98000000 196000000 196000000 1000000 1000000 11000000 11000000 142000000 142000000 136000000 136000000 241000000 241000000 343000000 343000000 86000000 86000000 0 0 2784000000 2943000000 2784000000 2963000000 2870000000 3029000000 2784000000 2963000000 INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 22.6% and 20.7% for the three months ended September 30, 2021, and 2020, respectively. The lower effective tax rate in the prior period was primarily due to the non-taxable portion of the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture. 0.226 0.207 NET EARNINGS PER SHARE (EPS)<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,980</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,346</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,042</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,729</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.575%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,980</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126,346</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive effect of stock options and other</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,383</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,042</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,729</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Antidilutive stock options and other</span></td><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,068</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 122980000 126346000 1062000 2383000 124042000 128729000 1068000 441000 COMPREHENSIVE INCOME <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of Comprehensive income for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Total comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income attributable to Clorox</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of Comprehensive income for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.574%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">434 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Total comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive income attributable to Clorox</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 143000000 417000000 -23000000 10000000 1000000 5000000 -1000000 -2000000 -21000000 17000000 122000000 434000000 1000000 2000000 121000000 432000000 STOCKHOLDERS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">’</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EQUITY</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the components of Stockholders’ equity were as follows for the periods indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:103%">(Dollars in millions except per share data; shares in thousands)</span></div></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Net (Loss) Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders’ Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,315)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,543)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.11 per share declared)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business combinations including purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,407)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.16 per share declared)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,389)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated other comprehensive net (loss) income</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense), and other</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in foreign currency translation adjustments are remeasurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the components of Stockholders’ equity were as follows for the periods indicated: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.022%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.894%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.063%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr style="height:29pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:103%">(Dollars in millions except per share data; shares in thousands)</span></div></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Net (Loss) Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-controlling interests</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Stockholders’ Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,567 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,315)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,543)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.11 per share declared)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(141)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Business combinations including purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">198 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,840 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,407)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32,704)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,311 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,741 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,036 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,961)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to Clorox stockholders ($1.16 per share declared)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends to non-controlling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other employee stock plan activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock purchased</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130,741 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,166 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,027 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,389)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7,885)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 159000000 158741000 1137000000 3567000000 -3315000000 32543000 -640000000 0 908000000 415000000 2000000 417000000 17000000 17000000 1.11 141000000 141000000 4000000 4000000 198000000 198000000 13000000 13000000 -4000000 -1000000 8000000 283000 3000000 100000000 444000 100000000 159000000 158741000 1146000000 3840000000 -3407000000 32704000 -623000000 196000000 1311000000 131000000 130741000 1186000000 1036000000 -1396000000 7961000 -546000000 181000000 592000000 142000000 1000000 143000000 -21000000 -21000000 1.16 143000000 143000000 3000000 3000000 9000000 9000000 -29000000 -8000000 32000000 228000 -5000000 25000000 152000 25000000 131000000 130741000 1166000000 1027000000 -1389000000 7885000 -567000000 179000000 547000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended September 30</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net unrealized gains (losses) on derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pension and postretirement benefit adjustments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated other comprehensive net (loss) income</span></td></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2020</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(450)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(640)</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(170)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="3" style="background-color:#c0c0c0;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of June 30, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(546)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive (loss) income before reclassifications</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from Accumulated other comprehensive net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit (expense), and other</span></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of September 30, 2021</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(426)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(163)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -450000000 -18000000 -172000000 -640000000 9000000 3000000 0 12000000 0 -3000000 -2000000 -5000000 -1000000 1000000 0 0 10000000 5000000 2000000 17000000 -440000000 -13000000 -170000000 -623000000 -403000000 21000000 -164000000 -546000000 -22000000 4000000 0 -18000000 0 3000000 -2000000 1000000 1000000 0 1000000 2000000 -23000000 1000000 1000000 -21000000 -426000000 22000000 -163000000 -567000000 0 0 0 0 EMPLOYEE BENEFIT PLANS<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:72.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.609%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2021 and 2020.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September 30, 2021 and 2020, the Company made $3 and $2 in contributions to its domestic retirement income plans, respectively. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs, all other components are reflected in Other (income) expense, net.</span></div> <div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"/><td style="width:72.727%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.608%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.609%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized items</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.</span></div> 0 0 4000000 4000000 4000000 4000000 -2000000 -3000000 2000000 3000000 0.030 0 0 3000000 2000000 OTHER CONTINGENCIES AND GUARANTEES<div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both September 30, 2021 and June 30, 2021, for its share of aggregate future remediation costs related to these matters. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One matter, which accounted for $14 of the recorded liability as of both September 30, 2021 and June 30, 2021, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2021 and June 30, 2021. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2021 and June 30, 2021.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, the Company was party to a letter of credit of $14, related to one of its insurance carriers, of which $0 had been drawn upon.</span></div> 28000000 28000000 14000000 14000000 P30Y 14000000 28000000 P30Y 10000000 10000000 0.243 P30Y 14000000 0 SEGMENT RESULTS<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.</span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% for the three months ended September 30, 2021, and 2020.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitamins, Minerals and Supplements</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food Products</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International. </span></div><div style="margin-bottom:8pt;margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.</span></div> 4 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.128%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.131%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">442 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,806 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,916 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (losses) before income taxes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health and Wellness </span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Household</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">526 </span></td><td style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.014%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net sales</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9/30/2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cleaning</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional Products</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vitamins, Minerals and Supplements</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Health and Wellness</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bags and Wraps</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cat Litter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grilling</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Household</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Food Products</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Natural Personal Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Water Filtration</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#c0c0c0;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lifestyle</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#c0c0c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#c0c0c0;padding:0 1pt"/><td colspan="2" style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#c0c0c0;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 745000000 813000000 442000000 500000000 331000000 318000000 288000000 285000000 0 0 1806000000 1916000000 105000000 251000000 36000000 109000000 93000000 102000000 30000000 124000000 -79000000 -60000000 185000000 526000000 0.25 0.25 0.33 0.29 0.05 0.09 0.03 0.04 0.41 0.42 0.12 0.11 0.07 0.06 0.06 0.09 0.25 0.26 0.09 0.09 0.04 0.04 0.05 0.04 0.18 0.17 0.16 0.15 1 1 XML 18 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover Page - shares
 3 Months Ended
Sep. 30, 2021
Oct. 19, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2021  
Document Transition Report false  
Entity File Number 1-07151  
Entity Registrant Name THE CLOROX COMPANY  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 31-0595760  
Entity Address, Address Line One 1221 Broadway  
Entity Address, City or Town Oakland  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94612-1888  
City Area Code 510  
Local Phone Number 271-7000  
Title of 12(b) Security Common Stock - $1.00 par value  
Trading Symbol CLX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   122,862,766
Entity Central Index Key 0000021076  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2022  
XML 19 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Income Statement [Abstract]    
Net sales $ 1,806 $ 1,916
Cost of products sold 1,136 996
Gross profit 670 920
Selling and administrative expenses 236 238
Advertising costs 182 179
Research and development costs 33 32
Interest expense 25 25
Other (income) expense, net 9 (80)
Earnings before income taxes 185 526
Income taxes 42 109
Net earnings 143 417
Less: Net earnings attributable to noncontrolling interests 1 2
Net earnings attributable to Clorox $ 142 $ 415
Net earnings per share attributable to Clorox    
Basic net earnings per share (in dollars per share) $ 1.15 $ 3.28
Diluted net earnings per share (in dollars per share) $ 1.14 $ 3.22
Weighted average shares outstanding (in thousands)    
Basic (in shares) 122,980 126,346
Diluted (in shares) 124,042 128,729
Comprehensive income $ 122 $ 434
Less: Total comprehensive income attributable to noncontrolling interests 1 2
Total comprehensive income attributable to Clorox $ 121 $ 432
XML 20 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2021
Jun. 30, 2021
Current assets    
Cash and cash equivalents $ 210 $ 319
Receivables, net 654 604
Inventories, net 785 752
Prepaid expenses and other current assets 171 154
Total current assets 1,820 1,829
Property, plant and equipment, net of accumulated depreciation and amortization of $2,422 and $2,382, respectively 1,301 1,302
Operating lease right-of-use assets 310 332
Goodwill 1,566 1,575
Trademarks, net 691 693
Other intangible assets, net 218 225
Other assets 368 378
Total assets 6,274 6,334
Current liabilities    
Notes and loans payable 86 0
Current maturities of long-term debt 899 300
Current operating lease liabilities 72 81
Accounts payable and accrued liabilities 1,582 1,675
Total current liabilities 2,639 2,056
Long-term debt 1,885 2,484
Long-term operating lease liabilities 288 301
Other liabilities 846 834
Deferred income taxes 69 67
Total liabilities 5,727 5,742
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September 30, 2021 and June 30, 2021; and 122,856,251 and 122,780,220 shares outstanding as of September 30, 2021 and June 30, 2021, respectively 131 131
Additional paid-in capital 1,166 1,186
Retained earnings 1,027 1,036
Treasury stock, at cost: 7,885,210 and 7,961,241 shares as of September 30, 2021 and June 30, 2021, respectively (1,389) (1,396)
Accumulated other comprehensive net (loss) income (567) (546)
Total Clorox stockholders’ equity 368 411
Noncontrolling interests 179 181
Total stockholders’ equity 547 592
Total liabilities and stockholders’ equity $ 6,274 $ 6,334
XML 21 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2021
Jun. 30, 2021
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation and amortization $ 2,422 $ 2,382
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 130,741,461 130,741,461
Common stock, shares outstanding (in shares) 122,856,251 122,780,220
Treasury stock, shares (in shares) 7,885,210 7,961,241
XML 22 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Operating activities:    
Net earnings $ 143 $ 417
Adjustments to reconcile net earnings to net cash provided by operations:    
Depreciation and amortization 55 51
Stock-based compensation 9 13
Deferred income taxes 2 20
Other 8 (71)
Changes in:    
Receivables, net (53) (8)
Inventories, net (37) (70)
Prepaid expenses and other current assets (14) (18)
Accounts payable and accrued liabilities (96) 20
Operating lease right-of-use assets and liabilities, net 0 (1)
Income taxes payable / prepaid 24 30
Net cash provided by operations 41 383
Investing activities:    
Capital expenditures (52) (69)
Businesses acquired, net of cash acquired 0 (85)
Other (4) 3
Net cash used for investing activities (56) (151)
Financing activities:    
Notes and loans payable, net 86 0
Treasury stock purchased (25) (100)
Cash dividends paid to Clorox stockholders (142) (140)
Issuance of common stock for employee stock plans and other (11) (7)
Net cash used for financing activities (92) (247)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash (3) 3
Net increase (decrease) in cash, cash equivalents, and restricted cash (110) (12)
Cash, cash equivalents, and restricted cash:    
Beginning of period 324 879
End of period $ 214 $ 867
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 3 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.
XML 24 R7.htm IDEA: XBRL DOCUMENT v3.21.2
BUSINESS ACQUIRED
 3 Months Ended
Sep. 30, 2021
Business Combination and Asset Acquisition [Abstract]  
BUSINESS ACQUIRED BUSINESS ACQUIRED
Saudi Joint Venture Acquisition

On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture) from 30 percent to 51 percent. The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. With the additional investment, the Company has consolidated this joint venture into its consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests. As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, noncash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021.

The Saudi joint venture acquisition was accounted for under the acquisition method of accounting for business combinations. The total purchase consideration was $111 consisting of $100 cash paid and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date. The fair value of the total net assets and noncontrolling interests recorded as of the date of acquisition was $412 and $198, respectively. The purchase price allocation was finalized during the second quarter of fiscal year 2021.

Refer to the Notes to Consolidated Financial Statements in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2021 for the final purchase price allocation, valuation methodology and other information related to the Saudi joint venture acquisition.
XML 25 R8.htm IDEA: XBRL DOCUMENT v3.21.2
INVENTORIES, NET
 3 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NETInventories, net, consisted of the following as of:
9/30/20216/30/2021
Finished goods$594 $543 
Raw materials and packaging220 229 
Work in process13 11 
LIFO allowances(42)(31)
Total$785 $752 
XML 26 R9.htm IDEA: XBRL DOCUMENT v3.21.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
 3 Months Ended
Sep. 30, 2021
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of September 30, 2021, the notional amount of commodity derivatives was $35, of which $24 related to soybean oil futures used for the Food products business and $11 related to jet fuel swaps used for the Grilling business. As of June 30, 2021, the notional amount of commodity derivatives was $32, of which $23 related to soybean oil futures and $9 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $50 and $70, respectively, as of September 30, 2021 and June 30, 2021.

Interest Rate Risk Management

The Company may enter into over-the-counter interest rate contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt. These interest rate contracts generally have durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by bond dealers.

The notional amounts of outstanding interest rate contracts used by the Company were $300 as of both September 30, 2021 and June 30, 2021. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.

Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate contracts for forecasted interest payments as cash flow hedges.
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contracts$— $1 
Foreign exchange derivative contracts1 (1)
Interest rate derivative contracts3 3 
Total$4 $3 

Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contractsCost of products sold$5 $(1)
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$3 $(3)

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of September 30, 2021, that is expected to be reclassified into Net earnings (losses) within the next twelve months is $7.

Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of both September 30, 2021 and June 30, 2021, $0 contained such terms. As of September 30, 2021 and June 30, 2021, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both September 30, 2021 and June 30, 2021, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of September 30, 2021 and June 30, 2021, the Company maintained cash margin balances related to exchange-traded futures contracts of $2 and $0, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.
Trust Assets

The Company holds interests in mutual funds and cash equivalents as part of trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which their compensation deferrals are invested in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value of Financial Instruments

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2021 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsPrepaid expenses and other current assets1$1 $1 $5 $5 
Commodity purchase swaps contractsPrepaid expenses and other current assets24 4 4 4 
Foreign exchange forward contractsPrepaid expenses and other current assets22 2 — — 
Interest rate contractsPrepaid expenses and other current assets226 26 24 24 
 $33 $33 $33 $33 

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
equivalents (1)
1$98 $98 $196 $196 
Time deposits
Cash and cash
equivalents (1)
21 1 11 11 
Trust assets for nonqualified deferred compensation plansOther assets1142 142 136 136 
 $241 $241 $343 $343 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$86 $86 $— $— 
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (3)
22,784 2,943 2,784 2,963 
$2,870 $3,029 $2,784 $2,963 

(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.
(3)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
XML 27 R10.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES
 3 Months Ended
Sep. 30, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings was 22.6% and 20.7% for the three months ended September 30, 2021, and 2020, respectively. The lower effective tax rate in the prior period was primarily due to the non-taxable portion of the remeasurement gain recognized on the previously held equity interest in the Saudi joint venture.
XML 28 R11.htm IDEA: XBRL DOCUMENT v3.21.2
NET EARNINGS PER SHARE (EPS)
 3 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
NET EARNINGS PER SHARE (EPS) NET EARNINGS PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20219/30/2020
Basic122,980126,346
Dilutive effect of stock options and other1,0622,383
Diluted124,042128,729
Antidilutive stock options and other1,068441 

Basic net earnings per share and Diluted net earnings per share are calculated on Net earnings attributable to Clorox.
XML 29 R12.htm IDEA: XBRL DOCUMENT v3.21.2
COMPREHENSIVE INCOME
 3 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
COMPREHENSIVE INCOME COMPREHENSIVE INCOME The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20219/30/2020
Net earnings $143 $417 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments(23)10 
Net unrealized gains (losses) on derivatives1 5 
Pension and postretirement benefit adjustments1 2 
Total other comprehensive (loss) income, net of tax(21)17 
Comprehensive income122 434 
Less: Total comprehensive income attributable to noncontrolling interests1 2 
Total comprehensive income attributable to Clorox$121 $432 
XML 30 R13.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY
 3 Months Ended
Sep. 30, 2021
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITYChanges in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interestsTotal Stockholders’ Equity
AmountShares AmountShares
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings— — — 415 — — — 2 417 
Other comprehensive (loss) income— — — — — — 17 — 17 
Dividends to Clorox stockholders ($1.11 per share declared)
— — — (141)— — — — (141)
Dividends to non-controlling interests— — — — — — — (4)(4)
Business combinations including purchase accounting adjustments— — — — — — — 198 198 
Stock-based compensation— — 13 — — — — — 13 
Other employee stock plan activities— — (4)(1)8 283 — — 3 
Treasury stock purchased— — — — (100)(444)— — (100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 
Balance as of June 30, 2021$131 130,741 $1,186 $1,036 $(1,396)(7,961)$(546)$181 $592 
Net earnings— — — 142 — — — 1 143 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($1.16 per share declared)
— — — (143)— — — — (143)
Dividends to non-controlling interests— — — — — — — (3)(3)
Stock-based compensation— — 9 — — — — — 9 
Other employee stock plan activities— — (29)(8)32 228 — — (5)
Treasury stock purchased— — — — (25)(152)— — (25)
Balance as of September 30, 2021$131 130,741 $1,166 $1,027 $(1,389)(7,885)$(567)$179 $547 
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense)1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)
Balance as of June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before reclassifications(22)4 — (18)
Amounts reclassified from Accumulated other comprehensive net (loss) income— (3)2 (1)
Income tax benefit (expense), and other(1)— (1)(2)
Net current period other comprehensive (loss) income(23)1 1 (21)
Balance as of September 30, 2021$(426)$22 $(163)$(567)

Included in foreign currency translation adjustments are remeasurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
XML 31 R14.htm IDEA: XBRL DOCUMENT v3.21.2
EMPLOYEE BENEFIT PLANS
 3 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20219/30/2020
Service cost$— $— 
Interest cost4 4 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items2 3 
Total$2 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended September 30, 2021 and 2020.
During the three months ended September 30, 2021 and 2020, the Company made $3 and $2 in contributions to its domestic retirement income plans, respectively.
Service cost component of the net periodic benefit cost, if any, is reflected in employee benefit costs, all other components are reflected in Other (income) expense, net.
XML 32 R15.htm IDEA: XBRL DOCUMENT v3.21.2
OTHER CONTINGENCIES AND GUARANTEES
 3 Months Ended
Sep. 30, 2021
OTHER CONTINGENCIES AND GUARANTEES [Abstract]  
OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $28 as of both September 30, 2021 and June 30, 2021, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of both September 30, 2021 and June 30, 2021, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of September 30, 2021 and June 30, 2021. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of September 30, 2021 and June 30, 2021.
As of September 30, 2021, the Company was party to a letter of credit of $14, related to one of its insurance carriers, of which $0 had been drawn upon.
XML 33 R16.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT RESULTS
 3 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
SEGMENT RESULTS SEGMENT RESULTS
The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20219/30/2020
Health and Wellness$745 $813 
Household442 500 
Lifestyle331 318 
International288 285 
Corporate— — 
Total$1,806 $1,916 
Earnings (losses) before income taxes
Three Months Ended
9/30/20219/30/2020
Health and Wellness $105 $251 
Household36 109 
Lifestyle93 102 
International30 124 
Corporate(79)(60)
Total$185 $526 
All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 25% for the three months ended September 30, 2021, and 2020.
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:
Net sales
Three Months Ended
9/30/20219/30/2020
Cleaning33 %29 %
Professional Products5 %9 %
Vitamins, Minerals and Supplements3 %4 %
Health and Wellness41 %42 %
Bags and Wraps12 %11 %
Cat Litter7 %6 %
Grilling6 %9 %
Household25 %26 %
Food Products9 %9 %
Natural Personal Care4 %4 %
Water Filtration5 %4 %
Lifestyle18 %17 %
International16 %15 %
Total100 %100 %
XML 34 R17.htm IDEA: XBRL DOCUMENT v3.21.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 3 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three months ended September 30, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2021, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Adopted Accounting Standards
Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which removes certain exceptions to the general principles in ASC 740 and amends existing guidance to improve consistent application. Certain amendments must be applied prospectively, certain amendments must be applied on a retrospective basis, and certain amendments must be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings. The Company adopted this standard as of July 1, 2021. The adoption of this new standard did not have a material impact on the Company’s condensed consolidated financial statements.
Fair Value Measurement
Fair Value of Financial Instruments

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of September 30, 2021 and June 30, 2021, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results
The Company operates through strategic business units (SBUs) that are also the Company’s operating segments. The SBUs are then aggregated into four reportable segments: Health and Wellness, Household, Lifestyle and International.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
XML 35 R18.htm IDEA: XBRL DOCUMENT v3.21.2
INVENTORIES, NET (Tables)
 3 Months Ended
Sep. 30, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net Inventories, net, consisted of the following as of:
9/30/20216/30/2021
Finished goods$594 $543 
Raw materials and packaging220 229 
Work in process13 11 
LIFO allowances(42)(31)
Total$785 $752 
XML 36 R19.htm IDEA: XBRL DOCUMENT v3.21.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
 3 Months Ended
Sep. 30, 2021
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:
Gains (losses) recognized in Other comprehensive (loss) income
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contracts$— $1 
Foreign exchange derivative contracts1 (1)
Interest rate derivative contracts3 3 
Total$4 $3 
Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months Ended
9/30/20219/30/2020
Commodity purchase derivative contractsCost of products sold$5 $(1)
Foreign exchange derivative contractsCost of products sold— — 
Interest rate derivative contractsInterest expense(2)(2)
Total$3 $(3)
Schedule of Assets and Liabilities for Fair Value Disclosure The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Commodity purchase futures contractsPrepaid expenses and other current assets1$1 $1 $5 $5 
Commodity purchase swaps contractsPrepaid expenses and other current assets24 4 4 4 
Foreign exchange forward contractsPrepaid expenses and other current assets22 2 — — 
Interest rate contractsPrepaid expenses and other current assets226 26 24 24 
 $33 $33 $33 $33 
The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 9/30/20216/30/2021
Balance Sheet
Classification		Fair Value
Hierarchy
Level		Carrying
Amount		Estimated
Fair
Value		Carrying
Amount		Estimated
Fair
Value
Assets
Interest-bearing investments, including money market funds
Cash and cash
equivalents (1)
1$98 $98 $196 $196 
Time deposits
Cash and cash
equivalents (1)
21 1 11 11 
Trust assets for nonqualified deferred compensation plansOther assets1142 142 136 136 
 $241 $241 $343 $343 
Liabilities
Notes and loans payable
Notes and loans payable (2)
2$86 $86 $— $— 
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (3)
22,784 2,943 2,784 2,963 
$2,870 $3,029 $2,784 $2,963 

(1)Cash and cash equivalents are composed of time deposits and other interest-bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Notes and loans payable are composed of outstanding U.S. commercial paper balances, which are recorded at cost, which approximates fair value.
(3)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
XML 37 R20.htm IDEA: XBRL DOCUMENT v3.21.2
NET EARNINGS PER SHARE (EPS) (Tables)
 3 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months Ended
9/30/20219/30/2020
Basic122,980126,346
Dilutive effect of stock options and other1,0622,383
Diluted124,042128,729
Antidilutive stock options and other1,068441 
XML 38 R21.htm IDEA: XBRL DOCUMENT v3.21.2
COMPREHENSIVE INCOME (Tables)
 3 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of Comprehensive Income The following table provides a summary of Comprehensive income for the periods indicated:
Three Months Ended
9/30/20219/30/2020
Net earnings $143 $417 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments(23)10 
Net unrealized gains (losses) on derivatives1 5 
Pension and postretirement benefit adjustments1 2 
Total other comprehensive (loss) income, net of tax(21)17 
Comprehensive income122 434 
Less: Total comprehensive income attributable to noncontrolling interests1 2 
Total comprehensive income attributable to Clorox$121 $432 
XML 39 R22.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY (Tables)
 3 Months Ended
Sep. 30, 2021
Equity [Abstract]  
Schedule of Stockholders Equity Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended September 30
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income		Non-controlling interestsTotal Stockholders’ Equity
AmountShares AmountShares
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings— — — 415 — — — 2 417 
Other comprehensive (loss) income— — — — — — 17 — 17 
Dividends to Clorox stockholders ($1.11 per share declared)
— — — (141)— — — — (141)
Dividends to non-controlling interests— — — — — — — (4)(4)
Business combinations including purchase accounting adjustments— — — — — — — 198 198 
Stock-based compensation— — 13 — — — — — 13 
Other employee stock plan activities— — (4)(1)8 283 — — 3 
Treasury stock purchased— — — — (100)(444)— — (100)
Balance as of September 30, 2020$159 158,741 $1,146 $3,840 $(3,407)(32,704)$(623)$196 $1,311 
Balance as of June 30, 2021$131 130,741 $1,186 $1,036 $(1,396)(7,961)$(546)$181 $592 
Net earnings— — — 142 — — — 1 143 
Other comprehensive (loss) income— — — — — — (21)— (21)
Dividends to Clorox stockholders ($1.16 per share declared)
— — — (143)— — — — (143)
Dividends to non-controlling interests— — — — — — — (3)(3)
Stock-based compensation— — 9 — — — — — 9 
Other employee stock plan activities— — (29)(8)32 228 — — (5)
Treasury stock purchased— — — — (25)(152)— — (25)
Balance as of September 30, 2021$131 130,741 $1,166 $1,027 $(1,389)(7,885)$(567)$179 $547 
Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended September 30
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications9 3 — 12 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 3 2 5 
Income tax benefit (expense)1 (1)— — 
Net current period other comprehensive (loss) income10 5 2 17 
Balance as of September 30, 2020$(440)$(13)$(170)$(623)
Balance as of June 30, 2021$(403)$21 $(164)$(546)
Other comprehensive (loss) income before reclassifications(22)4 — (18)
Amounts reclassified from Accumulated other comprehensive net (loss) income— (3)2 (1)
Income tax benefit (expense), and other(1)— (1)(2)
Net current period other comprehensive (loss) income(23)1 1 (21)
Balance as of September 30, 2021$(426)$22 $(163)$(567)
XML 40 R23.htm IDEA: XBRL DOCUMENT v3.21.2
EMPLOYEE BENEFIT PLANS (Tables)
 3 Months Ended
Sep. 30, 2021
Retirement Benefits [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months Ended
9/30/20219/30/2020
Service cost$— $— 
Interest cost4 4 
Expected return on plan assets (1)
(4)(4)
Amortization of unrecognized items2 3 
Total$2 $3 
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2022 net periodic benefit cost is 3.0%.
XML 41 R24.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT RESULTS (Tables)
 3 Months Ended
Sep. 30, 2021
Segment Reporting [Abstract]  
Selected Financial Information Relating to the Company's Segments The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated net sales and earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months Ended
9/30/20219/30/2020
Health and Wellness$745 $813 
Household442 500 
Lifestyle331 318 
International288 285 
Corporate— — 
Total$1,806 $1,916 
Earnings (losses) before income taxes
Three Months Ended
9/30/20219/30/2020
Health and Wellness $105 $251 
Household36 109 
Lifestyle93 102 
International30 124 
Corporate(79)(60)
Total$185 $526 
The following table provides Net sales as a percentage of the Company’s consolidated net sales, disaggregated by SBU, for the periods indicated:
Net sales
Three Months Ended
9/30/20219/30/2020
Cleaning33 %29 %
Professional Products5 %9 %
Vitamins, Minerals and Supplements3 %4 %
Health and Wellness41 %42 %
Bags and Wraps12 %11 %
Cat Litter7 %6 %
Grilling6 %9 %
Household25 %26 %
Food Products9 %9 %
Natural Personal Care4 %4 %
Water Filtration5 %4 %
Lifestyle18 %17 %
International16 %15 %
Total100 %100 %
XML 42 R25.htm IDEA: XBRL DOCUMENT v3.21.2
BUSINESS ACQUIRED (Narrative) (Details)
$ in Millions
 3 Months Ended
Jul. 09, 2020
USD ($)
entity
Sep. 30, 2020
USD ($)
Joint Venture In Kingdom Of Saudi Arabia    
Business Combination, Separately Recognized Transactions [Line Items]    
Non-recurring, non-cash gain   $ 85
Purchase consideration $ 111  
Cash paid 100  
Loss on settlement 11  
Fair value of net assets acquired 412  
Fair value of non-controlling interest acquired $ 198  
Joint Venture In Kingdom Of Saudi Arabia    
Business Combination, Separately Recognized Transactions [Line Items]    
Noncontrolling interest, ownership percentage by parent 51.00%  
Joint Venture In Kingdom Of Saudi Arabia    
Business Combination, Separately Recognized Transactions [Line Items]    
Equity method investment, ownership percentage 30.00%  
Joint Venture In Kingdom Of Saudi Arabia | Joint Venture In Kingdom Of Saudi Arabia    
Business Combination, Separately Recognized Transactions [Line Items]    
Number of entities in joint venture | entity 2  
XML 43 R26.htm IDEA: XBRL DOCUMENT v3.21.2
INVENTORIES, NET (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Jun. 30, 2021
Inventory Disclosure [Abstract]    
Finished goods $ 594 $ 543
Raw materials and packaging 220 229
Work in process 13 11
LIFO allowances (42) (31)
Total $ 785 $ 752
XML 44 R27.htm IDEA: XBRL DOCUMENT v3.21.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)
 3 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Derivative [Line Items]    
Maximum duration, foreign exchange contracts (in years) 2 years  
Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months $ 7,000,000  
Derivative instruments subject to contractually defined counterparty liability position limits 0 $ 0
Interest rate contracts    
Derivative [Line Items]    
Notional amount $ 300,000,000 300,000,000
Maximum duration, interest rate contracts (in years) 3 years  
Purchases of Inventory | Foreign exchange derivative contracts    
Derivative [Line Items]    
Notional amount $ 50,000,000 70,000,000
Total Commodity Purchase Derivative Contracts    
Derivative [Line Items]    
Maximum duration, commodity contracts (in years) 2 years  
Notional amount $ 35,000,000 32,000,000
Soybean Oil Futures    
Derivative [Line Items]    
Notional amount 24,000,000 23,000,000
Soybean Oil Futures | Commodity contract    
Derivative [Line Items]    
Cash margin balances amount 2,000,000 0
Jet Fuel Swaps    
Derivative [Line Items]    
Notional amount $ 11,000,000 $ 9,000,000
XML 45 R28.htm IDEA: XBRL DOCUMENT v3.21.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income $ 4 $ 3
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 3 (3)
Commodity contract    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income 0 1
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 5 (1)
Foreign exchange derivative contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income 1 (1)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 0
Interest rate contracts    
Derivative Instruments, Gain (Loss) [Line Items]    
Gains (losses) recognized in Other comprehensive (loss) income 3 3
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ (2) $ (2)
XML 46 R29.htm IDEA: XBRL DOCUMENT v3.21.2
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) - USD ($)
$ in Millions
Sep. 30, 2021
Jun. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 210 $ 319
Total assets 6,274 6,334
Notes and loans payable 86 0
Total liabilities 5,727 5,742
Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 33 33
Total assets 241 343
Total liabilities 2,870 2,784
Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 33 33
Total other assets in the fair value hierarchy 241 343
Total other liabilities in the fair value hierarchy 3,029 2,963
Prepaid expenses and other current assets | Fair Value, Inputs, Level 1 | Carrying Amount | Commodity contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 1 5
Prepaid expenses and other current assets | Fair Value, Inputs, Level 1 | Estimated Fair Value | Commodity contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 1 5
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Carrying Amount | Commodity contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 4 4
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Carrying Amount | Foreign exchange forward contracts    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 2 0
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Carrying Amount | Interest rate contracts    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 26 24
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Estimated Fair Value | Commodity contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 4 4
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Estimated Fair Value | Foreign exchange forward contracts    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 2 0
Prepaid expenses and other current assets | Fair Value, Inputs, Level 2 | Estimated Fair Value | Interest rate contracts    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 26 24
Cash and Cash Equivalents | Fair Value, Inputs, Level 1 | Carrying Amount | Interest-bearing investments, including money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 98 196
Cash and Cash Equivalents | Fair Value, Inputs, Level 1 | Estimated Fair Value | Interest-bearing investments, including money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 98 196
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Carrying Amount | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 1 11
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Estimated Fair Value | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 1 11
Other assets | Trust assets for nonqualified deferred compensation plans | Fair Value, Inputs, Level 1 | Carrying Amount    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 142 136
Other assets | Trust assets for nonqualified deferred compensation plans | Fair Value, Inputs, Level 1 | Estimated Fair Value    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 142 136
Short-term Debt | Fair Value, Inputs, Level 2 | Carrying Amount | NotesAndLoansPayableMember    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Notes and loans payable 86 0
Short-term Debt | Fair Value, Inputs, Level 2 | Estimated Fair Value | NotesAndLoansPayableMember    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Short-term debt, fair value 86 0
Current maturities of long-term debt and Long-term debt | Fair Value, Inputs, Level 2 | Carrying Amount | Long-term Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt 2,784 2,784
Current maturities of long-term debt and Long-term debt | Fair Value, Inputs, Level 2 | Estimated Fair Value | Long-term Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt $ 2,943 $ 2,963
XML 47 R30.htm IDEA: XBRL DOCUMENT v3.21.2
INCOME TAXES (Narrative) (Details)
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Income Tax Disclosure [Abstract]    
Effective tax rate on earnings from continuing operations 22.60% 20.70%
XML 48 R31.htm IDEA: XBRL DOCUMENT v3.21.2
NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) - shares
shares in Thousands
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Earnings Per Share [Abstract]    
Basic (in shares) 122,980 126,346
Dilutive effect of stock options and other (in shares) 1,062 2,383
Diluted (in shares) 124,042 128,729
Antidilutive stock options and other (in shares) 1,068 441
XML 49 R32.htm IDEA: XBRL DOCUMENT v3.21.2
COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Stockholders' Equity Note [Abstract]    
Net earnings $ 143 $ 417
Other comprehensive (loss) income, net of tax:    
Foreign currency translation adjustments (23) 10
Net unrealized gains (losses) on derivatives 1 5
Pension and postretirement benefit adjustments 1 2
Total other comprehensive (loss) income, net of tax (21) 17
Comprehensive income 122 434
Less: Total comprehensive income attributable to noncontrolling interests 1 2
Total comprehensive income attributable to Clorox $ 121 $ 432
XML 50 R33.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Class of Stock [Line Items]    
Dividends declared per share (in dollars per share) $ 1.16 $ 1.11
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 592 $ 908
Net earnings 143 417
Other comprehensive (loss) income (21) 17
Dividends (143) (141)
Dividends to non-controlling interests (3) (4)
Business combinations including purchase accounting adjustments   198
Stock-based compensation 9 13
Other employee stock plan activities (5) 3
Treasury stock purchased (25) (100)
Balance, ending 547 1,311
Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 131 $ 159
Balance, beginning (in shares) 130,741 158,741
Balance, ending $ 131 $ 159
Balance, ending (in shares) 130,741 158,741
Additional Paid-in Capital    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ 1,186 $ 1,137
Stock-based compensation 9 13
Other employee stock plan activities (29) (4)
Balance, ending 1,166 1,146
Retained Earnings    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning 1,036 3,567
Net earnings 142 415
Dividends (143) (141)
Other employee stock plan activities (8) (1)
Balance, ending 1,027 3,840
Treasury Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ (1,396) $ (3,315)
Balance, beginning (in shares) 7,961 32,543
Other employee stock plan activities $ 32 $ 8
Other employee stock plan activities (in shares) 228 283
Treasury stock purchased $ (25) $ (100)
Treasury stock purchased (in shares) (152) (444)
Balance, ending $ (1,389) $ (3,407)
Balance, ending (in shares) 7,885 32,704
Accumulated Other Comprehensive Net (Loss) Income    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning $ (546) $ (640)
Other comprehensive (loss) income (21) 17
Balance, ending (567) (623)
Non-controlling interests    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning 181 0
Net earnings 1 2
Dividends to non-controlling interests (3) (4)
Business combinations including purchase accounting adjustments   198
Balance, ending $ 179 $ 196
XML 51 R34.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY (Narrative) (Details) - USD ($)
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Amounts reclassified from accumulated other comprehensive net (loss) income $ 1,000,000 $ (5,000,000)
Long-Term Inter-Company Loans    
Accumulated Other Comprehensive Income (Loss) [Line Items]    
Amounts reclassified from accumulated other comprehensive net (loss) income $ 0 $ 0
XML 52 R35.htm IDEA: XBRL DOCUMENT v3.21.2
STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning $ 411  
Other comprehensive (loss) income before reclassifications (18) $ 12
Amounts reclassified from Accumulated other comprehensive net (loss) income (1) 5
Income tax benefit (expense) (2) 0
Net current period other comprehensive (loss) income (21) 17
Balance, ending 368  
Foreign currency translation adjustments    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (403) (450)
Other comprehensive (loss) income before reclassifications (22) 9
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0
Income tax benefit (expense) (1) 1
Net current period other comprehensive (loss) income (23) 10
Balance, ending (426) (440)
Net unrealized gains (losses) on derivatives    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning 21 (18)
Other comprehensive (loss) income before reclassifications 4 3
Amounts reclassified from Accumulated other comprehensive net (loss) income (3) 3
Income tax benefit (expense) 0 (1)
Net current period other comprehensive (loss) income 1 5
Balance, ending 22 (13)
Pension and postretirement benefit adjustments    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (164) (172)
Other comprehensive (loss) income before reclassifications 0 0
Amounts reclassified from Accumulated other comprehensive net (loss) income 2 2
Income tax benefit (expense) (1) 0
Net current period other comprehensive (loss) income 1 2
Balance, ending (163) (170)
Accumulated Other Comprehensive Net (Loss) Income    
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]    
Balance, beginning (546) (640)
Balance, ending $ (567) $ (623)
XML 53 R36.htm IDEA: XBRL DOCUMENT v3.21.2
EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]    
Total $ 0 $ 0
Weighted average long-term expected rate or return on plan assets 3.00%  
Other Postretirement Benefits Plan | Retirement Income Plans    
Defined Benefit Plan Disclosure [Line Items]    
Service cost $ 0 0
Interest cost 4 4
Expected return on plan assets (4) (4)
Amortization of unrecognized items 2 3
Total $ 2 $ 3
XML 54 R37.htm IDEA: XBRL DOCUMENT v3.21.2
EMPLOYEE BENEFIT PLANS (Narrative) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Defined Benefit Plan Disclosure [Line Items]    
Net periodic benefit cost (benefit) $ 0 $ 0
Retirement Income Plans | UNITED STATES    
Defined Benefit Plan Disclosure [Line Items]    
Discretionary contributions $ 3 $ 2
XML 55 R38.htm IDEA: XBRL DOCUMENT v3.21.2
OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Jun. 30, 2021
Jun. 30, 2017
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 28 $ 28  
Letter of credit 14    
Letter of credit, amount outstanding 0    
Alameda County, California Matter      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 14 14 $ 14
Remediation period (in years) 30 years    
Maximum undiscounted costs $ 28    
Dickinson County, Michigan Matter      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 10 $ 10  
Remediation period (in years) 30 years    
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%    
XML 56 R39.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT RESULTS (Narrative) (Details) - reportableSegment
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Concentration Risk [Line Items]    
Number of reportable segments 4  
Revenue from Contract with Customer | Customer Concentration Risk | Walmart Stores, Inc.    
Concentration Risk [Line Items]    
Concentration percentage 25.00% 25.00%
XML 57 R40.htm IDEA: XBRL DOCUMENT v3.21.2
SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) - USD ($)
$ in Millions
 3 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Segment Reporting Information [Line Items]    
Net sales $ 1,806 $ 1,916
Earnings (losses) before income taxes $ 185 $ 526
Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 100.00% 100.00%
Health and Wellness | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 41.00% 42.00%
Health and Wellness | Cleaning | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 33.00% 29.00%
Health and Wellness | Professional Products | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 5.00% 9.00%
Health and Wellness | Vitamins, Minerals and Supplements | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 3.00% 4.00%
Household | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 25.00% 26.00%
Household | Bags and Wraps | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 12.00% 11.00%
Household | Cat Litter | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 7.00% 6.00%
Household | Grilling | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 6.00% 9.00%
Lifestyle | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 18.00% 17.00%
Lifestyle | Food Products | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 9.00% 9.00%
Lifestyle | Natural Personal Care | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 4.00% 4.00%
Lifestyle | Water Filtration | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 5.00% 4.00%
International | Product Concentration Risk | Revenue from Contract with Customer    
Segment Reporting Information [Line Items]    
Concentration percentage 16.00% 15.00%
Operating Segments | Health and Wellness    
Segment Reporting Information [Line Items]    
Net sales $ 745 $ 813
Earnings (losses) before income taxes 105 251
Operating Segments | Household    
Segment Reporting Information [Line Items]    
Net sales 442 500
Earnings (losses) before income taxes 36 109
Operating Segments | Lifestyle    
Segment Reporting Information [Line Items]    
Net sales 331 318
Earnings (losses) before income taxes 93 102
Operating Segments | International    
Segment Reporting Information [Line Items]    
Net sales 288 285
Earnings (losses) before income taxes 30 124
Corporate, Non-Segment    
Segment Reporting Information [Line Items]    
Net sales 0 0
Earnings (losses) before income taxes $ (79) $ (60)
EXCEL 58 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 59 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 60 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 61 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 177 274 1 false 59 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.clorox.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 2103102 - Disclosure - BUSINESS ACQUIRED Sheet http://www.clorox.com/role/BUSINESSACQUIRED BUSINESS ACQUIRED Notes 7 false false R8.htm 2105103 - Disclosure - INVENTORIES, NET Sheet http://www.clorox.com/role/INVENTORIESNET INVENTORIES, NET Notes 8 false false R9.htm 2108104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 2113105 - Disclosure - INCOME TAXES Sheet http://www.clorox.com/role/INCOMETAXES INCOME TAXES Notes 10 false false R11.htm 2115106 - Disclosure - NET EARNINGS PER SHARE (EPS) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPS NET EARNINGS PER SHARE (EPS) Notes 11 false false R12.htm 2118107 - Disclosure - COMPREHENSIVE INCOME Sheet http://www.clorox.com/role/COMPREHENSIVEINCOME COMPREHENSIVE INCOME Notes 12 false false R13.htm 2121108 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 13 false false R14.htm 2126109 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 14 false false R15.htm 2130110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES Sheet http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES OTHER CONTINGENCIES AND GUARANTEES Notes 15 false false R16.htm 2132111 - Disclosure - SEGMENT RESULTS Sheet http://www.clorox.com/role/SEGMENTRESULTS SEGMENT RESULTS Notes 16 false false R17.htm 2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 17 false false R18.htm 2306301 - Disclosure - INVENTORIES, NET (Tables) Sheet http://www.clorox.com/role/INVENTORIESNETTables INVENTORIES, NET (Tables) Tables http://www.clorox.com/role/INVENTORIESNET 18 false false R19.htm 2309302 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables) Tables http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS 19 false false R20.htm 2316303 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables NET EARNINGS PER SHARE (EPS) (Tables) Tables http://www.clorox.com/role/NETEARNINGSPERSHAREEPS 20 false false R21.htm 2319304 - Disclosure - COMPREHENSIVE INCOME (Tables) Sheet http://www.clorox.com/role/COMPREHENSIVEINCOMETables COMPREHENSIVE INCOME (Tables) Tables http://www.clorox.com/role/COMPREHENSIVEINCOME 21 false false R22.htm 2322305 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.clorox.com/role/STOCKHOLDERSEQUITY 22 false false R23.htm 2327306 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables EMPLOYEE BENEFIT PLANS (Tables) Tables http://www.clorox.com/role/EMPLOYEEBENEFITPLANS 23 false false R24.htm 2333307 - Disclosure - SEGMENT RESULTS (Tables) Sheet http://www.clorox.com/role/SEGMENTRESULTSTables SEGMENT RESULTS (Tables) Tables http://www.clorox.com/role/SEGMENTRESULTS 24 false false R25.htm 2404401 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details) Sheet http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails BUSINESS ACQUIRED (Narrative) (Details) Details http://www.clorox.com/role/BUSINESSACQUIRED 25 false false R26.htm 2407402 - Disclosure - INVENTORIES, NET (Details) Sheet http://www.clorox.com/role/INVENTORIESNETDetails INVENTORIES, NET (Details) Details http://www.clorox.com/role/INVENTORIESNETTables 26 false false R27.htm 2410403 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 27 false false R28.htm 2411404 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 28 false false R29.htm 2412405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) Sheet http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) Details http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables 29 false false R30.htm 2414406 - Disclosure - INCOME TAXES (Narrative) (Details) Sheet http://www.clorox.com/role/INCOMETAXESNarrativeDetails INCOME TAXES (Narrative) (Details) Details http://www.clorox.com/role/INCOMETAXES 30 false false R31.htm 2417407 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) Sheet http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) Details http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables 31 false false R32.htm 2420408 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) Sheet http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details) Details http://www.clorox.com/role/COMPREHENSIVEINCOMETables 32 false false R33.htm 2423409 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 33 false false R34.htm 2424410 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails STOCKHOLDERS' EQUITY (Narrative) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 34 false false R35.htm 2425411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) Sheet http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) Details http://www.clorox.com/role/STOCKHOLDERSEQUITYTables 35 false false R36.htm 2428412 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) Details http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables 36 false false R37.htm 2429413 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details) Sheet http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails EMPLOYEE BENEFIT PLANS (Narrative) (Details) Details http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables 37 false false R38.htm 2431414 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details) Sheet http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails OTHER CONTINGENCIES AND GUARANTEES (Details) Details http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES 38 false false R39.htm 2434415 - Disclosure - SEGMENT RESULTS (Narrative) (Details) Sheet http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails SEGMENT RESULTS (Narrative) (Details) Details http://www.clorox.com/role/SEGMENTRESULTSTables 39 false false R40.htm 2435416 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) Sheet http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) Details http://www.clorox.com/role/SEGMENTRESULTSTables 40 false false All Reports Book All Reports clx-20210930.htm clx-20210930.xsd clx-20210930_cal.xml clx-20210930_def.xml clx-20210930_lab.xml clx-20210930_pre.xml clxq1fy22exhibit101.htm clxq1fy22exhibit102.htm clxq1fy22exhibit103.htm clxq1fy22exhibit104.htm clxq1fy22exhibit105.htm clxq1fy22exhibit106.htm clxq1fy22exhibit311.htm clxq1fy22exhibit312.htm clxq1fy22exhibit32.htm clx-20210930_g1.jpg http://xbrl.sec.gov/dei/2021 http://xbrl.sec.gov/country/2021 http://fasb.org/us-gaap/2021-01-31 http://fasb.org/srt/2021-01-31 true true JSON 63 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "clx-20210930.htm": { "axisCustom": 1, "axisStandard": 24, "contextCount": 177, "dts": { "calculationLink": { "local": [ "clx-20210930_cal.xml" ] }, "definitionLink": { "local": [ "clx-20210930_def.xml" ] }, "inline": { "local": [ "clx-20210930.htm" ] }, "labelLink": { "local": [ "clx-20210930_lab.xml" ] }, "presentationLink": { "local": [ "clx-20210930_pre.xml" ] }, "schema": { "local": [ "clx-20210930.xsd" ], "remote": [ "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 366, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 5, "total": 5 }, "keyCustom": 15, "keyStandard": 259, "memberCustom": 26, "memberStandard": 31, "nsprefix": "clx", "nsuri": "http://www.clorox.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.clorox.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - INCOME TAXES", "role": "http://www.clorox.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115106 - Disclosure - NET EARNINGS PER SHARE (EPS)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS", "shortName": "NET EARNINGS PER SHARE (EPS)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118107 - Disclosure - COMPREHENSIVE INCOME", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOME", "shortName": "COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121108 - Disclosure - STOCKHOLDERS' EQUITY", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITY", "shortName": "STOCKHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2126109 - Disclosure - EMPLOYEE BENEFIT PLANS", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:OTHERCONTINGENCIESANDGUARANTEESTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2130110 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES", "role": "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES", "shortName": "OTHER CONTINGENCIES AND GUARANTEES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:OTHERCONTINGENCIESANDGUARANTEESTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2132111 - Disclosure - SEGMENT RESULTS", "role": "http://www.clorox.com/role/SEGMENTRESULTS", "shortName": "SEGMENT RESULTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - INVENTORIES, NET (Tables)", "role": "http://www.clorox.com/role/INVENTORIESNETTables", "shortName": "INVENTORIES, NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "shortName": "Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316303 - Disclosure - NET EARNINGS PER SHARE (EPS) (Tables)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables", "shortName": "NET EARNINGS PER SHARE (EPS) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319304 - Disclosure - COMPREHENSIVE INCOME (Tables)", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOMETables", "shortName": "COMPREHENSIVE INCOME (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2322305 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2327306 - Disclosure - EMPLOYEE BENEFIT PLANS (Tables)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables", "shortName": "EMPLOYEE BENEFIT PLANS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2333307 - Disclosure - SEGMENT RESULTS (Tables)", "role": "http://www.clorox.com/role/SEGMENTRESULTSTables", "shortName": "SEGMENT RESULTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ia146ca86e53949d5ae21b9e6cc2923ce_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404401 - Disclosure - BUSINESS ACQUIRED (Narrative) (Details)", "role": "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails", "shortName": "BUSINESS ACQUIRED (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ia146ca86e53949d5ae21b9e6cc2923ce_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - INVENTORIES, NET (Details)", "role": "http://www.clorox.com/role/INVENTORIESNETDetails", "shortName": "INVENTORIES, NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoodsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details)", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "id316dfb5087142989f8e947046bf551f_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - INCOME TAXES (Narrative) (Details)", "role": "http://www.clorox.com/role/INCOMETAXESNarrativeDetails", "shortName": "INCOME TAXES (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417407 - Disclosure - NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details)", "role": "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails", "shortName": "NET EARNINGS PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-3", "lang": "en-US", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420408 - Disclosure - COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details)", "role": "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "shortName": "COMPREHENSIVE INCOME (Schedule of Comprehensive Income) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423409 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Equity) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails", "shortName": "STOCKHOLDERS' EQUITY (Schedule of Equity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424410 - Disclosure - STOCKHOLDERS' EQUITY (Narrative) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "shortName": "STOCKHOLDERS' EQUITY (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i963b7d699b234c58800e17fbce7ad91d_D20210701-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i7e34b6f1b27047d58fb0883bd668e3dc_I20210630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425411 - Disclosure - STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details)", "role": "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "shortName": "STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428412 - Disclosure - EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "shortName": "EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "3", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429413 - Disclosure - EMPLOYEE BENEFIT PLANS (Narrative) (Details)", "role": "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails", "shortName": "EMPLOYEE BENEFIT PLANS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie5505b03a3cc4907a72a417cc5573c2d_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanContributionsByEmployer", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - OTHER CONTINGENCIES AND GUARANTEES (Details)", "role": "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails", "shortName": "OTHER CONTINGENCIES AND GUARANTEES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccrualForEnvironmentalLossContingencies", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434415 - Disclosure - SEGMENT RESULTS (Narrative) (Details)", "role": "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "shortName": "SEGMENT RESULTS (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "reportablesegment", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ie2d24ecaa7bf4c1b8859438082ad68e3_I20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details)", "role": "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails", "shortName": "SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "ica11ebdda6b94d90b02c4f8ef2da73c6_D20210701-20210930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DepreciationDepletionAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - BUSINESS ACQUIRED", "role": "http://www.clorox.com/role/BUSINESSACQUIRED", "shortName": "BUSINESS ACQUIRED", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - INVENTORIES, NET", "role": "http://www.clorox.com/role/INVENTORIESNET", "shortName": "INVENTORIES, NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "role": "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS", "shortName": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "clx-20210930.htm", "contextRef": "i6dfa203e34044837880f97b12c76d1fd_D20210701-20210930", "decimals": null, "first": true, "lang": "en-US", "name": "clx:FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 59, "tag": { "clx_AlamedaCountyCaliforniaMatterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Alameda County, California Matter [Member]", "label": "Alameda County, California Matter [Member]", "terseLabel": "Alameda County, California Matter" } } }, "localname": "AlamedaCountyCaliforniaMatterMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "clx_BagsWrapsAndContainersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bags, Wraps, And Containers [Member]", "label": "Bags, Wraps, And Containers [Member]", "terseLabel": "Bags and Wraps" } } }, "localname": "BagsWrapsAndContainersMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_BusinessCombinationSettlementOfPreExistingNetLiabilities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Settlement Of Pre-Existing Net Liabilities", "label": "Business Combination, Settlement Of Pre-Existing Net Liabilities", "terseLabel": "Loss on settlement" } } }, "localname": "BusinessCombinationSettlementOfPreExistingNetLiabilities", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_CatLitterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cat Litter [Member]", "label": "Cat Litter [Member]", "terseLabel": "Cat Litter" } } }, "localname": "CatLitterMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_CleaningMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cleaning [Member]", "label": "Cleaning [Member]", "terseLabel": "Cleaning" } } }, "localname": "CleaningMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_CommodityPurchaseDerivativeContractsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commodity Purchase Derivative Contracts [Axis]", "label": "Commodity Purchase Derivative Contracts [Axis]", "terseLabel": "Commodity Purchase Derivative Contracts [Axis]" } } }, "localname": "CommodityPurchaseDerivativeContractsAxis", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "clx_CommodityPurchaseDerivativeContractsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commodity Purchase Derivative Contracts [Domain]", "label": "Commodity Purchase Derivative Contracts [Domain]", "terseLabel": "Commodity Purchase Derivative Contracts [Domain]" } } }, "localname": "CommodityPurchaseDerivativeContractsDomain", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Current Maturities of Long-term Debt and Long-term Debt [Member]", "label": "CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember", "verboseLabel": "Current maturities of long-term debt and Long-term debt" } } }, "localname": "CurrentMaturitiesOfLongTermDebtAndLongTermDebtMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "clx_DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Derivative instruments subject to contractually defined counterparty liability position limits.", "label": "Derivative Instruments Subject To Contractually Defined Counterparty Liability Position Limits", "terseLabel": "Derivative instruments subject to contractually defined counterparty liability position limits" } } }, "localname": "DerivativeInstrumentsSubjectToContractuallyDefinedCounterpartyLiabilityPositionLimits", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "clx_DickinsonCountyMichiganMatterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dickinson County, Michigan Matter [Member]", "label": "Dickinson County, Michigan Matter [Member]", "terseLabel": "Dickinson County, Michigan Matter" } } }, "localname": "DickinsonCountyMichiganMatterMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "clx_FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for financial instruments and fair value measurements.", "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Text Block]", "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS" } } }, "localname": "FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTextBlock", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "clx_FinancialInstrumentsAndFairValueMeasurementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial Instruments and Fair Value Measurements [Abstract]", "label": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]", "terseLabel": "FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]" } } }, "localname": "FinancialInstrumentsAndFairValueMeasurementsAbstract", "nsuri": "http://www.clorox.com/20210930", "xbrltype": "stringItemType" }, "clx_FoodProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Food Products [Member]", "label": "Food Products [Member]", "terseLabel": "Food Products" } } }, "localname": "FoodProductsMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_GrillingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grilling [Member]", "label": "Grilling [Member]", "terseLabel": "Grilling" } } }, "localname": "GrillingMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_HealthAndWellnessMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Health and Wellness", "label": "Health and Wellness [Member]", "terseLabel": "Health and Wellness" } } }, "localname": "HealthAndWellnessMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_HouseholdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Household [Member]", "label": "Household [Member]", "terseLabel": "Household" } } }, "localname": "HouseholdMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_InternationalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_IssuanceOfCommonStockForEmployeeStockPlansAndOther": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock options. Also includes the net cash inflow (outflow) from other financing activities.", "label": "Issuance Of Common Stock For Employee Stock Plans And Other", "terseLabel": "Issuance of common stock for employee stock plans and other" } } }, "localname": "IssuanceOfCommonStockForEmployeeStockPlansAndOther", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_JetFuelSwapsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jet Fuel Swaps [Member]", "label": "Jet Fuel Swaps [Member]", "terseLabel": "Jet Fuel Swaps" } } }, "localname": "JetFuelSwapsMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_JointVentureInKingdomOfSaudiArabiaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joint Venture In Kingdom Of Saudi Arabia", "label": "Joint Venture In Kingdom Of Saudi Arabia [Member]", "terseLabel": "Joint Venture In Kingdom Of Saudi Arabia" } } }, "localname": "JointVentureInKingdomOfSaudiArabiaMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_LetterOfCreditBorrowingCapacity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowing capacity under the letter of credit without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding.", "label": "Letter of credit", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditBorrowingCapacity", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "clx_LifestyleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lifestyle [Member]", "label": "Lifestyle [Member]", "terseLabel": "Lifestyle" } } }, "localname": "LifestyleMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_LongTermInterCompanyLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long-term inter-company loans included in foreign currency adjustments.", "label": "Long-Term Inter-Company Loans [Member]", "terseLabel": "Long-Term Inter-Company Loans" } } }, "localname": "LongTermInterCompanyLoansMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_MaximumExposureUndiscountedCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum potential amount of future payments (undiscounted) that the Company could incur over an estimated remediation period.", "label": "Maximum Exposure, Undiscounted Cost", "terseLabel": "Maximum undiscounted costs" } } }, "localname": "MaximumExposureUndiscountedCost", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "clx_NaturalPersonalCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Natural Personal Care [Member]", "label": "Natural Personal Care [Member]", "terseLabel": "Natural Personal Care" } } }, "localname": "NaturalPersonalCareMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_NotesAndLoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Notes and Loans Payable [Member]", "label": "NotesAndLoansPayableMember", "terseLabel": "NotesAndLoansPayableMember" } } }, "localname": "NotesAndLoansPayableMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "clx_NumberOfEntitiesInJointVenture": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Entities in Joint Venture", "label": "Number of Entities in Joint Venture", "terseLabel": "Number of entities in joint venture" } } }, "localname": "NumberOfEntitiesInJointVenture", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "integerItemType" }, "clx_OTHERCONTINGENCIESANDGUARANTEESTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This item represents the complete disclosure regarding the entity's exposure to loss pertaining to environmental matters, litigation and potential losses not disclosed in other notes and guarantees.", "label": "OTHER CONTINGENCIES AND GUARANTEES [Text Block]", "terseLabel": "OTHER CONTINGENCIES AND GUARANTEES" } } }, "localname": "OTHERCONTINGENCIESANDGUARANTEESTextBlock", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEES" ], "xbrltype": "textBlockItemType" }, "clx_OperatingLeaseRightofUseAssetAndLiabilityNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Operating Lease, Right-of-Use Asset And Liability, Net", "label": "Operating Lease, Right-of-Use Asset And Liability, Net", "terseLabel": "Operating lease right-of-use assets and liabilities, net" } } }, "localname": "OperatingLeaseRightofUseAssetAndLiabilityNet", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_OtherContingenciesAndGuaranteesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER CONTINGENCIES AND GUARANTEES [Abstract]", "terseLabel": "OTHER CONTINGENCIES AND GUARANTEES [Abstract]" } } }, "localname": "OtherContingenciesAndGuaranteesAbstract", "nsuri": "http://www.clorox.com/20210930", "xbrltype": "stringItemType" }, "clx_OtherEmployeeStockPlanActivitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount includes the value of stock granted during the period as a result of exercises of employee stock options or vesting of other share-based awards.", "label": "Other Employee Stock Plan Activities, Amount", "terseLabel": "Other employee stock plan activities" } } }, "localname": "OtherEmployeeStockPlanActivitiesAmount", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "clx_OtherEmployeeStockPlanActivitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of exercises of employee stock options or the vesting of other share-based awards.", "label": "Other Employee Stock Plan Activities, Shares", "terseLabel": "Other employee stock plan activities (in shares)" } } }, "localname": "OtherEmployeeStockPlanActivitiesShares", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "sharesItemType" }, "clx_OtherExpenseIncomeNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 6.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net amount of other income and expense, which does not qualify for separate disclosure on the income statement under materiality guidelines.", "label": "Other Expense (Income), Net", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherExpenseIncomeNet", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_ProfessionalProductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional Products [Member]", "label": "Professional Products [Member]", "terseLabel": "Professional Products" } } }, "localname": "ProfessionalProductsMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_PurchasesofInventoryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchases of Inventory [Member]", "label": "Purchases of Inventory [Member]", "terseLabel": "Purchases of Inventory" } } }, "localname": "PurchasesofInventoryMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_RemediationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated time frame of disbursements over which remediation efforts are estimated to occur for an individual site.", "label": "Remediation period", "terseLabel": "Remediation period (in years)" } } }, "localname": "RemediationPeriod", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "durationItemType" }, "clx_RetirementIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retirement Income [Member]", "label": "Retirement Income Plans [Member]", "terseLabel": "Retirement Income Plans" } } }, "localname": "RetirementIncomeMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_SiteContingencyAgreedPercentageOfCostSharing": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of costs that the entity has agreed to under cost-sharing arrangements with other potentially responsible parties for an individual site.", "label": "Percentage of liability for aggregate remediation and associated costs, other than legal fees", "terseLabel": "Percentage of liability for aggregate remediation and associated costs, other than legal fees" } } }, "localname": "SiteContingencyAgreedPercentageOfCostSharing", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "percentItemType" }, "clx_SoybeanOilFuturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Soybean Oil Futures [Member]", "label": "Soybean Oil Futures [Member]", "terseLabel": "Soybean Oil Futures" } } }, "localname": "SoybeanOilFuturesMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_TotalCommodityPurchaseDerivativeContractsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Total Commodity Purchase Derivative Contracts [Member]", "label": "Total Commodity Purchase Derivative Contracts [Member]", "terseLabel": "Total Commodity Purchase Derivative Contracts" } } }, "localname": "TotalCommodityPurchaseDerivativeContractsMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_TrademarksNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite or finite period of benefit.", "label": "Trademarks, net", "terseLabel": "Trademarks, net" } } }, "localname": "TrademarksNet", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "clx_TrustAssetsForNonqualifiedDeferredCompensationPlansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trust Assets For Nonqualified Deferred Compensation Plans [Member]", "label": "Trust Assets for nonqualified deferred compensation plans [Member]", "terseLabel": "Trust assets for nonqualified deferred compensation plans" } } }, "localname": "TrustAssetsForNonqualifiedDeferredCompensationPlansMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "clx_VitaminsMineralsAndSupplementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vitamins, Minerals and Supplements", "label": "Vitamins, Minerals and Supplements [Member]", "terseLabel": "Vitamins, Minerals and Supplements" } } }, "localname": "VitaminsMineralsAndSupplementsMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "clx_WalmartStoresIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Walmart Stores, Inc. and its affiliates [Member]", "label": "Walmart Stores, Inc. [Member]", "terseLabel": "Walmart Stores, Inc." } } }, "localname": "WalmartStoresIncMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "clx_WaterFiltrationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Water Filtration [Member]", "label": "Water Filtration [Member]", "terseLabel": "Water Filtration" } } }, "localname": "WaterFiltrationMember", "nsuri": "http://www.clorox.com/20210930", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "UNITED STATES" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r554" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r557" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r556" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r552" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r553" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.clorox.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r106", "r152", "r171", "r172", "r173", "r174", "r176", "r178", "r182", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r230", "r231" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r106", "r152", "r171", "r172", "r173", "r174", "r176", "r178", "r182", "r218", "r219", "r220", "r221", "r222", "r223", "r225", "r226", "r228", "r230", "r231" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r188", "r270", "r271", "r527" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r188", "r270", "r271", "r527" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r6", "r16", "r190", "r191" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Receivables, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccrualForEnvironmentalLossContingencies": { "auth_ref": [ "r204", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total costs accrued as of the balance sheet date for environmental loss contingencies.", "label": "Accrual for Environmental Loss Contingencies", "terseLabel": "Liability for aggregate future remediation costs" } } }, "localname": "AccrualForEnvironmentalLossContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r57", "r63", "r71", "r72", "r73", "r419" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension and postretirement benefit adjustments" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r33", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment, accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember": { "auth_ref": [ "r56", "r63", "r418" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges, attributable to the parent.", "label": "Accumulated Net Gain (Loss) from Cash Flow Hedges Attributable to Parent [Member]", "terseLabel": "Net unrealized gains (losses) on derivatives" } } }, "localname": "AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r60", "r62", "r63", "r512", "r532", "r533" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive net (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r71", "r72", "r471", "r472", "r473", "r474", "r475", "r477" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r59", "r63", "r71", "r72", "r73", "r108", "r109", "r110", "r419", "r528", "r529", "r558" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Net (Loss) Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r55", "r63", "r71", "r72", "r73", "r419", "r472", "r473", "r474", "r475", "r477" ], "lang": { "en-us": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r108", "r109", "r110", "r365", "r366", "r367", "r454" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r361", "r362", "r369", "r370" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net earnings to net cash provided by operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r371" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising costs" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive stock options and other (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_Assets": { "auth_ref": [ "r102", "r160", "r173", "r180", "r194", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r412", "r420", "r469", "r482", "r484", "r492", "r510" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r7", "r8", "r50", "r102", "r194", "r218", "r219", "r220", "r222", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r412", "r420", "r469", "r482", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r457" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total other assets in the fair value hierarchy" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r431", "r436" ], "lang": { "en-us": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BankTimeDepositsMember": { "auth_ref": [ "r506" ], "lang": { "en-us": { "role": { "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.", "label": "Bank Time Deposits [Member]", "terseLabel": "Time deposits" } } }, "localname": "BankTimeDepositsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r107" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r352", "r356" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r352", "r356", "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": { "auth_ref": [ "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.", "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value", "terseLabel": "Fair value of non-controlling interest acquired" } } }, "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r402", "r403", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Purchase consideration" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "BUSINESS ACQUIRED" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIRED" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r399", "r400" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "terseLabel": "Fair value of net assets acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Combination, Separately Recognized Transactions [Line Items]", "terseLabel": "Business Combination, Separately Recognized Transactions [Line Items]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTable": { "auth_ref": [ "r395" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing the disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.", "label": "Business Combination, Separately Recognized Transactions [Table]", "terseLabel": "Business Combination, Separately Recognized Transactions [Table]" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss": { "auth_ref": [ "r396" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of net gain (loss) recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain (Loss), Net", "terseLabel": "Non-recurring, non-cash gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGainOrLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r464", "r465" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Amount" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r4", "r32", "r98" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Period Increase (Decrease) [Abstract]", "terseLabel": "Cash, cash equivalents, and restricted cash:" } } }, "localname": "CashAndCashEquivalentsPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r93", "r98", "r99" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "End of period", "periodStartLabel": "Beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r93", "r470" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": { "auth_ref": [ "r451" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.", "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months", "terseLabel": "Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months" } } }, "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaper": { "auth_ref": [ "r12", "r493", "r511" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.", "label": "Commercial Paper", "terseLabel": "Notes and loans payable" } } }, "localname": "CommercialPaper", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r42", "r208", "r497", "r517" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommodityContractMember": { "auth_ref": [ "r298", "r443" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to commodity prices.", "label": "Commodity Contract [Member]", "terseLabel": "Commodity contract" } } }, "localname": "CommodityContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Dividends declared per share (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r108", "r109", "r454" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 shares issued as of September\u00a030, 2021 and June\u00a030, 2021; and 122,856,251 and 122,780,220 shares outstanding as of September\u00a030, 2021 and June\u00a030, 2021, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r67", "r69", "r70", "r81", "r503", "r522" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive income attributable to Clorox" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r67", "r69", "r80", "r410", "r411", "r424", "r502", "r521" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Total comprehensive income attributable to noncontrolling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r67", "r69", "r79", "r409", "r424", "r501", "r520" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive income", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r78", "r86", "r500", "r519" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "COMPREHENSIVE INCOME" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOME" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r144", "r145", "r188", "r466", "r467", "r550" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r144", "r145", "r188", "r466", "r467", "r534", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r144", "r145", "r188", "r466", "r467", "r534", "r550" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r144", "r145", "r188", "r466", "r467" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r141", "r144", "r145", "r146", "r466", "r468", "r550" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r144", "r145", "r188", "r466", "r467", "r550" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r171", "r172", "r173", "r174", "r176", "r182", "r184" ], "lang": { "en-us": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Corporate, Non-Segment" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r84", "r489" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of products sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r142", "r188" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r234", "r236", "r237", "r463" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "verboseLabel": "Current maturities of long-term debt and Long-term debt" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationPlanAssets": { "auth_ref": [ "r34" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.", "label": "Deferred Compensation Plan Assets", "terseLabel": "Trust assets for nonqualified deferred compensation plans" } } }, "localname": "DeferredCompensationPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r96", "r103", "r380", "r385", "r386", "r387" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "verboseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r373", "r374" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r275", "r313", "r340", "r346", "r347" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Amortization of unrecognized items" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": { "auth_ref": [ "r321", "r345" ], "lang": { "en-us": { "role": { "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.", "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets", "terseLabel": "Weighted average long-term expected rate or return on plan assets" } } }, "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r290", "r298", "r300", "r344", "r346", "r347" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Discretionary contributions" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r275", "r312", "r339", "r346", "r347" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r275", "r279", "r311", "r338", "r346", "r347" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r309", "r336", "r346", "r347" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Total", "verboseLabel": "Net periodic benefit cost (benefit)" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r277", "r310", "r337", "r346", "r347" ], "calculation": { "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r96", "r155" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r51", "r52", "r53", "r463" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "Derivative assets" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r53", "r432", "r435", "r440", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r429", "r432", "r440", "r444", "r445", "r448", "r450" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r426", "r428" ], "lang": { "en-us": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r425", "r427", "r428", "r429", "r430", "r437", "r440", "r446", "r447", "r450", "r453" ], "lang": { "en-us": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r264", "r509" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedTerseLabel": "Dividends" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticPlanMember": { "auth_ref": [ "r351", "r355", "r359" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Domestic Plan [Member]", "terseLabel": "Domestic Plan" } } }, "localname": "DomesticPlanMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net earnings per share attributable to Clorox" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r82", "r113", "r114", "r115", "r116", "r117", "r121", "r123", "r128", "r129", "r130", "r135", "r136", "r455", "r456", "r504", "r523" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r82", "r113", "r114", "r115", "r116", "r117", "r123", "r128", "r129", "r130", "r135", "r136", "r455", "r456", "r504", "r523" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net earnings per share (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r131", "r133", "r134", "r137" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET EARNINGS PER SHARE (EPS)" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPS" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r470" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate on earnings from continuing operations" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INCOMETAXESNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r71", "r72", "r73", "r108", "r109", "r110", "r112", "r118", "r120", "r138", "r195", "r257", "r264", "r365", "r366", "r367", "r381", "r382", "r454", "r471", "r472", "r473", "r474", "r475", "r477", "r528", "r529", "r530", "r558" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r234", "r236", "r237", "r463" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Estimated Fair Value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r457", "r458", "r459", "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "auth_ref": [ "r457", "r464" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities for Fair Value Disclosure" } } }, "localname": "FairValueByBalanceSheetGroupingTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r234", "r236", "r237", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r346", "r458", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r234", "r236", "r237", "r457", "r461" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r234", "r236", "r237" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r234", "r298", "r300", "r305", "r346", "r458", "r485" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r234", "r236", "r237", "r298", "r300", "r305", "r346", "r458", "r486" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r234", "r236", "r237", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r346", "r485", "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.", "label": "Financial Liabilities Fair Value Disclosure", "totalLabel": "Total other liabilities in the fair value hierarchy" } } }, "localname": "FinancialLiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r53", "r298", "r442" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange derivative contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign exchange forward contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r198", "r199", "r484", "r491" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r83", "r102", "r160", "r172", "r176", "r179", "r182", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r469" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r76", "r160", "r172", "r176", "r179", "r182", "r490", "r498", "r507", "r524" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Earnings (losses) before income taxes", "totalLabel": "Earnings before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r104", "r377", "r378", "r379", "r383", "r388", "r392", "r393", "r394" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r105", "r119", "r120", "r158", "r375", "r384", "r390", "r525" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes.", "label": "Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable", "verboseLabel": "Income taxes payable / prepaid" } } }, "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories, net" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInReceivables": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Receivables", "negatedLabel": "Receivables, net" } } }, "localname": "IncreaseDecreaseInReceivables", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r124", "r125", "r126", "r130" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Dilutive effect of stock options and other (in shares)" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceByDescriptionAxis": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Information by name or description of the entity to which the long-term intercompany foreign balances of the entity relate.", "label": "Intercompany Foreign Currency Balance by Description [Axis]", "terseLabel": "Intercompany Foreign Currency Balance by Description [Axis]" } } }, "localname": "IntercompanyForeignCurrencyBalanceByDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntercompanyForeignCurrencyBalanceNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name or description of the foreign entity or investment that is of a long-term nature.", "label": "Intercompany Foreign Currency Balance, Name [Domain]", "terseLabel": "Intercompany Foreign Currency Balance, Name [Domain]" } } }, "localname": "IntercompanyForeignCurrencyBalanceNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r75", "r154", "r478", "r479", "r505" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r53", "r298", "r441" ], "lang": { "en-us": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate contracts" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r197" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "INVENTORIES, NET" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r23", "r196" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r48" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 4.0, "parentTag": "us-gaap_InventoryNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "LIFO allowances" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r5", "r47", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories, net", "totalLabel": "Total" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": { "auth_ref": [ "r25", "r26", "r196" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.", "label": "Inventory, Raw Materials and Supplies, Net of Reserves", "terseLabel": "Raw materials and packaging" } } }, "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r24", "r196" ], "calculation": { "http://www.clorox.com/role/INVENTORIESNETDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r457" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "verboseLabel": "Trust assets for nonqualified deferred compensation plans" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit, amount outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r38", "r102", "r174", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r413", "r420", "r421", "r469", "r482", "r483" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 }, "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r102", "r194", "r469", "r484", "r496", "r515" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r102", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r413", "r420", "r421", "r469", "r482", "r483", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r13", "r233", "r235", "r236", "r237", "r494", "r511" ], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Current maturities of long-term debt and Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r37" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Current maturities of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.", "label": "Long-term Debt [Member]", "terseLabel": "Long-term Debt" } } }, "localname": "LongTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r40" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r40", "r217" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/OTHERCONTINGENCIESANDGUARANTEESDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarginDepositAssets": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash or securities placed with a broker or counterparty as security for a trading or derivatives securities position which was partially obtained with funds provided by the broker dealer.", "label": "Margin Deposit Assets", "terseLabel": "Cash margin balances amount" } } }, "localname": "MarginDepositAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.", "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge", "terseLabel": "Maximum duration, foreign exchange contracts (in years)" } } }, "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInCashFlowHedge1": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Maximum length of time over which the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Cash Flow Hedge", "terseLabel": "Maximum duration, commodity contracts (in years)" } } }, "localname": "MaximumLengthOfTimeHedgedInCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1": { "auth_ref": [ "r452" ], "lang": { "en-us": { "role": { "documentation": "Maximum period the entity is hedging its exposure to the variability in future cash flows for forecasted transactions, excluding those forecasted transactions related to the payment of variable interest on existing financial instruments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Maximum Length of Time Hedged in Interest Rate Cash Flow Hedge", "terseLabel": "Maximum duration, interest rate contracts (in years)" } } }, "localname": "MaximumLengthOfTimeHedgedInInterestRateCashFlowHedge1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r46", "r102", "r194", "r218", "r223", "r224", "r225", "r231", "r232", "r469", "r495", "r514" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Dividends to non-controlling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Noncontrolling interest, ownership percentage by parent" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Interest-bearing investments, including money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used for financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r93" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used for investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r93", "r94", "r97" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r3", "r65", "r68", "r73", "r77", "r97", "r102", "r111", "r113", "r114", "r115", "r116", "r119", "r120", "r127", "r160", "r172", "r176", "r179", "r182", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r456", "r469", "r499", "r518" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net earnings attributable to Clorox" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r65", "r68", "r73", "r119", "r120", "r415", "r423" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net earnings attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r265", "r401", "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Business combinations including purchase accounting adjustments" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r108", "r109", "r110", "r264", "r407" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non-controlling interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r148" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r481" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r481" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Long-term operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r480" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r171", "r172", "r173", "r174", "r176", "r182" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r431", "r448" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r58", "r60", "r409", "r418" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Pension and postretirement benefit adjustments" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r409", "r410", "r418" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax": { "auth_ref": [ "r63", "r71", "r72", "r471", "r473", "r477" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), before Reclassifications, before Tax", "terseLabel": "Other comprehensive (loss) income before reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r60" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "terseLabel": "Net unrealized gains (losses) on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r56", "r60", "r433", "r438", "r449" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gains (losses) recognized in Other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r60", "r64", "r439" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "terseLabel": "Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleoftheEffectsofDerivativeInstrumentsDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r66", "r69", "r71", "r72", "r74", "r78", "r257", "r471", "r476", "r477", "r500", "r519" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Net current period other comprehensive (loss) income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive (loss) income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r66", "r69", "r409", "r410", "r418" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive (loss) income", "totalLabel": "Total other comprehensive (loss) income, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTax": { "auth_ref": [ "r61", "r71", "r78", "r375", "r389", "r391", "r471", "r474", "r477", "r500", "r519" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Tax", "negatedLabel": "Income tax benefit (expense)" } } }, "localname": "OtherComprehensiveIncomeLossTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Other Intangible Assets, Net", "terseLabel": "Other intangible assets, net" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r41" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r97" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r327", "r331", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefits Plan" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r87", "r90" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Treasury stock purchased" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r91" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Cash dividends paid to Clorox stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r88", "r405" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Cash paid" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/BUSINESSACQUIREDNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r88" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Businesses acquired, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r89" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r297", "r299", "r305", "r323", "r325", "r326", "r327", "r328", "r329", "r346", "r348", "r349", "r350", "r360" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLANS" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r363", "r364" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r462" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14", "r241" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14", "r241" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r7", "r30", "r31" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Notes and loans payable, net" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]", "terseLabel": "Product Concentration Risk" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r3", "r65", "r68", "r73", "r92", "r102", "r111", "r119", "r120", "r160", "r172", "r176", "r179", "r182", "r194", "r218", "r219", "r220", "r223", "r224", "r225", "r227", "r229", "r231", "r232", "r409", "r414", "r416", "r423", "r424", "r456", "r469", "r507" ], "calculation": { "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net earnings", "totalLabel": "Net earnings", "verboseLabel": "Net earnings" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMEScheduleofComprehensiveIncomeDetails", "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r11", "r202", "r484", "r508", "r516" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net of accumulated depreciation and amortization of $2,422 and $2,382, respectively" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax": { "auth_ref": [ "r63", "r71", "r72", "r471", "r475", "r477" ], "calculation": { "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax", "negatedLabel": "Amounts reclassified from Accumulated other comprehensive net (loss) income", "terseLabel": "Amounts reclassified from accumulated other comprehensive net (loss) income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYNarrativeDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]", "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r372", "r488", "r551" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development costs" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r264", "r368", "r484", "r513", "r531", "r533" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r108", "r109", "r110", "r112", "r118", "r120", "r195", "r365", "r366", "r367", "r381", "r382", "r454", "r528", "r530" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r327", "r332", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r351", "r355", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r324", "r327", "r332", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r351", "r355", "r359" ], "lang": { "en-us": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r327", "r331", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r272", "r273", "r274", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r321", "r322", "r324", "r327", "r331", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r171", "r177", "r178", "r185", "r186", "r188", "r269", "r270", "r489" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net sales" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r144", "r188" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue from Contract with Customer" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSNarrativeDetails", "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r63", "r476", "r477" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effects of Derivative Instruments Designated as Hedging Instruments on OCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r54" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.", "label": "Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Comprehensive Income" } } }, "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/COMPREHENSIVEINCOMETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r330", "r331", "r334", "r335", "r346" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSComponentsoftheNetCostofRetirementIncomeDetails", "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative instruments (including nonderivative instruments that are designated and qualify as hedging instruments) of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings" } } }, "localname": "ScheduleOfDerivativesInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r27", "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories, Net" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/INVENTORIESNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Schedule of Components of Net Periodic Benefit Cost" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/EMPLOYEEBENEFITPLANSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r160", "r163", "r175", "r200" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r160", "r163", "r175", "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Selected Financial Information Relating to the Company's Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r43", "r100", "r139", "r140", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r250", "r255", "r258", "r259", "r260", "r261", "r262", "r263", "r264" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Schedule of Stockholders Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "terseLabel": "Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares" } } }, "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r147", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r171", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r182", "r188", "r205", "r206", "r526" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r147", "r149", "r150", "r160", "r164", "r176", "r180", "r181", "r182", "r183", "r185", "r187", "r188", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT RESULTS" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r170", "r186" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Results" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r85" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling and administrative expenses" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r95" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance, ending (in shares)", "periodStartLabel": "Balance, beginning (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.", "label": "Short-term Debt [Member]", "terseLabel": "Short-term Debt" } } }, "localname": "ShortTermDebtMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-term Debt, Type [Axis]", "terseLabel": "Short-term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.", "label": "Short-term Debt, Type [Domain]", "terseLabel": "Short-term Debt, Type [Domain]" } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShorttermDebtFairValue": { "auth_ref": [], "calculation": { "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails": { "order": 1.0, "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents the amount of short-term debt existing as of the balance sheet date.", "label": "Short-term Debt, Fair Value", "terseLabel": "Short-term debt, fair value" } } }, "localname": "ShorttermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSScheduleofAssetsandLiabilitiesforFairValueDisclosureDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r147", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r171", "r172", "r173", "r174", "r176", "r177", "r178", "r179", "r180", "r182", "r188", "r200", "r203", "r205", "r206", "r526" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r45", "r71", "r72", "r73", "r108", "r109", "r110", "r112", "r118", "r120", "r138", "r195", "r257", "r264", "r365", "r366", "r367", "r381", "r382", "r454", "r471", "r472", "r473", "r474", "r475", "r477", "r528", "r529", "r530", "r558" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r20", "r21", "r102", "r192", "r194", "r469", "r484" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "totalLabel": "Total Clorox stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofChangesinAccumulatedOtherComprehensiveNetLossesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r72", "r102", "r108", "r109", "r110", "r112", "r118", "r194", "r195", "r264", "r365", "r366", "r367", "r381", "r382", "r407", "r408", "r422", "r454", "r469", "r471", "r472", "r477", "r529", "r530", "r558" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance, ending", "periodStartLabel": "Balance, beginning", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]", "terseLabel": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r101", "r242", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r256", "r264", "r268" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments [Axis]", "terseLabel": "Subsegments [Axis]" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Subsegments [Domain]", "terseLabel": "Subsegments [Domain]" } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/SEGMENTRESULTSSelectedFinancialInformationRelatingToCompanysSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]", "terseLabel": "Transaction [Domain]" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]", "terseLabel": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/FINANCIALINSTRUMENTSANDFAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r44", "r266" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r44", "r266" ], "lang": { "en-us": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock, shares (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r15", "r257", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "negatedTerseLabel": "Treasury stock purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r44", "r266", "r267" ], "calculation": { "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedLabel": "Treasury stock, at cost: 7,885,210 and 7,961,241 shares as of September\u00a030, 2021 and June\u00a030, 2021, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r257", "r264", "r266" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedTerseLabel": "Treasury stock purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/STOCKHOLDERSEQUITYScheduleofEquityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r122", "r130" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average shares outstanding (in thousands)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r121", "r130" ], "calculation": { "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.clorox.com/role/CondensedConsolidatedStatementsofEarningsandComprehensiveIncomeUnaudited", "http://www.clorox.com/role/NETEARNINGSPERSHAREEPSScheduleofWeightedAverageNumberofSharesDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r107": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r197": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6393242&loc=d3e13207-110859" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=6395460&loc=d3e13647-108346" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e39076-109324" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r394": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r406": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8,17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Subparagraph": "b.", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e526-108580" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r552": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r553": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r554": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r555": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r556": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r557": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r86": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" } }, "version": "2.1" } ZIP 64 0000021076-21-000020-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000021076-21-000020-xbrl.zip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�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end